{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1:  Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets\n",
      "Megan Lynn Otte, Raju Lama Tamang, Julia Papapanagiotou, Rizwan Ahmad, Punita Dhawan, Amar B Singh\n",
      "World J Gastroenterol. 2023 Feb 21; 29(7): 1157–1172.  Published online 2023 Feb 21. doi: 10.3748/wjg.v29.i7.1157\n",
      "PMCID: PMC10011951\n",
      "\n",
      "2:  Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy\n",
      "Amber G. Bozward, Vincenzo Ronca, Daniel Osei-Bordom, Ye Htun Oo\n",
      "Front Immunol. 2021; 12: 711217.  Published online 2021 Aug 25. doi: 10.3389/fimmu.2021.711217\n",
      "PMCID: PMC8425300\n",
      "\n",
      "3:  Severity of Psychologic Stressors Reflects Course of Crohn’s Disease in Two Siblings\n",
      "Jessica Budiselic, Mary Sadlek, Keon Simpson\n",
      "Cureus. 2021 Jul; 13(7): e16533.  Published online 2021 Jul 21. doi: 10.7759/cureus.16533\n",
      "PMCID: PMC8378317\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'server-errorServer returned response code 404 Service Unavailable. Url: http%3A%2F%2F130.14.22.90%2Futils%2Fportal%2Fportaltoc.fcgi%3Fncbi_sid%3D6F1CBA0EE09BC26E%255FB8EESID%26ncbi_phid%3D322C225246E54735000025D1955E884B%252E1%252E1%252E3%252E3%26myncbi_id%3D0%26port%3Dlive404Service Unavailable<?apply-render exception?><?ncbi_sid 6F1CBA0EE09BC26E_B8EESID?><?ncbi_phid 322C225246E54735000025D1955E884B.1.1.3.3?><?hostname 21?><?ExcErrorId 864141053?><?ExcTime 07/03/2023 21:43:33?><?UserAgent NCBI-Portal NCBIHttpConnector (CXX Toolkit)?><?ExcRequestUrl http://130.14.22.90/utils/portal/portaltoc.fcgi?ncbi_sid=6F1CBA0EE09BC26E%5FB8EESID&#x00026;ncbi_phid=322C225246E54735000025D1955E884B%2E1%2E1%2E3%2E3&#x00026;myncbi_id=0&#x00026;port=live?><exception/>'"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from Bio import Entrez\n",
    "\n",
    "Entrez.email = 'your_email@example.com'\n",
    "\n",
    "fetch_handle = Entrez.efetch(db='pmc', id=35301512, rettype='json', retmode='text')\n",
    "\n",
    "output = fetch_handle.read()\n",
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event = {\"search\":\"Vedolizumab\"}\n",
    "lambda_handler(event, \"context\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import random\n",
    "import PyPDF2\n",
    "import io\n",
    "\n",
    "\n",
    "def lambda_handler(event, context):\n",
    "    url = event['url']  # Assuming the URL is passed as an input in the event\n",
    "\n",
    "    userAgents = [\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/114.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/114.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:109.0) Gecko/20100101 Firefox/114.0\",\n",
    "        \"Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/114.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/113.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:109.0) Gecko/20100101 Firefox/113.0\",\n",
    "        \"Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/113.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (X11; Linux x86_64; rv:109.0) Gecko/20100101 Firefox/114.0\",\n",
    "        \"Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/605.1.15 (KHTML, like Gecko) Version/16.5 Safari/605.1.15\",\n",
    "        \"Mozilla/5.0 (Macintosh; Intel Mac OS X 10.15; rv:109.0) Gecko/20100101 Firefox/114.0\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; rv:114.0) Gecko/20100101 Firefox/114.0\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/114.0.0.0 Safari/537.36 Edg/114.0.1823.43\",\n",
    "        \"Mozilla/5.0 (X11; Linux x86_64; rv:102.0) Gecko/20100101 Firefox/102.0\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/113.0.0.0 Safari/537.36 OPR/99.0.0.0\",\n",
    "        \"Mozilla/5.0 (X11; Ubuntu; Linux x86_64; rv:109.0) Gecko/20100101 Firefox/114.0\",\n",
    "        \"Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/113.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/109.0.0.0 Safari/537.36\",\n",
    "        \"Mozilla/5.0 (X11; Linux x86_64; rv:109.0) Gecko/20100101 Firefox/113.0\"\n",
    "    ]\n",
    "\n",
    "    headers = {\"User-Agent\": random.choice(userAgents)}\n",
    "\n",
    "    session = requests.Session()\n",
    "    session.headers.update(headers)\n",
    "\n",
    "    try:\n",
    "        response = session.get(url, stream=True)\n",
    "        response.raise_for_status()  # Raise an exception if the request was not successful\n",
    "\n",
    "        pdf_content = response.content\n",
    "\n",
    "        # Create a file-like object from the PDF content\n",
    "        pdf_file = io.BytesIO(pdf_content)\n",
    "\n",
    "        # Parse the PDF content using PyPDF2\n",
    "        pdf = PyPDF2.PdfReader(pdf_file)\n",
    "        text = \"\"\n",
    "        for page in pdf.pages:\n",
    "            text = page.extract_text()\n",
    "    except Exception as e:\n",
    "        print(f\"Error occurred while processing PDF: {str(e)}\")\n",
    "        text = \"N/A\"\n",
    "\n",
    "    return {\n",
    "        'statusCode': 200,\n",
    "        'fulltext': text\n",
    "    }\n",
    "    \n",
    "    \n",
    "    \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'statusCode': 200,\n",
       " 'fulltext': '                                      © 2018 Baishideng Publishing Group Inc . All rights reserved.Published by Baishideng Publishing Group Inc\\n7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA\\nTelephone: +1-925-223-8242\\nFax: +1-925-223-8243\\nE-mail: bpgoffice@wjgnet.com\\nHelp Desk: http://www.f6publishing.com/helpdesk\\nhttp://www.wjgnet.com\\nI S S N  1 0  0 7  -   9  3 2  7\\n9    7 7 1 0  07   9 3 2 0 452  3'}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event = {\"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010939/pdf/WJG-24-2457.pdf\"}\n",
    "lambda_handler(event, \"context\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from Bio import Entrez\n",
    "from bs4 import BeautifulSoup\n",
    "import boto3\n",
    "\n",
    "#client = boto3.client('lambda')\n",
    "\n",
    "# Provide your email address to the Entrez API\n",
    "Entrez.email = 'your_email@example.com'\n",
    "\n",
    "def fetch_pmc_articles():\n",
    "    fetch_handle = Entrez.efetch(db='pmc', id=9178865, rettype='json', retmode='text')\n",
    "    return fetch_handle.read()\n",
    "\n",
    "\n",
    "def lambda_handler(event, context):\n",
    "\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/pmc/?term={event['search']}\"\n",
    "\n",
    "    # Send a GET request to the URL\n",
    "    response = requests.get(url)\n",
    "\n",
    "    # Create a BeautifulSoup object to parse the HTML content\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "\n",
    "    # Find all the \"dd\" elements\n",
    "    dd_elements = soup.find_all(\"dd\")\n",
    "\n",
    "    pmc_ids = []\n",
    "\n",
    "    # Iterate over each \"dd\" element\n",
    "    for dd in dd_elements:\n",
    "        # Check if the text starts with \"PMC\"\n",
    "        if dd.text.startswith(\"PMC\"):\n",
    "            # Remove the \"<dd>\" and \"</dd>\" tags and append the PMC ID\n",
    "            pmc_id = dd.text.replace(\"<dd>\", \"\").replace(\"</dd>\", \"\").strip()\n",
    "            pmc_ids.append(pmc_id)\n",
    "            pmc_set = set(pmc_ids)\n",
    "\n",
    "        xml_content = fetch_pmc_articles(pmc_set)\n",
    "        print(xml_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "event = {\"search\": \"Vendolizumab\"}\n",
    "lambda_handler(event, \"context\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "b'<?xml version=\"1.0\" ?>\\n<!DOCTYPE pmc-articleset PUBLIC \"-//NLM//DTD ARTICLE SET 2.0//EN\" \"https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd\">\\n<pmc-articleset><article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" article-type=\"research-article\" dtd-version=\"1.3\">\\n  <?properties open_access?>\\n  <processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\">\\n    <restricted-by>pmc</restricted-by>\\n  </processing-meta>\\n  <front>\\n    <journal-meta>\\n      <journal-id journal-id-type=\"nlm-ta\">BMC Gastroenterol</journal-id>\\n      <journal-id journal-id-type=\"iso-abbrev\">BMC Gastroenterol</journal-id>\\n      <journal-title-group>\\n        <journal-title>BMC Gastroenterology</journal-title>\\n      </journal-title-group>\\n      <issn pub-type=\"epub\">1471-230X</issn>\\n      <publisher>\\n        <publisher-name>BioMed Central</publisher-name>\\n        <publisher-loc>London</publisher-loc>\\n      </publisher>\\n    </journal-meta>\\n    <article-meta>\\n      <article-id pub-id-type=\"pmid\">35676620</article-id>\\n      <article-id pub-id-type=\"pmc\">9178865</article-id>\\n      <article-id pub-id-type=\"publisher-id\">2347</article-id>\\n      <article-id pub-id-type=\"doi\">10.1186/s12876-022-02347-1</article-id>\\n      <article-categories>\\n        <subj-group subj-group-type=\"heading\">\\n          <subject>Research Article</subject>\\n        </subj-group>\\n      </article-categories>\\n      <title-group>\\n        <article-title>Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis</article-title>\\n      </title-group>\\n      <contrib-group>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Peyrin-Biroulet</surname>\\n            <given-names>Laurent</given-names>\\n          </name>\\n          <address>\\n            <email>peyrinbiroulet@gmail.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff1\">1</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Arkkila</surname>\\n            <given-names>Perttu</given-names>\\n          </name>\\n          <address>\\n            <email>perttu.arkkila@helsinki.fi</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff2\">2</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Armuzzi</surname>\\n            <given-names>Alessandro</given-names>\\n          </name>\\n          <address>\\n            <email>Alessandro.armuzzi@policlinicogemelli.it</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff3\">3</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Danese</surname>\\n            <given-names>Silvio</given-names>\\n          </name>\\n          <address>\\n            <email>sdanese@hotmail.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff4\">4</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Guardiola</surname>\\n            <given-names>Jordi</given-names>\\n          </name>\\n          <address>\\n            <email>jguardiola@bellvitgehospital.cat</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff5\">5</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Jahnsen</surname>\\n            <given-names>J&#xF8;rgen</given-names>\\n          </name>\\n          <address>\\n            <email>jorgen.jahnsen@medisin.uio.no</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff6\">6</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Lees</surname>\\n            <given-names>Charles</given-names>\\n          </name>\\n          <address>\\n            <email>charlie.lees@ed.ac.uk</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff7\">7</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Louis</surname>\\n            <given-names>Edouard</given-names>\\n          </name>\\n          <address>\\n            <email>edouard.louis@uliege.be</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff8\">8</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Luk&#xE1;&#x161;</surname>\\n            <given-names>Milan</given-names>\\n          </name>\\n          <address>\\n            <email>milan.lukas@email.cz</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff9\">9</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Reinisch</surname>\\n            <given-names>Walter</given-names>\\n          </name>\\n          <address>\\n            <email>walter.reinisch@meduniwien.ac.at</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff10\">10</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Roblin</surname>\\n            <given-names>Xavier</given-names>\\n          </name>\\n          <address>\\n            <email>xavier.roblin@chu-st-etienne.fr</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff11\">11</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Jang</surname>\\n            <given-names>Minyoung</given-names>\\n          </name>\\n          <address>\\n            <email>MinYoung.Jang@celltrionhc.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff12\">12</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Byun</surname>\\n            <given-names>Han Geul</given-names>\\n          </name>\\n          <address>\\n            <email>hangeulbyun@gmail.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff12\">12</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Kim</surname>\\n            <given-names>Dong-Hyeon</given-names>\\n          </name>\\n          <address>\\n            <email>Donghyeon.kim2@celltrionhc.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff12\">12</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Lee</surname>\\n            <given-names>Sung Jeong</given-names>\\n          </name>\\n          <address>\\n            <email>sungjeong.lee@celltrion.com</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff12\">12</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" corresp=\"yes\">\\n          <contrib-id contrib-id-type=\"orcid\">http://orcid.org/0000-0002-8556-8433</contrib-id>\\n          <name>\\n            <surname>Atreya</surname>\\n            <given-names>Raja</given-names>\\n          </name>\\n          <address>\\n            <email>raja.atreya@uk-erlangen.de</email>\\n          </address>\\n          <xref ref-type=\"aff\" rid=\"Aff13\">13</xref>\\n        </contrib>\\n        <aff id=\"Aff1\"><label>1</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.410527.5</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1765 1301</institution-id><institution>Centre Hospitalier R&#xE9;gional Universitaire de Nancy, </institution></institution-wrap>Nancy, France </aff>\\n        <aff id=\"Aff2\"><label>2</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.15485.3d</institution-id><institution-id institution-id-type=\"ISNI\">0000 0000 9950 5666</institution-id><institution>Department of Gastroenterology, </institution><institution>Helsinki University and Helsinki University Hospital, </institution></institution-wrap>Helsinki, Finland </aff>\\n        <aff id=\"Aff3\"><label>3</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.417728.f</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1756 8807</institution-id><institution>Humanitas Research Hospital, </institution></institution-wrap>Milan, Rozzano Italy </aff>\\n        <aff id=\"Aff4\"><label>4</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.15496.3f</institution-id><institution-id institution-id-type=\"ISNI\">0000 0001 0439 0892</institution-id><institution>Gastroenterology and Endoscopy, </institution><institution>University Vita-Salute San Raffaele, </institution></institution-wrap>Milan, Italy </aff>\\n        <aff id=\"Aff5\"><label>5</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.418284.3</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 0427 2257</institution-id><institution>Digestive Diseases Department, </institution><institution>Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, </institution></institution-wrap>L&#x2019;Hospitalet de Llobregat, Barcelona, Spain </aff>\\n        <aff id=\"Aff6\"><label>6</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.5510.1</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1936 8921</institution-id><institution>Department of Gastroenterology, Institute of Clinical Medicine, </institution><institution>Akershus University Hospital, University of Oslo, </institution></institution-wrap>Oslo, Norway </aff>\\n        <aff id=\"Aff7\"><label>7</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.4305.2</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1936 7988</institution-id><institution>Center of Genomics and Experimental Medicine, </institution><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>\\n        <aff id=\"Aff8\"><label>8</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.411374.4</institution-id><institution-id institution-id-type=\"ISNI\">0000 0000 8607 6858</institution-id><institution>Department of Gastroenterology, </institution><institution>University Hospital CHU of Li&#xE8;ge, </institution></institution-wrap>Li&#xE8;ge, Belgium </aff>\\n        <aff id=\"Aff9\"><label>9</label>ISCARE Clinical Centre, Prague, Czech Republic </aff>\\n        <aff id=\"Aff10\"><label>10</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.22937.3d</institution-id><institution-id institution-id-type=\"ISNI\">0000 0000 9259 8492</institution-id><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff>\\n        <aff id=\"Aff11\"><label>11</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.412954.f</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1765 1491</institution-id><institution>University Hospital of Saint-Etienne, </institution></institution-wrap>Saint-Etienne, France </aff>\\n        <aff id=\"Aff12\"><label>12</label>Celltrion Healthcare, Incheon, Republic of Korea </aff>\\n        <aff id=\"Aff13\"><label>13</label><institution-wrap><institution-id institution-id-type=\"GRID\">grid.411668.c</institution-id><institution-id institution-id-type=\"ISNI\">0000 0000 9935 6525</institution-id><institution>Medical Department 1, </institution><institution>University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-N&#xFC;rnberg, </institution></institution-wrap>Ulmenweg 18, 91054 Erlangen, Germany </aff>\\n      </contrib-group>\\n      <pub-date pub-type=\"epub\">\\n        <day>8</day>\\n        <month>6</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <pub-date pub-type=\"pmc-release\">\\n        <day>8</day>\\n        <month>6</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <pub-date pub-type=\"collection\">\\n        <year>2022</year>\\n      </pub-date>\\n      <volume>22</volume>\\n      <elocation-id>291</elocation-id>\\n      <history>\\n        <date date-type=\"received\">\\n          <day>21</day>\\n          <month>12</month>\\n          <year>2021</year>\\n        </date>\\n        <date date-type=\"accepted\">\\n          <day>24</day>\\n          <month>5</month>\\n          <year>2022</year>\\n        </date>\\n      </history>\\n      <permissions>\\n        <copyright-statement>&#xA9; The Author(s) 2022</copyright-statement>\\n        <license>\\n          <ali:license_ref specific-use=\"textmining\" content-type=\"ccbylicense\">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>\\n          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article\\'s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\\'s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by/4.0/\">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/publicdomain/zero/1.0/\">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>\\n        </license>\\n      </permissions>\\n      <abstract id=\"Abs1\">\\n        <sec>\\n          <title>Background and aims</title>\\n          <p id=\"Par1\">There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients.\\n</p>\\n        </sec>\\n        <sec>\\n          <title>Methods</title>\\n          <p id=\"Par2\">We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn&#x2019;s disease or ulcerative colitis.</p>\\n        </sec>\\n        <sec>\\n          <title>Results</title>\\n          <p id=\"Par3\">We identified six eligible Crohn&#x2019;s disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn&#x2019;s disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn&#x2019;s disease and clinical response and clinical remission for ulcerative colitis) during the induction phase, with non-overlapping 95% confidence intervals. In the maintenance phase, similar proportions of infliximab- or vedolizumab-treated patients achieved clinical response, clinical remission, or mucosal healing in both Crohn&#x2019;s disease and ulcerative colitis. For the safety outcomes, rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar in infliximab- and vedolizumab-treated patients in both diseases. The infection rate was higher in infliximab for Crohn&#x2019;s disease and higher in vedolizumab when treating patients with ulcerative colitis. There was no difference between the treatments in the proportions of patients who reported serious infections in both indications.</p>\\n        </sec>\\n        <sec>\\n          <title>Conclusions</title>\\n          <p id=\"Par4\">Indirect comparison of infliximab and vedolizumab trials in adult patients with moderate-to severe Crohn&#x2019;s disease or ulcerative colitis demonstrated that infliximab has better efficacy in the induction phase and comparable efficacy during the maintenance phase and overall safety profile compared to vedolizumab.</p>\\n        </sec>\\n        <sec>\\n          <title>Supplementary Information</title>\\n          <p>The online version contains supplementary material available at 10.1186/s12876-022-02347-1.</p>\\n        </sec>\\n      </abstract>\\n      <kwd-group xml:lang=\"en\">\\n        <title>Keywords</title>\\n        <kwd>Biological therapy</kwd>\\n        <kwd>Tumor Necrosis Factor-alpha</kwd>\\n        <kwd>Antibodies</kwd>\\n        <kwd>Monoclonal</kwd>\\n        <kwd>IBD</kwd>\\n        <kwd>Crohn&#x2019;s disease</kwd>\\n        <kwd>Ulcerative colitis</kwd>\\n      </kwd-group>\\n      <funding-group>\\n        <award-group>\\n          <funding-source>\\n            <institution>Universit&#xE4;tsklinikum Erlangen (8546)</institution>\\n          </funding-source>\\n        </award-group>\\n        <open-access>\\n          <p>Open Access funding enabled and organized by Projekt DEAL.</p>\\n        </open-access>\\n      </funding-group>\\n      <custom-meta-group>\\n        <custom-meta>\\n          <meta-name>issue-copyright-statement</meta-name>\\n          <meta-value>&#xA9; The Author(s) 2022</meta-value>\\n        </custom-meta>\\n      </custom-meta-group>\\n    </article-meta>\\n  </front>\\n  <body>\\n    <sec id=\"Sec1\">\\n      <title>Introduction</title>\\n      <p id=\"Par20\">Inflammatory bowel diseases (IBD) is a heterogeneous group of chronic inflammatory disorders that mainly affects the gastrointestinal tract, of which the principal phenotypes are Crohn&#x2019;s disease (CD) [<xref ref-type=\"bibr\" rid=\"CR1\">1</xref>] and ulcerative colitis (UC) [<xref ref-type=\"bibr\" rid=\"CR2\">2</xref>]. Several biological treatment options are available. Tumour necrosis factor-&#x3B1; inhibitors (TNFis), such as infliximab and adalimumab, were the first class of biological agents approved for the treatment of patients with IBD and are highly effective against luminal and extra-intestinal manifestations of the disease [<xref ref-type=\"bibr\" rid=\"CR3\">3</xref>&#x2013;<xref ref-type=\"bibr\" rid=\"CR9\">9</xref>]. Anti-integrin agents (e.g., vedolizumab and natalizumab&#x2014;only in the United States) are the second class of biological agents that have proven effective in both IBD entities.</p>\\n      <p id=\"Par21\">Treatment guidelines for CD recommend TNFis for patients who have not responded to conventional therapy (e.g., steroids and/or thiopurines), whereas vedolizumab and ustekinumab, anti-interleukin (IL)-12 and IL-23, are recommended for patients who have had an inadequate response to conventional therapy and/or TNFis [<xref ref-type=\"bibr\" rid=\"CR10\">10</xref>]. The use of TNFi therapy early in the disease course (in the first 2&#xA0;years) may be more effective in CD and could be particularly beneficial in patients with poor prognostic factors (e.g., in patients with fistulising perianal disease) [<xref ref-type=\"bibr\" rid=\"CR10\">10</xref>]. Guidelines for UC recommend treatment escalation with thiopurines, TNFi therapy, vedolizumab, ustekinumab or tofacitinib for patients receiving high dose mesalazine maintenance therapy who become corticosteroid dependent or refractory [<xref ref-type=\"bibr\" rid=\"CR11\">11</xref>]. In the case of TNFi treatment failure, second-line therapy with vedolizumab, ustekinumab or tofacitinib should be considered [<xref ref-type=\"bibr\" rid=\"CR11\">11</xref>]. US guidelines are broadly aligned with European guidelines with respect to appropriate biological therapies for patients with moderate-to-severe IBD [<xref ref-type=\"bibr\" rid=\"CR12\">12</xref>, <xref ref-type=\"bibr\" rid=\"CR13\">13</xref>].</p>\\n      <p id=\"Par22\">Guidelines recommend that the choice of first-line biological agent should be determined by clinical factors, cost, safety, availability of local infusion capacity, as well as patient preference and likely adherence [<xref ref-type=\"bibr\" rid=\"CR11\">11</xref>]; however, there is limited evidence regarding the comparative efficacy and safety of these agents for the treatment of these patient populations. No head-to-head RCTs have compared infliximab and vedolizumab for the treatment of patients with IBD, and comparative data from real-world studies [<xref ref-type=\"bibr\" rid=\"CR14\">14</xref>, <xref ref-type=\"bibr\" rid=\"CR15\">15</xref>] are difficult to contextualise in the absence of mutually supplementary RCTs [<xref ref-type=\"bibr\" rid=\"CR16\">16</xref>].</p>\\n      <p id=\"Par23\">Several systematic reviews have synthesised data for multiple biological agents (including infliximab and vedolizumab) in IBD to draw preliminary conclusions; however, one did not evaluate the relative safety of infliximab and vedolizumab [<xref ref-type=\"bibr\" rid=\"CR17\">17</xref>], and the other covered only the induction phase in patients with UC [<xref ref-type=\"bibr\" rid=\"CR18\">18</xref>]. Furthermore, existing systematic reviews do not include data from more recent pivotal trials (e.g., of subcutaneous [SC] infliximab) [<xref ref-type=\"bibr\" rid=\"CR19\">19</xref>]. Therefore, to our knowledge, we have conducted the first systematic review and meta-analysis to comprehensively evaluate the comparative efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe CD or UC.</p>\\n    </sec>\\n    <sec id=\"Sec2\">\\n      <title>Methods</title>\\n      <p id=\"Par24\">The current systematic review was performed using a pre-established protocol. (PROSPERO number: CRD42021177954) [<xref ref-type=\"bibr\" rid=\"CR20\">20</xref>].</p>\\n      <sec id=\"Sec3\">\\n        <title>Search strategy</title>\\n        <p id=\"Par25\">We performed systematic electronic searches of PubMed, Embase and the Cochrane Library (comprising the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, and the Health Technology Assessment database). Search strategies were developed using Medical Subject Headings and free-text terms (Supplementary materials). All searches were performed for the period of 1 January 2010 through 30 April 2021 to ensure the inclusion of recently published data.</p>\\n      </sec>\\n      <sec id=\"Sec4\">\\n        <title>Criteria for considering studies for this review</title>\\n        <sec id=\"Sec5\">\\n          <title>Study design</title>\\n          <p id=\"Par26\">Parallel-group RCTs were included for the analysis.</p>\\n        </sec>\\n        <sec id=\"Sec6\">\\n          <title>Participants</title>\\n          <p id=\"Par27\">Two cohorts of patients (analysed separately) were included: adults (aged&#x2009;&#x2265;&#x2009;18&#xA0;years) with moderate-to-severe CD or adults (aged&#x2009;&#x2265;&#x2009;18&#xA0;years) with moderate-to-severe UC. Patients with unspecified disease severity or those who had undergone intestinal surgery were excluded.</p>\\n        </sec>\\n        <sec id=\"Sec7\">\\n          <title>Interventions</title>\\n          <p id=\"Par28\">We included trials that evaluated infliximab (reference product or biosimilar) or vedolizumab. Dosing regimens were required to align with the summary of product characteristics (SmPC) for approved drugs, or with the SmPC of the originator product for unapproved biosimilars.</p>\\n        </sec>\\n        <sec id=\"Sec8\">\\n          <title>Outcomes</title>\\n          <p id=\"Par29\">Studies that reported one or more of the following outcomes at Week 6 (induction phase) and/or at 1&#xA0;year (Weeks 50&#x2013;54; maintenance phase) were included. Efficacy outcomes for CD included the proportion of patients achieving a Crohn&#x2019;s Disease Activity Index (CDAI)-70 response, defined as a 70&#x2009;&#x2265;&#x2009;points decrease from the baseline value, proportion of patients achieving a CDAI-100 response (a decrease in CDAI score of&#x2009;&#x2265;&#x2009;100 points from the baseline value) and proportion of patients achieving clinical remission (an absolute CDAI score of&#x2009;&lt;&#x2009;150 points). Efficacy outcomes for UC included the proportion of patients achieving clinical response (defined as a decrease from baseline in total Mayo score of&#x2009;&#x2265;&#x2009;3 points and&#x2009;&#x2265;&#x2009;30%, with an accompanying decrease in rectal bleeding subscore of&#x2009;&#x2265;&#x2009;1 point or an absolute rectal bleeding subscore of 0 or 1), proportion of patients achieving clinical remission (a total Mayo score of&#x2009;&#x2264;&#x2009;2 points with no individual subscore exceeding 1 point) and proportion of patients achieving mucosal healing (an absolute endoscopic subscore of 0 or 1 per the Mayo Scoring System). Safety outcomes (CD and UC) included the proportions of patients experiencing any adverse event (AE), serious adverse event (SAE), any infection or serious infection, and the proportion who discontinued due to AEs or lack of efficacy that are evaluated at any point of time in a year.</p>\\n        </sec>\\n      </sec>\\n      <sec id=\"Sec9\">\\n        <title>Study selection</title>\\n        <p id=\"Par30\">Two investigators (HGB, MJ) independently screened the titles and abstracts of the retrieved records (per eligibility criteria in Sect.&#xA0;2.2) to exclude studies that are irrelevant to the research question. A third reviewer (Taek Sang Kwon, Celltrion Healthcare) mediated in the points of disagreement. The third reviewer randomly selected sample of excluded studies to validate appropriate application of the exclusion criteria.</p>\\n        <p id=\"Par31\">Full-text articles of studies identified as potentially relevant for inclusion during title and abstract screening were reviewed independently by two authors HGB and MJ to determine inclusion (recording reasons), and the third reviewer arbitrated in the case of disagreement. Multiple reports of the same study were collected so that studies were the unit of interest for the review. The screening and full-text review process was thoroughly documented to complete a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [<xref ref-type=\"bibr\" rid=\"CR21\">21</xref>].</p>\\n      </sec>\\n      <sec id=\"Sec10\">\\n        <title>Data extraction and management</title>\\n        <p id=\"Par32\">Study characteristics and outcome data were extracted from the included studies and recorded using a Microsoft Excel template (Microsoft Corp., Redmond, WA, USA). The following study characteristics were extracted: design (study duration, randomisation method, blinding), population (demographics, baseline disease activity, number of randomised participants, prior TNFi use, concomitant medication), interventions (type, dose, regimen), and prespecified outcome measures (see above 2.2.4; Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Table 1).</p>\\n      </sec>\\n      <sec id=\"Sec11\">\\n        <title>Data synthesis and measures of treatment effect</title>\\n        <p id=\"Par33\">Data for each prespecified outcome of interest were pooled in two separate analyses for patients with CD or UC, respectively. Outcomes reported as proportions (<italic>n:</italic> event<italic>; N:</italic> population) were analysed, and the overall proportions from each study were combined using a random-effects meta-analysis. A meta-analysis was only performed if studies were deemed to have similar characteristics (e.g., study populations and treatments). The <italic>I</italic><sup>2</sup> statistic was used to evaluate heterogeneity among the trials included in each meta-analysis. All statistical analyses were performed using R (version 4.0.2).</p>\\n      </sec>\\n      <sec id=\"Sec12\">\\n        <title>Quality assessment</title>\\n        <p id=\"Par34\">Risk of bias and generalisability for the included studies were evaluated according to criteria defined in the <italic>Cochrane Handbook for Systematic Reviews of Interventions</italic> [<xref ref-type=\"bibr\" rid=\"CR22\">22</xref>]. The following domains were utilised in order to assess the risk of bias: random sequence generation; allocation concealment; blinding of participants and personnel, blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other bias. Each potential source of bias was rated as high, low, or unclear. Assessments were completed by an author (HGB) responsible for data extraction and checked by a second author (MJ).</p>\\n      </sec>\\n    </sec>\\n    <sec id=\"Sec13\">\\n      <title>Results</title>\\n      <sec id=\"Sec14\">\\n        <title>Search results</title>\\n        <p id=\"Par35\">The selection of studies for inclusion is summarised in a PRISMA flow diagram to illustrate the flow of information for studies enrolling patients with CD (Fig.&#xA0;<xref rid=\"Fig1\" ref-type=\"fig\">1</xref>A). We identified 2,661 records through the searches. After removal of duplicates, 2,019 records were screened (1,855 records excluded) and 164 full-text articles were assessed against the eligibility criteria (150 articles excluded). Six studies (reported in 13 articles) were included in the qualitative synthesis and in the quantitative synthesis, as follows:<list list-type=\"bullet\"><list-item><p id=\"Par36\">Infliximab (four studies): NCT00094458 (SONIC) [<xref ref-type=\"bibr\" rid=\"CR23\">23</xref>&#x2013;<xref ref-type=\"bibr\" rid=\"CR26\">26</xref>], NCT02096861 (PLANET CD) [<xref ref-type=\"bibr\" rid=\"CR6\">6</xref>, <xref ref-type=\"bibr\" rid=\"CR27\">27</xref>], NCT02148640 (NOR-SWITCH) [<xref ref-type=\"bibr\" rid=\"CR28\">28</xref>, <xref ref-type=\"bibr\" rid=\"CR29\">29</xref>], NCT02883452 (CT-P13 SC trial) [<xref ref-type=\"bibr\" rid=\"CR19\">19</xref>].</p></list-item><list-item><p id=\"Par37\">Vedolizumab (two studies): NCT00783692 (GEMINI 2) [<xref ref-type=\"bibr\" rid=\"CR30\">30</xref>&#x2013;<xref ref-type=\"bibr\" rid=\"CR33\">33</xref>], NCT01224171 (GEMINI 3) [<xref ref-type=\"bibr\" rid=\"CR31\">31</xref>, <xref ref-type=\"bibr\" rid=\"CR32\">32</xref>, <xref ref-type=\"bibr\" rid=\"CR34\">34</xref>].</p></list-item></list><fig id=\"Fig1\"><label>Fig. 1</label><caption><p>PRISMA flow diagrams for <bold>A</bold> Crohn&#x2019;s disease and <bold>B</bold> ulcerative colitis. Abbreviation: <italic>PRISMA</italic> Preferred reporting items for systematic reviews and meta-analyses</p></caption><graphic xlink:href=\"12876_2022_2347_Fig1_HTML\" id=\"MO1\"/></fig></p>\\n        <p id=\"Par38\">A PRISMA flow diagram summarising the flow of information for studies enrolling patients with UC is presented in Fig.&#xA0;<xref rid=\"Fig1\" ref-type=\"fig\">1</xref>B. We identified 1,959 records through the electronic searches and one record from another source. Specifically, as data for ACT 1 and 2 study by Adedokun et al. (2018) was not utilizable in our analysis because the article did not evaluate the prespecified timeframe and outcomes of our interest [<xref ref-type=\"bibr\" rid=\"CR35\">35</xref>]. The current review evaluated ACT 1 and 2 data as more data were needed for UC in order to perform meta-analyses in some outcomes (Fig.&#xA0;<xref rid=\"Fig2\" ref-type=\"fig\">2</xref>A, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;11, 12, 18), largely accounting for the fact that infliximab had few available RCT data for the past decade. Thus, we instead have taken data from the reference list of the article as an exception [<xref ref-type=\"bibr\" rid=\"CR5\">5</xref>]. After removal of duplicates, 1,138 records were screened (894 articles excluded) and 244 full-text articles were assessed against the eligibility criteria (232 articles excluded). Seven studies (reported in 12 articles) were included in the qualitative synthesis and quantitative analyses, as follows:<list list-type=\"bullet\"><list-item><p id=\"Par39\">Infliximab (four studies): NCT00036439 (ACT1) [<xref ref-type=\"bibr\" rid=\"CR5\">5</xref>, <xref ref-type=\"bibr\" rid=\"CR35\">35</xref>], NCT00096655 (ACT2) [<xref ref-type=\"bibr\" rid=\"CR5\">5</xref>, <xref ref-type=\"bibr\" rid=\"CR35\">35</xref>], NCT02148640 (NOR-SWITCH) [<xref ref-type=\"bibr\" rid=\"CR28\">28</xref>, <xref ref-type=\"bibr\" rid=\"CR29\">29</xref>], NCT02883452 (CT-P13 SC trial) [<xref ref-type=\"bibr\" rid=\"CR19\">19</xref>].</p></list-item><list-item><p id=\"Par40\">Vedolizumab (three studies): NCT00783718 (GEMINI 1) [<xref ref-type=\"bibr\" rid=\"CR36\">36</xref>&#x2013;<xref ref-type=\"bibr\" rid=\"CR40\">40</xref>], NCT02497469 (VARSITY) [<xref ref-type=\"bibr\" rid=\"CR41\">41</xref>], NCT02611830 (VISIBLE 1) [<xref ref-type=\"bibr\" rid=\"CR42\">42</xref>].</p></list-item></list><fig id=\"Fig2\"><label>Fig. 2</label><caption><p>Quality assessment results for studies contributing data to the analyses for <bold>A</bold> Crohn&#x2019;s disease and <bold>B</bold> ulcerative colitis. Panel <bold>A</bold>: Risk of bias determined based on assessment of the following study publications: SONIC, NOR-SWITCH, GEMINI 2, GEMINI 3, CT-P13 SC trial, and PLANET CD. Abbreviation: SC, subcutaneous. Panel <bold>B</bold>: Risk of bias determined based on assessment of the following study publications: GEMINI 1, NOR- SWITCH, ACT 1, ACT 2, VISIBLE 1, VARSITY, and CT-P13 SC trial. Abbreviation: SC, subcutaneous</p></caption><graphic xlink:href=\"12876_2022_2347_Fig2_HTML\" id=\"MO2\"/></fig></p>\\n      </sec>\\n      <sec id=\"Sec15\">\\n        <title>Study characteristics</title>\\n        <sec id=\"Sec16\">\\n          <title>Studies contributing to CD analyses</title>\\n          <p id=\"Par41\">The design and eligibility criteria of the six studies that contributed data to the CD analyses were generally consistent (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Table 1). All six studies were randomised trials with a duration of&#x2009;&#x2265;&#x2009;50&#xA0;weeks: five studies included a double-blind period, and one study was conducted using an open-label design (CT-P13 SC trial). Two of the six studies included an open-label extension (NOR-SWITCH and GEMINI&#xA0;3) and three studies (PLANET CD, NOR-SWITCH and CT-P13) included switching phases wherein participants switched between infliximab products. Five of six studies were multinational, whereas one study was conducted in Norway (NOR-SWITCH).</p>\\n          <p id=\"Par42\">Across studies, inclusion criteria required participants to be adults (aged&#x2009;&#x2265;&#x2009;18) with a diagnosis of CD; four of six studies required participants to have a CDAI score of 220&#x2013;450, one study (GEMINI 3) specified 220&#x2013;400 and another (NOR-SWITCH) did not specify a CDAI score. Prior TNFi use was not permitted in three studies (SONIC, PLANET CD, CT-P13 SC trial), stable treatment with infliximab for&#x2009;&#x2265;&#x2009;6&#xA0;months was an inclusion criterion in NOR-SWITCH, and treatment failure with corticosteroids, immunosuppressive agents or TNFis was an inclusion criterion for GEMINI 2 and GEMINI 3 (within the past 5&#xA0;years).</p>\\n          <p id=\"Par43\">All studies included a treatment arm of either infliximab or vedolizumab. An intravenous formulation of infliximab or vedolizumab was initially administered at Weeks 0, 2, and 6 for induction and every 8&#xA0;weeks (Q8W) thereafter while a subcutaneous formulation of infliximab was initially administered at Weeks 0 and 2 for induction and every 2&#xA0;weeks (Q2W) from Week 6 [<xref ref-type=\"bibr\" rid=\"CR43\">43</xref>, <xref ref-type=\"bibr\" rid=\"CR44\">44</xref>].</p>\\n          <p id=\"Par44\">A total of 2,020 participants were initially randomised/assigned to relevant treatment arms of the selected studies. The mean/median age ranged from 32.0 to 39.5&#xA0;years, 39% to 56% of participants were female, mean/median body weight ranged from 66.1 to 72.0&#xA0;kg (where reported) and mean/median disease duration ranged from 2.2 to 14.3&#xA0;years (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Table&#xA0;2).</p>\\n        </sec>\\n        <sec id=\"Sec17\">\\n          <title>Studies contributing to UC analyses</title>\\n          <p id=\"Par45\">The design and eligibility criteria of the seven studies that contributed data to the UC analyses were generally consistent (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Table 1). All seven studies were randomised trials with a duration of&#x2009;&#x2265;&#x2009;46&#xA0;weeks, except for ACT2 (22&#xA0;weeks): six studies included double-blind periods and one study was open-label (CT-P13 SC trial). Two studies included an open-label extension (NOR-SWITCH and VISIBLE 1). Three studies included switching phases wherein participants switched between infliximab products (NOR-SWITCH and CT-P13 SC trial) or between IV and SC vedolizumab (VISIBLE 1). Six of the seven studies were multinational, whereas one study (NOR-SWITCH) was conducted in Norway.</p>\\n          <p id=\"Par46\">Across studies, inclusion criteria required participants to be adults (aged&#x2009;&#x2265;&#x2009;18&#xA0;years) with active UC (Mayo score 6&#x2013;12 and endoscopic sub-score&#x2009;&#x2265;&#x2009;2) despite treatment with conventional therapies (e.g., corticosteroids, azathioprine or mercaptopurine). Prior TNFi treatment was not permitted in four studies (ACT 1, ACT 2, CT-P13 SC trial and VARSITY), stable treatment with infliximab for&#x2009;&#x2265;&#x2009;6&#xA0;months was an inclusion criterion in NOR-SWITCH and use of TNFi and biological agents were not permitted within 60&#xA0;days before study initiation in GEMINI 1 and VISIBLE 1, respectively.</p>\\n          <p id=\"Par47\">Four of the seven studies evaluated infliximab (ACT&#xA0;1, ACT 2, NOR-SWITCH and CT-P13 SC trial) and three evaluated vedolizumab (GEMINI 1, VISIBLE 1 and VARSITY). All of the infliximab studies included a treatment arm wherein infliximab was administered at Weeks 0, 2 and 6 (induction) and Q8W thereafter (maintenance) except for the CT-P13 SC trial. The CT-P13 SC trial included evaluation of subcutaneous infliximab Q2W from Week 6 following IV induction at Weeks 0 and 2 (see Sect.&#xA0;3.2.1). All of the vedolizumab studies included a treatment arm wherein IV vedolizumab was administered at Weeks 0, 2, and 6 and Q8W thereafter except for one study that included a treatment arm wherein IV vedolizumab was administered at Weeks 0 and 2 for induction, followed by SC vedolizumab Q2W from Week 6.</p>\\n          <p id=\"Par48\">A total of 1,999 participants were initially randomised to relevant treatment arms of the included studies. The mean/median age ranged from 33.0 to 45.8&#xA0;years, 30% to 46% of participants were female, mean/median body weight ranged from 66.1 to 80.0&#xA0;kg (where reported) and mean/median disease duration ranged from 5.7 to 11.5&#xA0;years (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Table&#xA0;3).</p>\\n        </sec>\\n      </sec>\\n      <sec id=\"Sec18\">\\n        <title>Risk of bias and generalisability in the included studies</title>\\n        <p id=\"Par49\">A summary of the risk-of-bias assessment for studies contributing to the CD analyses is presented in Fig.&#xA0;<xref rid=\"Fig3\" ref-type=\"fig\">3</xref>A. Across 42 assessments (six studies and seven risk-of-bias domains), 29 were considered to be at low risk of bias, 10 at high risk and three to have an unclear risk of bias. All six studies had low risk of bias for random sequence generation and selective reporting. NOR-SWITCH was the only study considered at low or unclear risk of bias for all domains. Most studies (five out of six) had one or more domains considered to be at high risk, and the CT-P13 SC and GEMINI 2 trials were at high risk of bias for three and four domains, respectively. The CT-P13 SC study was considered to be at high risk of bias due to the nature of an open-label trial and the results were combined as inflammatory bowel disease, not categorized into CD and UC. GEMINI 2, NOR-SWITCH, and PLANET CD were considered to be at high risk of &#x2018;other bias&#x2019; because of the selective inclusion of induction responders in the maintenance phase; notably, this high risk of bias applies only to the maintenance-phase data for these studies as the induction phase included all enrolled patients.<fig id=\"Fig3\"><label>Fig. 3</label><caption><p><bold>A</bold> A comparison of infliximab versus vedolizumab for key efficacy outcomes in patients with Crohn&#x2019;s disease. Abbreviation: CDAI, Crohn&#x2019;s Disease Activity Index; IFX, infliximab; VDZ, vedolizumab. <bold>B</bold> A comparison of infliximab versus vedolizumab for key efficacy outcomes in patients with ulcerative colitis. Abbreviation: IFX, infliximab; VDZ, vedolizumab</p></caption><graphic xlink:href=\"12876_2022_2347_Fig3_HTML\" id=\"MO3\"/></fig></p>\\n        <p id=\"Par50\">Figure&#xA0;<xref rid=\"Fig3\" ref-type=\"fig\">3</xref>B presents a summary of the risk-of-bias assessment for studies contributing to the UC analyses. Across 49 assessments (seven studies and seven risk-of-bias domains), 36 were considered to be at low risk of bias, nine at high risk and four to have an unclear risk of bias. All seven studies were considered to be at low risk of bias for random sequence generation and selective reporting. Four studies were considered at low or unclear risk of bias for all domains (VARSITY, ACT&#xA0;1, ACT 2, NOR-SWITCH). Three studies had three domains considered to be at high risk of bias (GEMINI 1, VISIBLE 1, CT-P13 SC trial). The results from CT-P13 SC trial have the same risk of bias as CD such as having an open-label study design and did not fully categorised the safety outcomes. GEMINI 1 and VISIBLE 1 were considered to be at high risk of &#x2018;other bias&#x2019; because of the selective inclusion of induction responders in the maintenance phase; again, this high risk of bias applies only to the maintenance-phase data for these studies as the induction phase included all enrolled patients.</p>\\n      </sec>\\n      <sec id=\"Sec19\">\\n        <title>Comparative efficacy and safety between the treatments in treating IBD</title>\\n        <p id=\"Par51\">A summary of findings for the meta-analyses for infliximab and vedolizumab in patients with CD is presented in Table <xref rid=\"Tab1\" ref-type=\"table\">1</xref>. For most efficacy outcomes during the induction and maintenance phases, infliximab yielded better efficacy than vedolizumab, with non-overlapping 95% confidence intervals (CIs) (Fig.&#xA0;<xref rid=\"Fig4\" ref-type=\"fig\">4</xref>A). During the induction phase, pooled results for efficacy outcomes in patients with CD showed that a higher proportion of patients treated with infliximab achieved a CDAI-70 response, CDAI-100 response or clinical remission with non-overlapping 95% CIs, in comparison with patients treated with vedolizumab (Fig.&#xA0;<xref rid=\"Fig5\" ref-type=\"fig\">5</xref>A, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;1&#x2013;2). In the maintenance phase, a CDAI-70 response was not reported for vedolizumab, so only the data for infliximab is presented (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;3); a numerical advantage with overlapping 95% CIs was observed with infliximab over vedolizumab for CDAI-100 and clinical remission (Fig.&#xA0;<xref rid=\"Fig5\" ref-type=\"fig\">5</xref>B, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;4). Pooled results for safety outcomes (Fig.&#xA0;<xref rid=\"Fig6\" ref-type=\"fig\">6</xref>A; Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;5&#x2013;10) showed that the proportions of patients experiencing AEs, SAEs, or who discontinued due to AEs were similar in infliximab- and vedolizumab-treated patients. A higher rate of infection was reported with infliximab; however, when it comes to serious infections, similar rates between infliximab and vedolizumab are observed. Six percent of patients treated with infliximab discontinued because the treatment was ineffective (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;10) while one study was available for vedolizumab, where almost one-third of patients (37.7%) discontinued vedolizumab treatment due to lack of efficacy in the maintenance phase [<xref ref-type=\"bibr\" rid=\"CR30\">30</xref>].<table-wrap id=\"Tab1\"><label>Table 1</label><caption><p>Comparative efficacy and safety between infliximab and vedolizumab in patients with Crohn&#x2019;s disease</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Outcome</th><th align=\"left\">Treatment</th><th align=\"left\">Participants, <italic>N</italic></th><th align=\"left\">Infliximab, estimate (95% CI)<sup>a</sup></th><th align=\"left\">Heterogeneity (%)</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"5\">Efficacy: Induction phase (Week 6)</td></tr><tr><td align=\"left\" rowspan=\"2\">CDAI-70</td><td align=\"left\">Infliximab</td><td align=\"left\">220</td><td align=\"left\">72% (66%, 77%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">214</td><td align=\"left\">45% (32%, 60%)</td><td align=\"left\">89</td></tr><tr><td align=\"left\" rowspan=\"2\">CDAI-100</td><td align=\"left\">Infliximab</td><td align=\"left\">273</td><td align=\"left\">62% (56%, 68%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">423</td><td align=\"left\">36% (29%, 44%)</td><td align=\"left\">68</td></tr><tr><td align=\"left\" rowspan=\"2\">Clinical remission</td><td align=\"left\">Infliximab</td><td align=\"left\">611</td><td align=\"left\">38% (32%, 45%)</td><td align=\"left\">69</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">423</td><td align=\"left\">17% (12%, 24%)</td><td align=\"left\">71</td></tr><tr><td align=\"left\" colspan=\"5\">Efficacy: Maintenance phase (Week 50 to 54)</td></tr><tr><td align=\"left\">CDAI-70</td><td align=\"left\">Infliximab</td><td align=\"left\">220</td><td align=\"left\">74% (68%, 79%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\" rowspan=\"2\">CDAI-100</td><td align=\"left\">Infliximab</td><td align=\"left\">273</td><td align=\"left\">70% (64%, 75%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">148</td><td align=\"left\">44% (24%, 67%)</td><td align=\"left\">93</td></tr><tr><td align=\"left\" rowspan=\"2\">Clinical remission</td><td align=\"left\">Infliximab</td><td align=\"left\">611</td><td align=\"left\">54% (48%, 60%)</td><td align=\"left\">57</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">148</td><td align=\"left\">39% (24%, 56%)</td><td align=\"left\">88</td></tr><tr><td align=\"left\" colspan=\"5\">Safety (&#x2264;&#x2009;1&#xA0;year)</td></tr><tr><td align=\"left\" rowspan=\"2\">Any AE</td><td align=\"left\">Infliximab</td><td align=\"left\">717</td><td align=\"left\">75% (66%, 83%)</td><td align=\"left\">86</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">985</td><td align=\"left\">78% (59%, 90%)</td><td align=\"left\">98</td></tr><tr><td align=\"left\" rowspan=\"2\">Any SAE</td><td align=\"left\">Infliximab</td><td align=\"left\">717</td><td align=\"left\">12% (8%, 17%)</td><td align=\"left\">65</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">993</td><td align=\"left\">16% (8%, 30%)</td><td align=\"left\">93</td></tr><tr><td align=\"left\" rowspan=\"2\">Any infection</td><td align=\"left\">Infliximab</td><td align=\"left\">717</td><td align=\"left\">29% (22%, 37%)</td><td align=\"left\">80</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">427</td><td align=\"left\">17% (14%, 21%)</td><td align=\"left\">24</td></tr><tr><td align=\"left\" rowspan=\"2\">Any serious infection</td><td align=\"left\">Infliximab</td><td align=\"left\">562</td><td align=\"left\">4% (2%, 6%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">985</td><td align=\"left\">4% (2%, 8%)</td><td align=\"left\">67</td></tr><tr><td align=\"left\" rowspan=\"2\">Discontinuation due to AE</td><td align=\"left\">Infliximab</td><td align=\"left\">717</td><td align=\"left\">6% (3%, 12%)</td><td align=\"left\">79</td></tr><tr><td align=\"left\">Vedolizumab</td><td align=\"left\">976</td><td align=\"left\">7% (3%, 15%)</td><td align=\"left\">84</td></tr><tr><td align=\"left\">Discontinuation due to lack of efficacy</td><td align=\"left\">Infliximab</td><td align=\"left\">311</td><td align=\"left\">6% (4%, 10%)</td><td align=\"left\">49</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Random-effects model</p><p>All results reported as the proportion of patients achieving the response</p><p>AE Adverse event, <italic>CDAI</italic> Crohn&#x2019;s disease activity index, <italic>CI</italic> Confidence interval, <italic>SAE</italic> Serious adverse event</p></table-wrap-foot></table-wrap><fig id=\"Fig4\"><label>Fig. 4</label><caption><p><bold>A</bold> A comparison of infliximab versus vedolizumab for key safety outcomes in patients with Crohn&#x2019;s disease (&#x2264;&#x2009;1&#xA0;year) Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumab. <bold>B</bold>. A comparison of infliximab versus vedolizumab for key safety outcomes in patients with ulcerative colitis (&#x2264;&#x2009;1&#xA0;year). Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumab</p></caption><graphic xlink:href=\"12876_2022_2347_Fig4_HTML\" id=\"MO4\"/></fig><fig id=\"Fig5\"><label>Fig. 5</label><caption><p>Forest plots showing the proportion of patients with Crohn&#x2019;s disease achieving clinical remission during <bold>A</bold> the induction phase and <bold>B</bold> the maintenance phase with infliximab (upper plot) or vedolizumab (lower plot). Panel A SONIC (a): IFX IV (corticosteroid free); SONIC (b): combination therapy; PLANET CD (a): patients with CT-P13 IV only; PLANET CD (b): patients with CT-P13 IV and IFX IV; GEMINI 2 (a): VDZ before TNFi; GEMINI 2 (b): VDZ after TNFi failure; GEMINI 3 (a): VDZ IV before TNFi; GEMINI 3 (b): VDZ IV after TNFi failure. Abbreviation: CI, confidence interval; IFX, infliximab; IV, intravenous; TNFi, tumour necrosis factor-&#x3B1; inhibitor; VDZ, vedolizumab. Panel B SONIC (a): IFX IV (corticosteroid free); SONIC (b): combination therapy; PLANET CD (a): CT-P13 IV only; PLANET CD (b): CT-P13 IV switch to IFX IV; PLANET CD (c): IFX IV only; PLANET CD (d): IFX IV switch to CT-P13 IV; CT-P13 SC trial (a): CT-P13 SC only; CT-P13 SC trial (b): CT-P13 IV switch to CT-P13 SC; GEMINI 2 (a): VDZ before TNFi; GEMINI 2 (b): VDZ after TNFi failure. Abbreviation: CI, confidence interval; IFX, infliximab; IV, intravenous; SC, subcutaneous; TNFi, tumour necrosis factor-&#x3B1; inhibitor; VDZ, vedolizumab</p></caption><graphic xlink:href=\"12876_2022_2347_Fig5_HTML\" id=\"MO5\"/></fig><fig id=\"Fig6\"><label>Fig. 6</label><caption><p>Forest plots showing the proportion of patients with ulcerative colitis achieving clinical remission during <bold>A</bold> the induction phase and <bold>B</bold> the maintenance phase with infliximab (upper plot) or vedolizumab (lower plot). Panel <bold>A</bold> Abbreviation: CI, confidence interval. Panel <bold>B</bold> CT-P13 SC trial (a): CT-P13 SC only; CT-P13 SC trial (b): CT-P13 IV switch to CT-P13 SC; VISIBLE 1 (a): VDZ SC; VISIBLE 1 (b): VDZ IV Abbreviation: CI, confidence interval; IV, intravenous; SC, subcutaneous</p></caption><graphic xlink:href=\"12876_2022_2347_Fig6_HTML\" id=\"MO6\"/></fig></p>\\n        <p id=\"Par52\">The findings for the meta-analyses for infliximab and vedolizumab in patients with UC are presented in Figs.&#xA0;<xref rid=\"Fig4\" ref-type=\"fig\">4</xref>B and <xref rid=\"Fig6\" ref-type=\"fig\">6</xref>B (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;11&#x2013;20), with a summary presented in Table <xref rid=\"Tab2\" ref-type=\"table\">2</xref>. Pooled results for efficacy outcomes in patients with UC showed that in the induction phase, a higher proportion of patients treated with infliximab achieved a clinical response or clinical remission with non-overlapping 95% CIs, compared with patients treated with vedolizumab (Fig.&#xA0;<xref rid=\"Fig2\" ref-type=\"fig\">2</xref>A, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;11). In the maintenance phase, similar proportions of patients treated with infliximab or vedolizumab achieved a clinical response, clinical remission or mucosal healing, with overlapping 95% CIs (Fig.&#xA0;<xref rid=\"Fig2\" ref-type=\"fig\">2</xref>B; Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;13&#x2013;14). Pooled results for safety outcomes showed that the proportions of patients experiencing AEs or infections, or who discontinued due to AEs, were similar in the infliximab and vedolizumab groups (Fig.&#xA0;<xref rid=\"Fig6\" ref-type=\"fig\">6</xref>B; Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Figs.&#xA0;15&#x2013;20); rates of SAEs and serious infections were also similar with overlapping 95% CIs. Fourteen percent of patients with vedolizumab discontinued due to lack of efficacy (Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;20); no available was available for infliximab.<table-wrap id=\"Tab2\"><label>Table 2</label><caption><p>Comparative efficacy and safety between infliximab and vedolizumab in patients with ulcerative colitis</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Outcome</th><th align=\"left\">Treatment</th><th align=\"left\">Participants, <italic>N</italic></th><th align=\"left\">Infliximab and biosimilars, estimate (95% CI)<sup>a</sup></th><th align=\"left\">Heterogeneity (%)</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"5\">Efficacy: Induction phase (Week 6)</td></tr><tr><td align=\"left\">Clinical response<sup>b</sup></td><td align=\"left\">Infliximab</td><td align=\"left\">242</td><td align=\"left\">67% (61%, 73%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">608</td><td align=\"left\">52% (46%, 58%)</td><td align=\"left\">78</td></tr><tr><td align=\"left\">Mucosal healing</td><td align=\"left\">Infliximab</td><td align=\"left\">242</td><td align=\"left\">61% (55%, 67%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Clinical remission<sup>b</sup></td><td align=\"left\">Infliximab</td><td align=\"left\">242</td><td align=\"left\">36% (31%, 43%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">608</td><td align=\"left\">21% (16%, 28%)</td><td align=\"left\">82</td></tr><tr><td align=\"left\" colspan=\"5\">Efficacy: Maintenance phase (Week 50 to 54)</td></tr><tr><td align=\"left\">Clinical response<sup>b</sup></td><td align=\"left\">Infliximab</td><td align=\"left\">198</td><td align=\"left\">54% (43%, 65%)</td><td align=\"left\">62</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">282</td><td align=\"left\">63% (56%, 69%)</td><td align=\"left\">51</td></tr><tr><td align=\"left\">Mucosal healing</td><td align=\"left\">Infliximab</td><td align=\"left\">198</td><td align=\"left\">49% (43%, 56%)</td><td align=\"left\">2</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">665</td><td align=\"left\">49% (42%, 57%)</td><td align=\"left\">78</td></tr><tr><td align=\"left\">Clinical remission<sup>b</sup></td><td align=\"left\">Infliximab</td><td align=\"left\">198</td><td align=\"left\">43% (33%, 54%)</td><td align=\"left\">60</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">665</td><td align=\"left\">39% (33%, 46%)</td><td align=\"left\">73</td></tr><tr><td align=\"left\" colspan=\"5\">Safety (&#x2264;&#x2009;1&#xA0;year)</td></tr><tr><td align=\"left\">Any AE</td><td align=\"left\">Infliximab</td><td align=\"left\">214</td><td align=\"left\">75% (60%, 86%)</td><td align=\"left\">86</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">543</td><td align=\"left\">64% (60%, 68%)</td><td align=\"left\">44</td></tr><tr><td align=\"left\">Any SAE</td><td align=\"left\">Infliximab</td><td align=\"left\">214</td><td align=\"left\">12% (6%, 23%)</td><td align=\"left\">72</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">543</td><td align=\"left\">11% (9%, 14%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Any infection</td><td align=\"left\">Infliximab</td><td align=\"left\">214</td><td align=\"left\">21% (8%, 43%)</td><td align=\"left\">91</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">543</td><td align=\"left\">26% (22%, 29%)</td><td align=\"left\">14</td></tr><tr><td align=\"left\">Any serious infection</td><td align=\"left\">Infliximab</td><td align=\"left\">242</td><td align=\"left\">2% (1%, 5%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">489</td><td align=\"left\">2% (1%, 3%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Discontinuation due to AE</td><td align=\"left\">Infliximab</td><td align=\"left\">214</td><td align=\"left\">4% (1%, 14%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\"/><td align=\"left\">Vedolizumab</td><td align=\"left\">667</td><td align=\"left\">5% (3%, 7%)</td><td align=\"left\">0</td></tr><tr><td align=\"left\">Discontinuation due to lack of efficacy</td><td align=\"left\">Vedolizumab</td><td align=\"left\">667</td><td align=\"left\">15% (10%, 22%)</td><td align=\"left\">82</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Random-effects model</p><p><sup>b</sup> Based on total Mayo score</p><p>All results reported as the proportion of patients achieving the response</p><p>AE Adverse event, <italic>CDAI</italic> Crohn&#x2019;s disease activity index, CI Confidence interval, <italic>SAE</italic> Serious adverse event</p></table-wrap-foot></table-wrap></p>\\n      </sec>\\n    </sec>\\n    <sec id=\"Sec20\">\\n      <title>Discussion</title>\\n      <p id=\"Par53\">The present study is the first systematic review to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe CD or moderate-to-severe UC in order to address a lack of evidence of a direct comparison between the treatments. Data were extracted and pooled for the prespecified outcomes of interest at the corresponding 6-week and/or 50- to 54-week timepoints, respectively. Notably, the present evidence synthesis is the first to our knowledge to incorporate data for CT-P13 SC, an SC formulation of the infliximab.</p>\\n      <p id=\"Par54\">Our results show that infliximab yielded better efficacy than vedolizumab for all the efficacy outcomes in patients with CD or UC during the induction phase, and comparable clinical efficacies with overlapping 95% CI in both diseases during the maintenance phase. The safety profiles of infliximab and vedolizumab in both cohorts were generally similar in terms of the proportions of patients experiencing AEs, SAEs, infection, and serious infection, as well as the rates of discontinuations due to AEs in the analysed study period.</p>\\n      <p id=\"Par55\">Based on the demographics and clinical characteristics of the study populations contributing to the review, the present findings are applicable to patients with moderate-to-severe CD or UC and support the use of infliximab as a first-line biologic in these populations, per guideline recommendations. The quality of the evidence was broadly considered to be moderate to high on the guidelines. Prespecified outcomes of interest were well reported in the included studies, and meta-analyses included&#x2009;&#x2265;&#x2009;200 patients for the majority of outcomes evaluated.</p>\\n      <p id=\"Par56\">Risk of bias in the included studies was principally considered to be low or was unclear (i.e. due to a lack of necessary information in the study reports). However, several studies were considered to be at high risk of &#x2018;other bias&#x2019;. Notably, the GEMINI 1 [<xref ref-type=\"bibr\" rid=\"CR36\">36</xref>], GEMINI&#xA0;2 [<xref ref-type=\"bibr\" rid=\"CR30\">30</xref>], VISIBLE 1 [<xref ref-type=\"bibr\" rid=\"CR42\">42</xref>], and PLANETCD [<xref ref-type=\"bibr\" rid=\"CR6\">6</xref>] studies were considered to be at high risk of bias on the basis of only including patients in the maintenance phase if they had responded during the induction phase (i.e. at 6&#xA0;weeks). This practice may potentially lead to overestimation of efficacy in the maintenance phase and overall safety, compared with studies in which both responders and non-responders were included in the maintenance phase. Therefore, the data relating to non-responders&#x2019; efficacy in infliximab (NOR-SWITCH and PLANETCD) and vedolizumab (GEMINI 1, GEMINI 2, and VISIBLE 1) during maintenance phase may not be generalized. Future studies should address the limitation of selectively progressing responders to the maintenance period, to permit transparent comparability of biological agents available for the treatment of IBD.</p>\\n      <p id=\"Par57\">The level of heterogeneity observed within the meta-analyses was generally high, with <italic>I</italic><sup><italic>2</italic></sup> values exceeding 60% in a number of instances. This was likely influenced by the inclusion of studies with heterogeneous populations (e.g., TNFi-na&#xEF;ve patients and patients who had not responded adequately to prior TNFi therapy), as evidenced by the broad range of median disease durations reported across studies. It was not possible to conduct sensitivity analyses to address the source of heterogeneity due to small amount of available data. Likewise, the head-to-head trial is in need to address biases among the population and different study designs.</p>\\n      <p id=\"Par58\">Several systematic reviews have examined the efficacy and/or safety of infliximab and vedolizumab in IBD. Our results confirm a prior comparative effectiveness and safety study in CD [<xref ref-type=\"bibr\" rid=\"CR45\">45</xref>]. A study by Singh et al. (2018) concluded that infliximab was ranked highest among biological therapies for induction and maintenance of clinical remission [<xref ref-type=\"bibr\" rid=\"CR45\">45</xref>]. When comparing infliximab and vedolizumab in TNF-na&#xEF;ve patients, infliximab yielded significantly better clinical response rates during the induction phase (Odds ratio (OR) 95% confidence interval [CI]: 0.08 [0.02&#x2009;&#x2212;&#x2009;0.36]) and numerical advantages in clinical remission rates during both induction and maintenance phases (OR [95% CI]: induction 0.46 [0.16&#x2009;&#x2212;&#x2009;1.26], maintenance 0.81 [0.39&#x2009;&#x2212;&#x2009;1.67]). Consistent with these findings, the present study demonstrated the similar patterns of outcomes even when we included the most recent data from infliximab and vedolizumab studies (i.e., VISIBLE, VARSITY, the CT-P13 SC trial).</p>\\n      <p id=\"Par59\">In UC, two network meta-analyses and one meta-analysis were conducted. The most recent network meta-analysis by Zhou et al. (2021) found no significant difference between vedolizumab and infliximab on clinical response [<xref ref-type=\"bibr\" rid=\"CR18\">18</xref>]. Zhou and colleagues also found no difference between the treatments in clinical remission rates during induction phase [<xref ref-type=\"bibr\" rid=\"CR18\">18</xref>], while Singh et al. reported a better clinical remission rate of infliximab in biologic-na&#xEF;ve patients (OR [95% CI]: clinical remission 0.62 [0.34&#x2009;&#x2212;&#x2009;1.15]) [<xref ref-type=\"bibr\" rid=\"CR46\">46</xref>]. The present study is in line with the clinical remission results of the past studies.</p>\\n      <p id=\"Par60\">According to Zhou, endoscopic improvement rates were higher in infliximab compared to vedolizumab in biologic-na&#xEF;ve patients during induction therapy in UC (OR [95% CI]: 0.76 [0.42&#x2009;&#x2212;&#x2009;1.37]) [<xref ref-type=\"bibr\" rid=\"CR46\">46</xref>]; however, research by Cholapranee et al. (2017) reported that vedolizumab had higher mucosal healing rates than infliximab in the induction phase (OR [95% CI]: 0.63 [0.29&#x2009;&#x2212;&#x2009;1.41]) [<xref ref-type=\"bibr\" rid=\"CR17\">17</xref>]. Nevertheless, vedolizumab resulted in lower rates of mucosal healing compared to infliximab during the maintenance phase (OR [95% CI]: 1.17 [0.35&#x2013;3.84]) [<xref ref-type=\"bibr\" rid=\"CR17\">17</xref>]. The mucosal healing rates were numerically similar in the maintenance phase in the current study which disagrees to the prior meta-analyses. The reason for such a discrepancy may be due to the fact that the timeframe of our interest was different from the other studies.</p>\\n      <p id=\"Par61\">Concerning the safety outcomes in patients with UC, Zhou and colleagues found that vedolizumab resulted in fewer occurrences of adverse events than infliximab (relative risk (RR): 0.79 [0.62&#x2009;&#x2212;&#x2009;0.94]) [<xref ref-type=\"bibr\" rid=\"CR18\">18</xref>]. Although insignificant, the serious adverse events were lower in vedolizumab; and a lower risk of infections was found in infliximab during maintenance therapy (RR [95% CI]: serious adverse event 1.12 [0.58&#x2009;&#x2212;&#x2009;2.14], infection 0.80 [0.48&#x2009;&#x2212;&#x2009;1.34]). The results conform to our safety outcomes, but in the current study, the proportions of patients experiencing serious adverse event and serious infection were comparable between the treatments with overlapping 95% CIs.</p>\\n      <p id=\"Par62\">Narula and colleagues reported a post-hoc analysis of three UC clinical trial programmes, to compare the efficacy of infliximab and vedolizumab in patients with moderate-to-severe biologic-na&#xEF;ve UC. Broadly in agreement with the findings of the present review, the authors reported higher 1-year rates of clinical remission (corticosteroid free) and endoscopic remission with infliximab in comparison with vedolizumab, although the agents appeared to have similar efficacy in clinical symptom improvement [<xref ref-type=\"bibr\" rid=\"CR27\">27</xref>].</p>\\n      <p id=\"Par63\">Strengths of the present review process include prospective registration of the protocol (as documented on PROSPERO [<xref ref-type=\"bibr\" rid=\"CR20\">20</xref>], comprehensive electronic searches and assessment of the included studies for risk of bias using gold-standard methods. Potential limitations of the review process include that a study was incorporated from outside of the prespecified time limits (to replace a recent article reporting data from the ACT 1 and ACT 2 studies); only articles published from 2010 onwards were used to ensure inclusion of studies relevant to current treatment practices, although we note that clinical practice continually evolves. For example, more recently, higher 10&#xA0;mg/kg doses of infliximab are used in severe cases of IBD, and trough levels are actively monitored [<xref ref-type=\"bibr\" rid=\"CR47\">47</xref>]. Such practices would tend to favour infliximab over vedolizumab, both in terms of observed efficacy and safety (e.g., monitoring of trough levels helps to reduce the risk of infusion reaction during induction phase and loss of response).</p>\\n      <p id=\"Par64\">During the review process, we also noted that several studies were not registered, and results were thus untraceable, potentially leading to omission of some relevant data. Furthermore, some studies were excluded from the present review because the timepoints assessed did not match those prespecified in the review protocol. This omission of potentially valuable data highlights the need to standardise future study designs. The present review did not assess longer-term follow-up (i.e., beyond 1&#xA0;year) despite a sustained response being important to patients. Longer-term follow-up in larger real-world cohorts may also be more relevant to analyse safety.</p>\\n      <p id=\"Par65\">Finally, the included studies enrolled different proportions of patients with previous biological treatment failure (potentially accounting for between-study differences in efficacy and accounting for some of the observed heterogeneity). Different proportions of TNFi-experienced patients in vedolizumab treatment groups compared to infliximab treatment group, which consists of TNF-na&#xEF;ve patients only. For instance, taking the VARSITY trial into account exhibited different results for vedolizumab. The VARSITY trial is a head-to-head trial that compared the efficacy and safety between adalimumab and vedolizumab in TNF-na&#xEF;ve patients with UC. Higher clinical response and remission rates were achieved during induction on the VARSITY trial in comparison with GEMINI 1 (Fig.&#xA0;<xref rid=\"Fig2\" ref-type=\"fig\">2</xref>A, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;11). On the other hand, considerably lower rates of mucosal healing and clinical remission were found in the VARSITY trial compared with the VISIBLE and GEMINI 1 during the maintenance phase (Fig.&#xA0;<xref rid=\"Fig2\" ref-type=\"fig\">2</xref>B, Additional file <xref rid=\"MOESM1\" ref-type=\"media\">1</xref>: Fig.&#xA0;14). Largely accounting for the fact that the VISIBLE and GEMINI 1 studies included Week 6 responders only to the maintenance phase, while the VARSITY trial included patients regardless of Week 6 responsiveness.</p>\\n      <p id=\"Par66\">Despite limitations in the evidence, the present systematic review represents an up-to-date evaluation of data from RCTs of infliximab and vedolizumab in IBD, capturing important new data from recently published studies.</p>\\n    </sec>\\n    <sec id=\"Sec21\">\\n      <title>Conclusions</title>\\n      <p id=\"Par67\">Indirect comparison of infliximab and vedolizumab based on RCT data for the treatment of patients with IBD demonstrated that infliximab has significantly better efficacy in the induction phase, and comparable efficacy during the maintenance phase. A comparable safety profile including serious adverse event and serious infection between infliximab and vedolizumab was found over a year.</p>\\n    </sec>\\n    <sec sec-type=\"supplementary-material\">\\n      <title>Supplementary Information</title>\\n      <sec id=\"Sec22\">\\n        <p>\\n<supplementary-material content-type=\"local-data\" id=\"MOESM1\"><media xlink:href=\"12876_2022_2347_MOESM1_ESM.docx\"><caption><p><bold>Additional file1: Table S1</bold>. Characteristics of the included studies (detailed). <bold>Table S2</bold>. Baseline characteristics of participants with CD. <bold>Table S3</bold>. Baseline characteristics of participants with UC. <bold>Figure S1</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease achieving a CDAI-70 response during the induction phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S2</bold>. Forest plots showing the proportion of with Crohn&#x2019;s disease achieving a CDAI-100 response during the induction phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S3</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease achieving a CDAI-70 response during the maintenance phase with infliximab. <bold>Figure S4</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease achieving a CDAI-100 response during the maintenance phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S5</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease experiencing any adverse event with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S6</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease experiencing any serious adverse event with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S7</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease experiencing any infection with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S8</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease experiencing any serious infection with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S9</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease who discontinued due to adverse events in the infliximab (upper plot) or vedolizumab (lower plot) treatment arms. <bold>Figure S10</bold>. Forest plots showing the proportion of patients with Crohn&#x2019;s disease who discontinued due to lack of efficacy in the infliximab treatment arm. <bold>Figure S11</bold>. Forest plots showing the proportion of patients with ulcerative colitis achieving a clinical response during the induction phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S12</bold>. Forest plot showing the proportion of patients with ulcerative colitis achieving mucosal healing during the induction phase with infliximab. <bold>Figure S13</bold>. Forest plots showing the proportion of patients with ulcerative colitis achieving a clinical response during the maintenance phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S14</bold>. Forest plots showing the proportion of patients with ulcerative colitis achieving mucosal healing during the maintenance phase with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S15</bold>. Forest plots showing the proportion of patients with ulcerative colitis experiencing any adverse event with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S16</bold>. Forest plots showing the proportion of patients with ulcerative colitis experiencing any serious adverse event with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S17</bold>. Forest plots showing the proportion of patients with ulcerative colitis experiencing any infection with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S18</bold>. Forest plots showing the proportion of patients with ulcerative colitis experiencing any serious infection with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S19</bold>. Forest plots showing the proportion of patients with ulcerative colitis who discontinued due to adverse events with infliximab (upper plot) or vedolizumab (lower plot). <bold>Figure S20</bold>. Forest plots showing the proportion of patients with ulcerative colitis who discontinued due to lack of efficacy with vedolizumab.</p></caption></media></supplementary-material></p>\\n      </sec>\\n    </sec>\\n  </body>\\n  <back>\\n    <glossary>\\n      <title>Abbreviations</title>\\n      <def-list>\\n        <def-item>\\n          <term>AE</term>\\n          <def>\\n            <p id=\"Par5\">Adverse event</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>CD</term>\\n          <def>\\n            <p id=\"Par6\">Crohn&#x2019;s disease</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>CDAI</term>\\n          <def>\\n            <p id=\"Par7\">Crohn&#x2019;s disease activity index</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>CI</term>\\n          <def>\\n            <p id=\"Par8\">Confidence interval</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>IBD</term>\\n          <def>\\n            <p id=\"Par9\">Inflammatory bowel disease</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>IV</term>\\n          <def>\\n            <p id=\"Par10\">Intravenous</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>PRISMA</term>\\n          <def>\\n            <p id=\"Par11\">Preferred reporting items for systematic reviews and meta-analyses</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>Q2W</term>\\n          <def>\\n            <p id=\"Par12\">Every 2&#xA0;weeks</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>Q8W</term>\\n          <def>\\n            <p id=\"Par13\">Every 8&#xA0;weeks</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>RCT</term>\\n          <def>\\n            <p id=\"Par14\">Randomised controlled trial</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>SAE</term>\\n          <def>\\n            <p id=\"Par15\">Serious adverse event</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>SC</term>\\n          <def>\\n            <p id=\"Par16\">Subcutaneous</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>SmPC</term>\\n          <def>\\n            <p id=\"Par17\">Summary of product characteristics</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>TNFi</term>\\n          <def>\\n            <p id=\"Par18\">Tumour necrosis factor-<italic>&#x3B1;</italic> inhibitor</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>UC</term>\\n          <def>\\n            <p id=\"Par19\">Ulcerative colitis</p>\\n          </def>\\n        </def-item>\\n      </def-list>\\n    </glossary>\\n    <fn-group>\\n      <fn>\\n        <p>\\n          <bold>Publisher\\'s Note</bold>\\n        </p>\\n        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>\\n      </fn>\\n    </fn-group>\\n    <ack>\\n      <title>Acknowledgements</title>\\n      <p>We would like to thank Taek Sang Kwon and Jee Young Kim for their assistance throughout the development of our study. Medical writing support was provided by Beatrice Tyrrell, DPhil, at Aspire Scientific Limited (Bollington, UK).</p>\\n    </ack>\\n    <notes notes-type=\"author-contribution\">\\n      <title>Author contributions</title>\\n      <p>The study protocol, data collection, interpretation and manuscript writing were performed by HGB. Data analysis performed by HGB and SJL. The authors LP, PA, AA, SD, JG, JJ, CL, EL, ML, WR, XR, MJ, HGB, D-HK, RA reviewed and critically revised the manuscript. All authors read and approved the final manuscript.</p>\\n    </notes>\\n    <notes notes-type=\"funding-information\">\\n      <title>Funding</title>\\n      <p>Open Access funding enabled and organized by Projekt DEAL. The study and medical writing support for the article were funded by Celltrion Healthcare (Incheon, Republic of Korea). Celltrion Healthcare did not play any roles in design of the study and collection, analysis, and interpretation of data in writing the manuscript.</p>\\n    </notes>\\n    <notes notes-type=\"data-availability\">\\n      <title>Availability of data and materials</title>\\n      <p>All data generated or analysed during this study are included in this published article and its supplementary information files.</p>\\n    </notes>\\n    <notes>\\n      <title>Declarations</title>\\n      <notes id=\"FPar1\">\\n        <title>Ethics approval and consent to participate</title>\\n        <p id=\"Par68\">Not applicable.</p>\\n      </notes>\\n      <notes id=\"FPar2\">\\n        <title>Consent for publication</title>\\n        <p id=\"Par69\">Not applicable.</p>\\n      </notes>\\n      <notes id=\"FPar3\" notes-type=\"COI-statement\">\\n        <title>Competing interests</title>\\n        <p id=\"Par70\">LP received personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger-Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance. PA has been an advisory board member of Janssen. AA has been a consultant for AbbVie, Allergan, Amgen, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda; SD has received consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer-Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., Vifor, and lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, and Takeda. Jordi Guardiola: Roche, MSD, Abbvie, Kern Pharma, Takeda, Janssen, Pfizer, Ferring, Chiesi, GE Healthcare; JJ has been a speaker, consultant or advisory board member (ABM) for AbbVie, Astro Pharma, Boerhinger-Ingelheim, BMS, Celltrion, Ferring, Giliad, Hikma, Janssen, Meda, MSD, Napp Pharma, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, Sandoz, Unimedic Pharma. CL has received research support from Abbvie, Gilead, and Trellus Health; acted as a consultant to Abbvie, Janssen, Takeda, Pfizer, Celltrion, Galapagos, GSK, Gilead, Vifor Pharma, Dr Falk, and Iterative Scopes; he has received speaking fees and travel support from Pfizer, Janssen, Abbvie, Celltion, Galapagos, Takeda, Shire, Ferring and Dr Falk. EL has received research grants from Takeda, Pfizer, Janssen, educational grants from Abbvie, Takeda, Janssen, has received speaker fees from Abbvie, Ferring, MSD, Falk, Takeda, Janssen, Pfizer, Celgene, has been an ABM of Abbvie, Ferring, MSD, Takeda, Celgene, Janssen, Gilead-Galapagos, Arena, Pfizer, Eli Lilly, and a consultant of Abbvie. ML has received financial supports for research and educational activities from Takeda, Janssen, Pfizer, has been an ABM of Janssen, Takeda, Egis. WR has been a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, a consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Galapagos, Gatehouse Bio Inc., Genentech, Gilead, Gr&#xFC;nenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, J&amp;J, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, 4SC, an ABM for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Gr&#xFC;nenthal, Inova, Janssen, J&amp;J, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter &amp; Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, 4SC, has received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk, Immundiagnostik, Janssen, MSD, Sandoz, Takeda. XR Celltrion, MSD, Janssen, Takeda, Pfizer, Amgen, Gilead, Tillots<italic>.</italic> MJ, HGB and D-HK are employees of Celltrion Healthcare. SJL is an employee of Celltrion, Inc. RA declares the following paid or unpaid consultancies, or sources of honoraria payments, which could potentially be viewed as a conflict of interest: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, DrFalk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, MSD Sharp &amp; Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, Viatris.</p>\\n        <p id=\"Par71\">JJ (J&#xF8;rgen Jahnsen) has served as a speaker, consultant or advisory board member for AbbVie, Astro Pharma, Boerhinger Ingelheim, BMS, Celltrion, Celgene, Ferring, Giliad, Hikma, Janssen, Meda, MSD, Napp Pharma, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, Sandoz and Unimedic Pharma.</p>\\n      </notes>\\n    </notes>\\n    <ref-list id=\"Bib1\">\\n      <title>References</title>\\n      <ref id=\"CR1\">\\n        <label>1.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Baumgart</surname>\\n              <given-names>DC</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Crohn\\'s disease</article-title>\\n          <source>Lancet</source>\\n          <year>2012</year>\\n          <volume>380</volume>\\n          <issue>9853</issue>\\n          <fpage>1590</fpage>\\n          <lpage>1605</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/S0140-6736(12)60026-9</pub-id>\\n          <pub-id pub-id-type=\"pmid\">22914295</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR2\">\\n        <label>2.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Ungaro</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Mehandru</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Allen</surname>\\n              <given-names>PB</given-names>\\n            </name>\\n            <name>\\n              <surname>Peyrin-Biroulet</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Ulcerative colitis</article-title>\\n          <source>Lancet</source>\\n          <year>2017</year>\\n          <volume>389</volume>\\n          <issue>10080</issue>\\n          <fpage>1756</fpage>\\n          <lpage>1770</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/S0140-6736(16)32126-2</pub-id>\\n          <pub-id pub-id-type=\"pmid\">27914657</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR3\">\\n        <label>3.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Targan</surname>\\n              <given-names>SR</given-names>\\n            </name>\\n            <name>\\n              <surname>Hanauer</surname>\\n              <given-names>SB</given-names>\\n            </name>\\n            <name>\\n              <surname>van Deventer</surname>\\n              <given-names>SJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Mayer</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Present</surname>\\n              <given-names>DH</given-names>\\n            </name>\\n            <name>\\n              <surname>Braakman</surname>\\n              <given-names>T</given-names>\\n            </name>\\n            <name>\\n              <surname>DeWoody</surname>\\n              <given-names>KL</given-names>\\n            </name>\\n            <name>\\n              <surname>Schaible</surname>\\n              <given-names>TF</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>PJ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\\'s disease. Crohn\\'s disease cA2 study group</article-title>\\n          <source>N Engl J Med</source>\\n          <year>1997</year>\\n          <volume>337</volume>\\n          <issue>15</issue>\\n          <fpage>1029</fpage>\\n          <lpage>1035</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJM199710093371502</pub-id>\\n          <pub-id pub-id-type=\"pmid\">9321530</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR4\">\\n        <label>4.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Anderson</surname>\\n              <given-names>FH</given-names>\\n            </name>\\n            <name>\\n              <surname>Bernstein</surname>\\n              <given-names>CN</given-names>\\n            </name>\\n            <name>\\n              <surname>Chey</surname>\\n              <given-names>WY</given-names>\\n            </name>\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Fedorak</surname>\\n              <given-names>RN</given-names>\\n            </name>\\n            <name>\\n              <surname>Kamm</surname>\\n              <given-names>MA</given-names>\\n            </name>\\n            <name>\\n              <surname>Korzenik</surname>\\n              <given-names>JR</given-names>\\n            </name>\\n            <name>\\n              <surname>Lashner</surname>\\n              <given-names>BA</given-names>\\n            </name>\\n            <name>\\n              <surname>Onken</surname>\\n              <given-names>JE</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Infliximab maintenance therapy for fistulizing Crohn\\'s disease</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2004</year>\\n          <volume>350</volume>\\n          <issue>9</issue>\\n          <fpage>876</fpage>\\n          <lpage>885</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa030815</pub-id>\\n          <pub-id pub-id-type=\"pmid\">14985485</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR5\">\\n        <label>5.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Olson</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Johanns</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Travers</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Rachmilewitz</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Hanauer</surname>\\n              <given-names>SB</given-names>\\n            </name>\\n            <name>\\n              <surname>Lichtenstein</surname>\\n              <given-names>GR</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Infliximab for induction and maintenance therapy for ulcerative colitis</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2005</year>\\n          <volume>353</volume>\\n          <issue>23</issue>\\n          <fpage>246</fpage>\\n          <lpage>276</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa050516</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR6\">\\n        <label>6.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Ye</surname>\\n              <given-names>BD</given-names>\\n            </name>\\n            <name>\\n              <surname>Pesegova</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Alexeeva</surname>\\n              <given-names>O</given-names>\\n            </name>\\n            <name>\\n              <surname>Osipenko</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Lahat</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Dorofeyev</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Fishman</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Levchenko</surname>\\n              <given-names>O</given-names>\\n            </name>\\n            <name>\\n              <surname>Cheon</surname>\\n              <given-names>JH</given-names>\\n            </name>\\n            <name>\\n              <surname>Scribano</surname>\\n              <given-names>ML</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\\'s disease: an international, randomised, double-blind, phase 3 non-inferiority study</article-title>\\n          <source>Lancet</source>\\n          <year>2019</year>\\n          <volume>393</volume>\\n          <issue>10182</issue>\\n          <fpage>1699</fpage>\\n          <lpage>1707</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/S0140-6736(18)32196-2</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30929895</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR7\">\\n        <label>7.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Van Assche</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Vermeire</surname>\\n              <given-names>S</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Review article: infliximab therapy for inflammatory bowel disease &#x2013; seven years on</article-title>\\n          <source>Aliment Pharmacol Ther</source>\\n          <year>2006</year>\\n          <volume>23</volume>\\n          <issue>4</issue>\\n          <fpage>451</fpage>\\n          <lpage>463</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1111/j.1365-2036.2006.02786.x</pub-id>\\n          <pub-id pub-id-type=\"pmid\">16441465</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR8\">\\n        <label>8.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Hanauer</surname>\\n              <given-names>SB</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Fedorak</surname>\\n              <given-names>RN</given-names>\\n            </name>\\n            <name>\\n              <surname>Lukas</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>MacIntosh</surname>\\n              <given-names>DG</given-names>\\n            </name>\\n            <name>\\n              <surname>Panaccione</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Wolf</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Kent</surname>\\n              <given-names>JD</given-names>\\n            </name>\\n            <name>\\n              <surname>Bittle</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Adalimumab for maintenance treatment of Crohn&#x2019;s disease: results of the CLASSIC II trial</article-title>\\n          <source>Gut</source>\\n          <year>2007</year>\\n          <volume>56</volume>\\n          <issue>9</issue>\\n          <fpage>1232</fpage>\\n          <lpage>1239</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1136/gut.2006.106781</pub-id>\\n          <pub-id pub-id-type=\"pmid\">17299059</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR9\">\\n        <label>9.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>van Assche</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>D\\'Haens</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Wolf</surname>\\n              <given-names>DC</given-names>\\n            </name>\\n            <name>\\n              <surname>Kron</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Tighe</surname>\\n              <given-names>MB</given-names>\\n            </name>\\n            <name>\\n              <surname>Lazar</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Thakkar</surname>\\n              <given-names>RB</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2012</year>\\n          <volume>142</volume>\\n          <issue>2</issue>\\n          <fpage>257</fpage>\\n          <lpage>265</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2011.10.032</pub-id>\\n          <pub-id pub-id-type=\"pmid\">22062358</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR10\">\\n        <label>10.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Torres</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Bonovas</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Doherty</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Kucharzik</surname>\\n              <given-names>T</given-names>\\n            </name>\\n            <name>\\n              <surname>Gisbert</surname>\\n              <given-names>JP</given-names>\\n            </name>\\n            <name>\\n              <surname>Raine</surname>\\n              <given-names>T</given-names>\\n            </name>\\n            <name>\\n              <surname>Adamina</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Armuzzi</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Bachmann</surname>\\n              <given-names>O</given-names>\\n            </name>\\n            <name>\\n              <surname>Bager</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>ECCO guidelines on therapeutics in Crohn\\'s disease: Medical treatment</article-title>\\n          <source>J Crohns Colitis</source>\\n          <year>2020</year>\\n          <volume>14</volume>\\n          <issue>1</issue>\\n          <fpage>4</fpage>\\n          <lpage>22</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1093/ecco-jcc/jjz180</pub-id>\\n          <pub-id pub-id-type=\"pmid\">31711158</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR11\">\\n        <label>11.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Lamb</surname>\\n              <given-names>CA</given-names>\\n            </name>\\n            <name>\\n              <surname>Kennedy</surname>\\n              <given-names>NA</given-names>\\n            </name>\\n            <name>\\n              <surname>Raine</surname>\\n              <given-names>T</given-names>\\n            </name>\\n            <name>\\n              <surname>Hendy</surname>\\n              <given-names>PA</given-names>\\n            </name>\\n            <name>\\n              <surname>Smith</surname>\\n              <given-names>PJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Limdi</surname>\\n              <given-names>JK</given-names>\\n            </name>\\n            <name>\\n              <surname>Hayee</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Lomer</surname>\\n              <given-names>MCE</given-names>\\n            </name>\\n            <name>\\n              <surname>Parkes</surname>\\n              <given-names>GC</given-names>\\n            </name>\\n            <name>\\n              <surname>Selinger</surname>\\n              <given-names>C</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults</article-title>\\n          <source>Gut</source>\\n          <year>2019</year>\\n          <volume>68</volume>\\n          <fpage>s1</fpage>\\n          <lpage>s106</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1136/gutjnl-2019-318484</pub-id>\\n          <pub-id pub-id-type=\"pmid\">31562236</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR12\">\\n        <label>12.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Rubin</surname>\\n              <given-names>DT</given-names>\\n            </name>\\n            <name>\\n              <surname>Ananthakrishnan</surname>\\n              <given-names>AN</given-names>\\n            </name>\\n            <name>\\n              <surname>Siegel</surname>\\n              <given-names>CA</given-names>\\n            </name>\\n            <name>\\n              <surname>Sauer</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Long</surname>\\n              <given-names>MD</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>ACG clinical guideline: Ulcerative colitis in adults</article-title>\\n          <source>Am J Gastroenterol</source>\\n          <year>2019</year>\\n          <volume>114</volume>\\n          <issue>3</issue>\\n          <fpage>384</fpage>\\n          <lpage>413</lpage>\\n          <pub-id pub-id-type=\"doi\">10.14309/ajg.0000000000000152</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30840605</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR13\">\\n        <label>13.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Lichtenstein</surname>\\n              <given-names>GR</given-names>\\n            </name>\\n            <name>\\n              <surname>Loftus</surname>\\n              <given-names>EV</given-names>\\n            </name>\\n            <name>\\n              <surname>Isaacs</surname>\\n              <given-names>KL</given-names>\\n            </name>\\n            <name>\\n              <surname>Regueiro</surname>\\n              <given-names>MD</given-names>\\n            </name>\\n            <name>\\n              <surname>Gerson</surname>\\n              <given-names>LB</given-names>\\n            </name>\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>ACG clinical guideline: Management of Crohn\\'s disease in adults</article-title>\\n          <source>Am J Gastroenterol</source>\\n          <year>2018</year>\\n          <volume>113</volume>\\n          <issue>4</issue>\\n          <fpage>481</fpage>\\n          <lpage>517</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1038/ajg.2018.27</pub-id>\\n          <pub-id pub-id-type=\"pmid\">29610508</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR14\">\\n        <label>14.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Allamneni</surname>\\n              <given-names>C</given-names>\\n            </name>\\n            <name>\\n              <surname>Venkata</surname>\\n              <given-names>K</given-names>\\n            </name>\\n            <name>\\n              <surname>Yun</surname>\\n              <given-names>H</given-names>\\n            </name>\\n            <name>\\n              <surname>Xie</surname>\\n              <given-names>F</given-names>\\n            </name>\\n            <name>\\n              <surname>DeLoach</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Malik</surname>\\n              <given-names>TA</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Comparative effectiveness of vedolizumab vs. Infliximab induction therapy in ulcerative colitis: Experience of a real-world cohort at a tertiary inflammatory bowel disease center</article-title>\\n          <source>Gastroenterology Res</source>\\n          <year>2018</year>\\n          <volume>11</volume>\\n          <issue>1</issue>\\n          <fpage>41</fpage>\\n          <lpage>45</lpage>\\n          <pub-id pub-id-type=\"doi\">10.14740/gr934w</pub-id>\\n          <pub-id pub-id-type=\"pmid\">29511405</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR15\">\\n        <label>15.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Patel</surname>\\n              <given-names>H</given-names>\\n            </name>\\n            <name>\\n              <surname>Latremouille-Viau</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Burne</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Shi</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Adsul</surname>\\n              <given-names>S</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease</article-title>\\n          <source>Crohn\\'s &amp; Colitis 360</source>\\n          <year>2019</year>\\n          <volume>1</volume>\\n          <issue>2</issue>\\n          <fpage>022</fpage>\\n          <pub-id pub-id-type=\"doi\">10.1093/crocol/otz022</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR16\">\\n        <label>16.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Kim</surname>\\n              <given-names>HS</given-names>\\n            </name>\\n            <name>\\n              <surname>Lee</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Kim</surname>\\n              <given-names>JH</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Real-world evidence versus randomized controlled trial: Clinical research based on electronic medical records</article-title>\\n          <source>J Korean Med Sci</source>\\n          <year>2018</year>\\n          <volume>33</volume>\\n          <issue>34</issue>\\n          <fpage>e213</fpage>\\n          <pub-id pub-id-type=\"doi\">10.3346/jkms.2018.33.e213</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30127705</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR17\">\\n        <label>17.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Cholapranee</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Hazlewood</surname>\\n              <given-names>GS</given-names>\\n            </name>\\n            <name>\\n              <surname>Kaplan</surname>\\n              <given-names>GG</given-names>\\n            </name>\\n            <name>\\n              <surname>Peyrin-Biroulet</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Ananthakrishnan</surname>\\n              <given-names>AN</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\\'s disease and ulcerative colitis controlled trials</article-title>\\n          <source>Aliment Pharmacol Ther</source>\\n          <year>2017</year>\\n          <volume>45</volume>\\n          <issue>10</issue>\\n          <fpage>1291</fpage>\\n          <lpage>1302</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1111/apt.14030</pub-id>\\n          <pub-id pub-id-type=\"pmid\">28326566</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR18\">\\n        <label>18.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Zhou</surname>\\n              <given-names>HY</given-names>\\n            </name>\\n            <name>\\n              <surname>Guo</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Lufumpa</surname>\\n              <given-names>E</given-names>\\n            </name>\\n            <name>\\n              <surname>Li</surname>\\n              <given-names>XM</given-names>\\n            </name>\\n            <name>\\n              <surname>Chen</surname>\\n              <given-names>LH</given-names>\\n            </name>\\n            <name>\\n              <surname>Meng</surname>\\n              <given-names>X</given-names>\\n            </name>\\n            <name>\\n              <surname>Li</surname>\\n              <given-names>BZ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Comparative of the effectiveness and safety of biological agents, tofacitinib, and fecal microbiota transplantation in ulcerative colitis: Systematic review and network meta-analysis</article-title>\\n          <source>Immunol Invest</source>\\n          <year>2021</year>\\n          <volume>50</volume>\\n          <issue>4</issue>\\n          <fpage>323</fpage>\\n          <lpage>337</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1080/08820139.2020.1714650</pub-id>\\n          <pub-id pub-id-type=\"pmid\">32009472</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR19\">\\n        <label>19.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Schreiber</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Ben-Horin</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Leszczyszyn</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Dudkowiak</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Lahat</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Gawdis-Wojnarska</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Pukitis</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Horynski</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Farkas</surname>\\n              <given-names>K</given-names>\\n            </name>\\n            <name>\\n              <surname>Kierkus</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Randomized controlled trial: Subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2021</year>\\n          <volume>160</volume>\\n          <issue>7</issue>\\n          <fpage>2340</fpage>\\n          <lpage>2353</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2021.02.068</pub-id>\\n          <pub-id pub-id-type=\"pmid\">33676969</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR20\">\\n        <label>20.</label>\\n        <mixed-citation publication-type=\"other\">Systematic review and meta-analysis of the efficacy and safety of infliximab versus vedolizumab in patients with inflammatory bowel diseases PROSPERO 2021 CRD42021177954 [<ext-link ext-link-type=\"uri\" xlink:href=\"https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=177954\">https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=177954</ext-link>]</mixed-citation>\\n      </ref>\\n      <ref id=\"CR21\">\\n        <label>21.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <collab>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P</collab>\\n          </person-group>\\n          <article-title>Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement</article-title>\\n          <source>PLoS Med</source>\\n          <year>2009</year>\\n          <volume>6</volume>\\n          <issue>7</issue>\\n          <fpage>e1000097</fpage>\\n          <pub-id pub-id-type=\"doi\">10.1371/journal.pmed.1000097</pub-id>\\n          <pub-id pub-id-type=\"pmid\">19621072</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR22\">\\n        <label>22.</label>\\n        <mixed-citation publication-type=\"other\">Higgins JPT, Savovi&#x107; J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from <ext-link ext-link-type=\"uri\" xlink:href=\"https://www.training.cochrane.org/handbook\">https://www.training.cochrane.org/handbook</ext-link>.\\n</mixed-citation>\\n      </ref>\\n      <ref id=\"CR23\">\\n        <label>23.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Mantzaris</surname>\\n              <given-names>GJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Kornbluth</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Rachmilewitz</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Lichtiger</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>D\\'Haens</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Diamond</surname>\\n              <given-names>RH</given-names>\\n            </name>\\n            <name>\\n              <surname>Broussard</surname>\\n              <given-names>DL</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Infliximab, azathioprine, or combination therapy for Crohn\\'s disease</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2010</year>\\n          <volume>362</volume>\\n          <issue>15</issue>\\n          <fpage>1383</fpage>\\n          <lpage>1395</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa0904492</pub-id>\\n          <pub-id pub-id-type=\"pmid\">20393175</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR24\">\\n        <label>24.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Ferrante</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Mantzaris</surname>\\n              <given-names>GJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Kornbluth</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Rachmilewitz</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Lichtiger</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>D\\'Haens</surname>\\n              <given-names>GR</given-names>\\n            </name>\\n            <name>\\n              <surname>van der Woude</surname>\\n              <given-names>CJ</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Validation of endoscopic activity scores in patients with Crohn\\'s disease based on a post hoc analysis of data from SONIC</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2013</year>\\n          <volume>145</volume>\\n          <issue>5</issue>\\n          <fpage>978</fpage>\\n          <lpage>986.e975</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2013.08.010</pub-id>\\n          <pub-id pub-id-type=\"pmid\">23954314</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR25\">\\n        <label>25.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Mantzaris</surname>\\n              <given-names>GJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Kornbluth</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Tang</surname>\\n              <given-names>KL</given-names>\\n            </name>\\n            <name>\\n              <surname>Oortwijn</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Bevelander</surname>\\n              <given-names>GS</given-names>\\n            </name>\\n            <name>\\n              <surname>Cornillie</surname>\\n              <given-names>FJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn\\'s disease - a SONIC post hoc analysis</article-title>\\n          <source>Aliment Pharmacol Ther</source>\\n          <year>2015</year>\\n          <volume>41</volume>\\n          <issue>8</issue>\\n          <fpage>734</fpage>\\n          <lpage>746</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1111/apt.13139</pub-id>\\n          <pub-id pub-id-type=\"pmid\">25728587</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR26\">\\n        <label>26.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Peyrin-Biroulet</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Mantzaris</surname>\\n              <given-names>GJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Kornbluth</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Diamond</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Tang</surname>\\n              <given-names>LK</given-names>\\n            </name>\\n            <name>\\n              <surname>Cornillie</surname>\\n              <given-names>FJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\\'s disease in the SONIC trial</article-title>\\n          <source>Gut</source>\\n          <year>2014</year>\\n          <volume>63</volume>\\n          <issue>1</issue>\\n          <fpage>88</fpage>\\n          <lpage>95</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1136/gutjnl-2013-304984</pub-id>\\n          <pub-id pub-id-type=\"pmid\">23974954</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR27\">\\n        <label>27.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Narula</surname>\\n              <given-names>N</given-names>\\n            </name>\\n            <name>\\n              <surname>Wong</surname>\\n              <given-names>ECL</given-names>\\n            </name>\\n            <name>\\n              <surname>Dulai</surname>\\n              <given-names>PS</given-names>\\n            </name>\\n            <name>\\n              <surname>Sengupta</surname>\\n              <given-names>NK</given-names>\\n            </name>\\n            <name>\\n              <surname>Marshall</surname>\\n              <given-names>JK</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Reinisch</surname>\\n              <given-names>W</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naive Crohn\\'s disease</article-title>\\n          <source>Clin Gastroenterol Hepatol</source>\\n          <year>2021</year>\\n          <pub-id pub-id-type=\"doi\">10.1016/j.cgh.2021.04.006</pub-id>\\n          <pub-id pub-id-type=\"pmid\">34425279</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR28\">\\n        <label>28.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Jorgensen</surname>\\n              <given-names>KK</given-names>\\n            </name>\\n            <name>\\n              <surname>Goll</surname>\\n              <given-names>GL</given-names>\\n            </name>\\n            <name>\\n              <surname>Sexton</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Bolstad</surname>\\n              <given-names>N</given-names>\\n            </name>\\n            <name>\\n              <surname>Olsen</surname>\\n              <given-names>IC</given-names>\\n            </name>\\n            <name>\\n              <surname>Asak</surname>\\n              <given-names>O</given-names>\\n            </name>\\n            <name>\\n              <surname>Berset</surname>\\n              <given-names>IP</given-names>\\n            </name>\\n            <name>\\n              <surname>Blomgren</surname>\\n              <given-names>IM</given-names>\\n            </name>\\n            <name>\\n              <surname>Dvergsnes</surname>\\n              <given-names>K</given-names>\\n            </name>\\n            <name>\\n              <surname>Florholmen</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyses from the NOR-SWITCH main and extension trials</article-title>\\n          <source>BioDrugs</source>\\n          <year>2020</year>\\n          <volume>34</volume>\\n          <issue>5</issue>\\n          <fpage>681</fpage>\\n          <lpage>694</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1007/s40259-020-00438-7</pub-id>\\n          <pub-id pub-id-type=\"pmid\">32965617</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR29\">\\n        <label>29.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>J&#xF8;rgensen</surname>\\n              <given-names>KK</given-names>\\n            </name>\\n            <name>\\n              <surname>Olsen</surname>\\n              <given-names>IC</given-names>\\n            </name>\\n            <name>\\n              <surname>Goll</surname>\\n              <given-names>GL</given-names>\\n            </name>\\n            <name>\\n              <surname>Lorentzen</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Bolstad</surname>\\n              <given-names>N</given-names>\\n            </name>\\n            <name>\\n              <surname>Haavardsholm</surname>\\n              <given-names>EA</given-names>\\n            </name>\\n            <name>\\n              <surname>Lundin</surname>\\n              <given-names>KEA</given-names>\\n            </name>\\n            <name>\\n              <surname>M&#xF8;rk</surname>\\n              <given-names>C</given-names>\\n            </name>\\n            <name>\\n              <surname>Jahnsen</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Kvien</surname>\\n              <given-names>TK</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial</article-title>\\n          <source>Lancet</source>\\n          <year>2017</year>\\n          <volume>389</volume>\\n          <issue>10086</issue>\\n          <fpage>2304</fpage>\\n          <lpage>2316</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/S0140-6736(17)30068-5</pub-id>\\n          <pub-id pub-id-type=\"pmid\">28502609</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR30\">\\n        <label>30.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Hanauer</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Lukas</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Fedorak</surname>\\n              <given-names>RN</given-names>\\n            </name>\\n            <name>\\n              <surname>Lee</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Bressler</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Vedolizumab as induction and maintenance therapy for Crohn\\'s disease</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2013</year>\\n          <volume>369</volume>\\n          <issue>8</issue>\\n          <fpage>711</fpage>\\n          <lpage>721</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa1215739</pub-id>\\n          <pub-id pub-id-type=\"pmid\">23964933</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR31\">\\n        <label>31.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Van Assche</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Lukas</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Xu</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>James</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Abhyankar</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Lasch</surname>\\n              <given-names>K</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Vedolizumab as induction and maintenance therapy for Crohn\\'s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy</article-title>\\n          <source>Inflamm Bowel Dis</source>\\n          <year>2017</year>\\n          <volume>23</volume>\\n          <issue>1</issue>\\n          <fpage>97</fpage>\\n          <lpage>106</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1097/MIB.0000000000000979</pub-id>\\n          <pub-id pub-id-type=\"pmid\">27930408</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR32\">\\n        <label>32.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Van Assche</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Tudor</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Akhundova-Unadkat</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Curtis</surname>\\n              <given-names>RI</given-names>\\n            </name>\\n            <name>\\n              <surname>Tan</surname>\\n              <given-names>T</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Vedolizumab in combination with corticosteroids for induction therapy in Crohn\\'s disease: A post hoc analysis of GEMINI 2 and 3</article-title>\\n          <source>Inflamm Bowel Dis</source>\\n          <year>2019</year>\\n          <volume>25</volume>\\n          <issue>8</issue>\\n          <fpage>1375</fpage>\\n          <lpage>1382</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1093/ibd/izy384</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30615117</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR33\">\\n        <label>33.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Banerjee</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Chuah</surname>\\n              <given-names>SW</given-names>\\n            </name>\\n            <name>\\n              <surname>Hilmi</surname>\\n              <given-names>IN</given-names>\\n            </name>\\n            <name>\\n              <surname>Wu</surname>\\n              <given-names>DC</given-names>\\n            </name>\\n            <name>\\n              <surname>Yang</surname>\\n              <given-names>SK</given-names>\\n            </name>\\n            <name>\\n              <surname>Demuth</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Lindner</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Adsul</surname>\\n              <given-names>S</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Efficacy and safety of vedolizumab in Crohn\\'s disease in patients from Asian countries in the GEMINI 2 study</article-title>\\n          <source>Intest Res</source>\\n          <year>2021</year>\\n          <volume>19</volume>\\n          <issue>1</issue>\\n          <fpage>83</fpage>\\n          <lpage>94</lpage>\\n          <pub-id pub-id-type=\"doi\">10.5217/ir.2019.09160</pub-id>\\n          <pub-id pub-id-type=\"pmid\">33378612</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR34\">\\n        <label>34.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Sy</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>D\\'Haens</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Ben-Horin</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Xu</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Rosario</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Effects of vedolizumab induction therapy for patients with Crohn\\'s disease in whom tumor necrosis factor antagonist treatment failed</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2014</year>\\n          <volume>147</volume>\\n          <issue>3</issue>\\n          <fpage>618</fpage>\\n          <lpage>627.e613</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2014.05.008</pub-id>\\n          <pub-id pub-id-type=\"pmid\">24859203</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR35\">\\n        <label>35.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Adedokun</surname>\\n              <given-names>OJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Xu</surname>\\n              <given-names>Z</given-names>\\n            </name>\\n            <name>\\n              <surname>Marano</surname>\\n              <given-names>CW</given-names>\\n            </name>\\n            <name>\\n              <surname>Johanns</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Zhou</surname>\\n              <given-names>H</given-names>\\n            </name>\\n            <name>\\n              <surname>Davis</surname>\\n              <given-names>HM</given-names>\\n            </name>\\n            <name>\\n              <surname>Cornillie</surname>\\n              <given-names>F</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2014</year>\\n          <volume>147</volume>\\n          <issue>6</issue>\\n          <fpage>1296</fpage>\\n          <lpage>1307.e1295</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2014.08.035</pub-id>\\n          <pub-id pub-id-type=\"pmid\">25173754</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR36\">\\n        <label>36.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Rutgeerts</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Hanauer</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Van Assche</surname>\\n              <given-names>G</given-names>\\n            </name>\\n            <name>\\n              <surname>Axler</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Kim</surname>\\n              <given-names>HJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Danese</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Vedolizumab as induction and maintenance therapy for ulcerative colitis</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2013</year>\\n          <volume>369</volume>\\n          <issue>8</issue>\\n          <fpage>699</fpage>\\n          <lpage>710</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa1215734</pub-id>\\n          <pub-id pub-id-type=\"pmid\">23964932</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR37\">\\n        <label>37.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Schreiber</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Wolf</surname>\\n              <given-names>DC</given-names>\\n            </name>\\n            <name>\\n              <surname>Axler</surname>\\n              <given-names>JL</given-names>\\n            </name>\\n            <name>\\n              <surname>Kaviya</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>James</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Curtis</surname>\\n              <given-names>RI</given-names>\\n            </name>\\n            <name>\\n              <surname>Geransar</surname>\\n              <given-names>P</given-names>\\n            </name>\\n            <name>\\n              <surname>Stallmach</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Ehehalt</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Sustained clinical remission with vedolizumab in patients with moderate-to-severe ulcerative colitis</article-title>\\n          <source>Inflamm Bowel Dis</source>\\n          <year>2019</year>\\n          <volume>25</volume>\\n          <issue>6</issue>\\n          <fpage>1028</fpage>\\n          <lpage>1035</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1093/ibd/izy323</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30365009</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR38\">\\n        <label>38.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Feagan</surname>\\n              <given-names>BG</given-names>\\n            </name>\\n            <name>\\n              <surname>Rubin</surname>\\n              <given-names>DT</given-names>\\n            </name>\\n            <name>\\n              <surname>Danese</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Vermeire</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Abhyankar</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Sankoh</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>James</surname>\\n              <given-names>A</given-names>\\n            </name>\\n            <name>\\n              <surname>Smyth</surname>\\n              <given-names>M</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists</article-title>\\n          <source>Clin Gastroenterol Hepatol</source>\\n          <year>2017</year>\\n          <volume>15</volume>\\n          <issue>2</issue>\\n          <fpage>229</fpage>\\n          <lpage>239.e225</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/j.cgh.2016.08.044</pub-id>\\n          <pub-id pub-id-type=\"pmid\">27639327</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR39\">\\n        <label>39.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Loftus</surname>\\n              <given-names>EV</given-names>\\n              <suffix>Jr</suffix>\\n            </name>\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>J-F</given-names>\\n            </name>\\n            <name>\\n              <surname>Dotan</surname>\\n              <given-names>I</given-names>\\n            </name>\\n            <name>\\n              <surname>Khalid</surname>\\n              <given-names>JM</given-names>\\n            </name>\\n            <name>\\n              <surname>Tudor</surname>\\n              <given-names>D</given-names>\\n            </name>\\n            <name>\\n              <surname>Geransar</surname>\\n              <given-names>P</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1</article-title>\\n          <source>Clin Exp Gastroenterol</source>\\n          <year>2020</year>\\n          <volume>13</volume>\\n          <fpage>211</fpage>\\n          <lpage>220</lpage>\\n          <pub-id pub-id-type=\"doi\">10.2147/CEG.S248597</pub-id>\\n          <pub-id pub-id-type=\"pmid\">32606883</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR40\">\\n        <label>40.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Panaccione</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <name>\\n              <surname>Dulai</surname>\\n              <given-names>PS</given-names>\\n            </name>\\n            <name>\\n              <surname>Rosario</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Cao</surname>\\n              <given-names>C</given-names>\\n            </name>\\n            <name>\\n              <surname>Barocas</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Lasch</surname>\\n              <given-names>K</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: A GEMINI 1 post hoc analysis</article-title>\\n          <source>J Crohns Colitis</source>\\n          <year>2019</year>\\n          <volume>13</volume>\\n          <issue>2</issue>\\n          <fpage>172</fpage>\\n          <lpage>181</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1093/ecco-jcc/jjy149</pub-id>\\n          <pub-id pub-id-type=\"pmid\">30285104</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR41\">\\n        <label>41.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sands</surname>\\n              <given-names>BE</given-names>\\n            </name>\\n            <name>\\n              <surname>Peyrin-Biroulet</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Loftus</surname>\\n              <given-names>EV</given-names>\\n              <suffix>Jr</suffix>\\n            </name>\\n            <name>\\n              <surname>Danese</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Colombel</surname>\\n              <given-names>JF</given-names>\\n            </name>\\n            <name>\\n              <surname>Toruner</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Jonaitis</surname>\\n              <given-names>L</given-names>\\n            </name>\\n            <name>\\n              <surname>Abhyankar</surname>\\n              <given-names>B</given-names>\\n            </name>\\n            <name>\\n              <surname>Chen</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Rogers</surname>\\n              <given-names>R</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis</article-title>\\n          <source>N Engl J Med</source>\\n          <year>2019</year>\\n          <volume>381</volume>\\n          <issue>13</issue>\\n          <fpage>1215</fpage>\\n          <lpage>1226</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1056/NEJMoa1905725</pub-id>\\n          <pub-id pub-id-type=\"pmid\">31553834</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR42\">\\n        <label>42.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Baert</surname>\\n              <given-names>F</given-names>\\n            </name>\\n            <name>\\n              <surname>Danese</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Krznaric</surname>\\n              <given-names>Z</given-names>\\n            </name>\\n            <name>\\n              <surname>Kobayashi</surname>\\n              <given-names>T</given-names>\\n            </name>\\n            <name>\\n              <surname>Yao</surname>\\n              <given-names>X</given-names>\\n            </name>\\n            <name>\\n              <surname>Chen</surname>\\n              <given-names>J</given-names>\\n            </name>\\n            <name>\\n              <surname>Rosario</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Bhatia</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Kisfalvi</surname>\\n              <given-names>K</given-names>\\n            </name>\\n            <etal/>\\n          </person-group>\\n          <article-title>Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis</article-title>\\n          <source>Gastroenterology</source>\\n          <year>2020</year>\\n          <volume>158</volume>\\n          <issue>3</issue>\\n          <fpage>562</fpage>\\n          <lpage>572.e512</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1053/j.gastro.2019.08.027</pub-id>\\n          <pub-id pub-id-type=\"pmid\">31470005</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR43\">\\n        <label>43.</label>\\n        <mixed-citation publication-type=\"other\">Summary of product characteristics: Remsima 100 mg powder for concentrate for solution for infusion [<ext-link ext-link-type=\"uri\" xlink:href=\"https://www.ema.europa.eu/en/medicines/human/EPAR/remsima\">https://www.ema.europa.eu/en/medicines/human/EPAR/remsima</ext-link>]</mixed-citation>\\n      </ref>\\n      <ref id=\"CR44\">\\n        <label>44.</label>\\n        <mixed-citation publication-type=\"other\">Summary of product characteristics: Entyvio 300 mg powder for concentrate for solution for infusion [<ext-link ext-link-type=\"uri\" xlink:href=\"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\">https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio</ext-link>]</mixed-citation>\\n      </ref>\\n      <ref id=\"CR45\">\\n        <label>45.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Singh</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Fumery</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n            <name>\\n              <surname>Murad</surname>\\n              <given-names>MH</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\\'s disease</article-title>\\n          <source>Aliment Pharmacol Ther</source>\\n          <year>2018</year>\\n          <volume>48</volume>\\n          <issue>4</issue>\\n          <fpage>394</fpage>\\n          <lpage>409</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1111/apt.14852</pub-id>\\n          <pub-id pub-id-type=\"pmid\">29920733</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR46\">\\n        <label>46.</label>\\n        <element-citation publication-type=\"journal\">\\n          <person-group person-group-type=\"author\">\\n            <name>\\n              <surname>Singh</surname>\\n              <given-names>S</given-names>\\n            </name>\\n            <name>\\n              <surname>Murad</surname>\\n              <given-names>MH</given-names>\\n            </name>\\n            <name>\\n              <surname>Fumery</surname>\\n              <given-names>M</given-names>\\n            </name>\\n            <name>\\n              <surname>Dulai</surname>\\n              <given-names>PS</given-names>\\n            </name>\\n            <name>\\n              <surname>Sandborn</surname>\\n              <given-names>WJ</given-names>\\n            </name>\\n          </person-group>\\n          <article-title>First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis</article-title>\\n          <source>Clin Gastroenterol Hepatol</source>\\n          <year>2020</year>\\n          <volume>18</volume>\\n          <issue>10</issue>\\n          <fpage>2179</fpage>\\n          <lpage>2191</lpage>\\n          <pub-id pub-id-type=\"doi\">10.1016/j.cgh.2020.01.008</pub-id>\\n          <pub-id pub-id-type=\"pmid\">31945470</pub-id>\\n        </element-citation>\\n      </ref>\\n      <ref id=\"CR47\">\\n        <label>47.</label>\\n        <mixed-citation publication-type=\"other\">Chao YS, Visintini S. In: Biologics dose escalation for the treatment of inflammatory bowel disease: a review of clinical effectiveness, cost-effectiveness, and guidelines. edn. Ottawa (ON); 2018.</mixed-citation>\\n      </ref>\\n    </ref-list>\\n  </back>\\n</article>\\n<article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" dtd-version=\"1.3\" id=\"apt16927\" xml:lang=\"en\" article-type=\"research-article\">\\n  <?properties open_access?>\\n  <processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\">\\n    <restricted-by>pmc</restricted-by>\\n  </processing-meta>\\n  <front>\\n    <journal-meta>\\n      <journal-id journal-id-type=\"nlm-ta\">Aliment Pharmacol Ther</journal-id>\\n      <journal-id journal-id-type=\"iso-abbrev\">Aliment Pharmacol Ther</journal-id>\\n      <journal-id journal-id-type=\"doi\">10.1111/(ISSN)1365-2036</journal-id>\\n      <journal-id journal-id-type=\"publisher-id\">APT</journal-id>\\n      <journal-title-group>\\n        <journal-title>Alimentary Pharmacology &amp; Therapeutics</journal-title>\\n      </journal-title-group>\\n      <issn pub-type=\"ppub\">0269-2813</issn>\\n      <issn pub-type=\"epub\">1365-2036</issn>\\n      <publisher>\\n        <publisher-name>John Wiley and Sons Inc.</publisher-name>\\n        <publisher-loc>Hoboken</publisher-loc>\\n      </publisher>\\n    </journal-meta>\\n    <article-meta>\\n      <article-id pub-id-type=\"pmid\">35470449</article-id>\\n      <article-id pub-id-type=\"pmc\">9322578</article-id>\\n      <article-id pub-id-type=\"doi\">10.1111/apt.16927</article-id>\\n      <article-id pub-id-type=\"publisher-id\">APT16927</article-id>\\n      <article-id pub-id-type=\"other\">APT-0322-2022.R1</article-id>\\n      <article-categories>\\n        <subj-group subj-group-type=\"overline\">\\n          <subject>Fast Track</subject>\\n        </subj-group>\\n        <subj-group subj-group-type=\"heading\">\\n          <subject>Switching from IV to Sc Vedolizumab in IBD</subject>\\n        </subj-group>\\n      </article-categories>\\n      <title-group>\\n        <article-title>Real&#x2010;world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease</article-title>\\n        <alt-title alt-title-type=\"left-running-head\">Bergqvist et al.</alt-title>\\n      </title-group>\\n      <contrib-group>\\n        <contrib id=\"apt16927-cr-0001\" contrib-type=\"author\">\\n          <name>\\n            <surname>Bergqvist</surname>\\n            <given-names>Viktoria</given-names>\\n          </name>\\n          <xref rid=\"apt16927-aff-0001\" ref-type=\"aff\">\\n<sup>1</sup>\\n</xref>\\n          <xref rid=\"apt16927-aff-0002\" ref-type=\"aff\">\\n<sup>2</sup>\\n</xref>\\n        </contrib>\\n        <contrib id=\"apt16927-cr-0002\" contrib-type=\"author\">\\n          <name>\\n            <surname>Holmgren</surname>\\n            <given-names>Johanna</given-names>\\n          </name>\\n          <xref rid=\"apt16927-aff-0001\" ref-type=\"aff\">\\n<sup>1</sup>\\n</xref>\\n          <xref rid=\"apt16927-aff-0002\" ref-type=\"aff\">\\n<sup>2</sup>\\n</xref>\\n        </contrib>\\n        <contrib id=\"apt16927-cr-0003\" contrib-type=\"author\">\\n          <name>\\n            <surname>Klintman</surname>\\n            <given-names>Daniel</given-names>\\n          </name>\\n          <xref rid=\"apt16927-aff-0001\" ref-type=\"aff\">\\n<sup>1</sup>\\n</xref>\\n          <xref rid=\"apt16927-aff-0002\" ref-type=\"aff\">\\n<sup>2</sup>\\n</xref>\\n        </contrib>\\n        <contrib id=\"apt16927-cr-0004\" contrib-type=\"author\" corresp=\"yes\">\\n          <name>\\n            <surname>Marsal</surname>\\n            <given-names>Jan</given-names>\\n          </name>\\n          <contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0003-4808-0014</contrib-id>\\n          <xref rid=\"apt16927-aff-0001\" ref-type=\"aff\">\\n<sup>1</sup>\\n</xref>\\n          <xref rid=\"apt16927-aff-0002\" ref-type=\"aff\">\\n<sup>2</sup>\\n</xref>\\n          <xref rid=\"apt16927-aff-0003\" ref-type=\"aff\">\\n<sup>3</sup>\\n</xref>\\n          <address>\\n            <email>jan.marsal@med.lu.se</email>\\n          </address>\\n        </contrib>\\n      </contrib-group>\\n      <aff id=\"apt16927-aff-0001\">\\n<label>\\n<sup>1</sup>\\n</label>\\n<named-content content-type=\"organisation-division\">Department of Gastroenterology</named-content>\\n<institution>Skane University Hospital</institution>\\n<city>Lund/Malm&#xF6;</city>\\n<country country=\"SE\">Sweden</country>\\n</aff>\\n      <aff id=\"apt16927-aff-0002\">\\n<label>\\n<sup>2</sup>\\n</label>\\n<named-content content-type=\"organisation-division\">Section of Medicine</named-content>\\n<institution>Department of Clinical Sciences, Lund University</institution>\\n<city>Lund</city>\\n<country country=\"SE\">Sweden</country>\\n</aff>\\n      <aff id=\"apt16927-aff-0003\">\\n<label>\\n<sup>3</sup>\\n</label>\\n<named-content content-type=\"organisation-division\">Section of Immunology</named-content>\\n<institution>Department of Experimental Medical Science, Lund University</institution>\\n<city>Lund</city>\\n<country country=\"SE\">Sweden</country>\\n</aff>\\n      <author-notes>\\n        <corresp id=\"correspondenceTo\">\\n<label>*</label>\\n<bold>Correspondence</bold>\\n<break/>\\nJan Marsal, Department of Gastroenterology, Skane University Hospital, SE&#x2010;22185 Lund, Sweden.<break/>\\nEmail: <email>jan.marsal@med.lu.se</email>\\n<break/>\\n</corresp>\\n      </author-notes>\\n      <pub-date pub-type=\"epub\">\\n        <day>25</day>\\n        <month>4</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <pub-date pub-type=\"ppub\">\\n        <month>6</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <volume>55</volume>\\n      <issue seq=\"40\">11</issue>\\n      <issue-id pub-id-type=\"doi\">10.1111/apt.v55.11</issue-id>\\n      <fpage>1389</fpage>\\n      <lpage>1401</lpage>\\n      <history>\\n<date date-type=\"rev-recd\"><day>02</day><month>3</month><year>2022</year></date>\\n<date date-type=\"received\"><day>24</day><month>2</month><year>2022</year></date>\\n<date date-type=\"accepted\"><day>01</day><month>4</month><year>2022</year></date>\\n</history>\\n      <permissions>\\n        <!--Copyright &#x000a9; 2022 John Wiley & Sons Ltd-->\\n        <copyright-statement content-type=\"article-copyright\">&#xA9; 2022 The Authors. <italic toggle=\"yes\">Alimentary Pharmacology &amp; Therapeutics</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>\\n        <license>\\n          <ali:license_ref xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" specific-use=\"textmining\" content-type=\"ccbynclicense\">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>\\n          <license-p>This is an open access article under the terms of the <ext-link ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by-nc/4.0/\">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>\\n        </license>\\n      </permissions>\\n      <self-uri content-type=\"pdf\" xlink:href=\"file:APT-55-1389.pdf\"/>\\n      <abstract>\\n        <title>Summary</title>\\n        <sec id=\"apt16927-sec-0001\">\\n          <title>Background and Aims</title>\\n          <p>Vedolizumab is a gut&#x2010;selective treatment approved for Crohn&#x2019;s disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of vedolizumab was approved. The aims of this study were to evaluate efficacy, safety, pharmacokinetics, patient experience and costs following a switch from intravenous to subcutaneous vedolizumab treatment.</p>\\n        </sec>\\n        <sec id=\"apt16927-sec-0002\">\\n          <title>Methods</title>\\n          <p>Patients were switched from intravenous to subcutaneous vedolizumab maintenance treatment and followed prospectively for 6 months and a subgroup for 12&#xA0;months. The primary endpoint was change in faecal calprotectin levels. Furthermore, we evaluated clinical disease activity, remission rates, plasma CRP, drug persistence, adverse events, local injection reactions, serum drug concentrations, patient satisfaction, quality&#x2010;of&#x2010;life and treatment costs.</p>\\n        </sec>\\n        <sec id=\"apt16927-sec-0003\">\\n          <title>Results</title>\\n          <p>Eighty&#x2010;nine patients were included (48 CD; 41 UC). Faecal calprotectin decreased significantly in CD but not in UC. Clinical indices, remission rates, plasma CRP levels and quality&#x2010;of&#x2010;life scores remained unchanged. Patients that had been on standard compared to optimised IV vedolizumab dosing displayed similar outcomes on standard SC dosing. Drug persistence at 6 and 12&#xA0;months was 95.5% and 88.5%, respectively. Frequencies of adverse events were similar before and after the switch. No serious adverse events occurred. Transient severe local injection reactions were experienced by 1.2% of patients. Median vedolizumab trough levels were 2.3 times higher on subcutaneous compared to intravenous treatment. Patient satisfaction was generally high. Annualised treatment costs were reduced by 15% following the switch.</p>\\n        </sec>\\n        <sec id=\"apt16927-sec-0004\">\\n          <title>Conclusions</title>\\n          <p>The switch from intravenous to subcutaneous vedolizumab could be done with preserved therapeutic effectiveness, safety, high patient satisfaction and low discontinuation rate, at a reduced cost.</p>\\n        </sec>\\n      </abstract>\\n      <abstract abstract-type=\"graphical\">\\n        <p>This prospective real&#x2010;world study examined switching patients with IBD from maintenance IV vedolizumab treatment to SC vedolizumab. The following was studied: efficacy, safety, pharmacokinetics, patient experience, and costs. All patients, including those that had been on optimized IV dosing, were switched to the standard SC dose. The switch could be done with preserved therapeutic effectiveness, preserved safety, high patient satisfaction, and low discontinuation rate, at a reduced cost.<boxed-text position=\"anchor\" content-type=\"graphic\" id=\"apt16927-blkfxd-0001\"><graphic xlink:href=\"APT-55-1389-g001.jpg\" position=\"anchor\" id=\"jats-graphic-1\"/></boxed-text>\\n</p>\\n      </abstract>\\n      <funding-group>\\n        <award-group id=\"funding-0001\">\\n          <funding-source>Healthcare Region of Southern Sweden</funding-source>\\n          <award-id>40783</award-id>\\n        </award-group>\\n        <award-group id=\"funding-0002\">\\n          <funding-source>the Swedish government</funding-source>\\n          <award-id>ALFSKANE&#x2010;539811</award-id>\\n        </award-group>\\n      </funding-group>\\n      <counts>\\n        <fig-count count=\"8\"/>\\n        <table-count count=\"2\"/>\\n        <page-count count=\"13\"/>\\n        <word-count count=\"7987\"/>\\n      </counts>\\n      <custom-meta-group>\\n        <custom-meta>\\n          <meta-name>source-schema-version-number</meta-name>\\n          <meta-value>2.0</meta-value>\\n        </custom-meta>\\n        <custom-meta>\\n          <meta-name>cover-date</meta-name>\\n          <meta-value>June 2022</meta-value>\\n        </custom-meta>\\n        <custom-meta>\\n          <meta-name>details-of-publishers-convertor</meta-name>\\n          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:26.07.2022</meta-value>\\n        </custom-meta>\\n      </custom-meta-group>\\n    </article-meta>\\n    <notes>\\n      <p content-type=\"self-citation\">\\n<mixed-citation publication-type=\"journal\" id=\"APT16927-cit-2001\">\\n<string-name>\\n<surname>Bergqvist</surname>\\n<given-names>V</given-names>\\n</string-name>, <string-name>\\n<surname>Holmgren</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Klintman</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Marsal</surname>\\n<given-names>J</given-names>\\n</string-name>. <article-title>Real&#x2010;world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2022</year>;<volume>55</volume>:<fpage>1389</fpage>&#x2013;<lpage>1401</lpage>. <pub-id pub-id-type=\"doi\">10.1111/apt.16927</pub-id>\\n<pub-id pub-id-type=\"pmid\">35470449</pub-id></mixed-citation>\\n</p>\\n      <fn-group id=\"apt16927-ntgp-0001\">\\n        <fn id=\"apt16927-note-0001\">\\n          <p>\\n<bold>Funding information</bold>\\n</p>\\n          <p>This work was made possible through financial support from the Healthcare Region of Southern Sweden, and by grants to researchers in public health care from the Swedish government (ALFSKANE&#x2010;539811) to Jan Marsal.</p>\\n        </fn>\\n        <fn id=\"apt16927-note-0002\">\\n          <p>The Handling Editor for this article was Dr Rohit Loomba, and it was accepted for publication after full peer&#x2010;review.</p>\\n        </fn>\\n      </fn-group>\\n    </notes>\\n  </front>\\n  <body id=\"apt16927-body-0001\">\\n    <sec id=\"apt16927-sec-0005\">\\n      <label>1</label>\\n      <title>INTRODUCTION</title>\\n      <p>The inflammatory process of Crohn&#x2019;s disease (CD) or ulcerative colitis (UC), which are the two main forms of inflammatory bowel disease (IBD), is thought to be driven by the infiltration of dysregulated proinflammatory immune cells into the inflamed intestinal tissue.<xref rid=\"apt16927-bib-0001\" ref-type=\"bibr\">\\n<sup>1</sup>\\n</xref> This infiltration is facilitated by the interaction between the integrin &#x3B1;4&#x3B2;7, which is expressed on several circulating immune cell subsets including previously activated T&#x2010;cells, and its counterreceptor Mucosal Addressin Cell Adhesion Molecule&#x2010;1 (MAdCAM&#x2010;1), which is selectively expressed on the endothelial cells of intestinal venules.<xref rid=\"apt16927-bib-0001\" ref-type=\"bibr\">\\n<sup>1</sup>\\n</xref>\\n</p>\\n      <p>Vedolizumab is a humanised monoclonal IgG1 antibody that binds to &#x3B1;4&#x3B2;7 and inhibits the interaction with MAdCAM&#x2010;1. This prevents &#x3B1;4&#x3B2;7&#x2010;expressing immune cells from extravasating which leads to a decrease in local inflammatory activity.<xref rid=\"apt16927-bib-0002\" ref-type=\"bibr\">\\n<sup>2</sup>\\n</xref> More recently, vedolizumab has been shown to modulate innate immunity, including macrophage and dendritic cell populations, in addition to adaptive immunity.<xref rid=\"apt16927-bib-0003\" ref-type=\"bibr\">\\n<sup>3</sup>\\n</xref> The limited expression pattern of MAdCAM&#x2010;1 is thought to account for vedolizumab&#x2019;s gut&#x2010;specific immunosuppressive effect which in turn translates into a beneficial safety profile.<xref rid=\"apt16927-bib-0002\" ref-type=\"bibr\">\\n<sup>2</sup>\\n</xref>\\n</p>\\n      <p>Vedolizumab is approved for the treatment of patients with moderate&#x2010;to&#x2010;severe CD or UC, where treatment with conventional therapy or an anti&#x2010;TNF agent has failed. Vedolizumab was originally developed for administration via intravenous (IV) infusions. Recently, a formulation for subcutaneous (SC) administration was approved for maintenance treatment following at least two IV infusions. This approval was based on the phase III trials VISIBLE 1 and VISIBLE 2 which evaluated SC vedolizumab treatment after two initial IV doses in CD and UC patients, respectively.<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> The proportion of subjects in clinical remission 52 weeks after the start of treatment, which was the primary endpoint, was significantly higher in the SC vedolizumab&#x2010;treated group compared to the placebo group, in both trials.<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> Median trough concentrations at steady state during SC vedolizumab were 30.2 and 34.6&#xA0;&#x3BC;g/ml for CD and UC patients, respectively, which was substantially higher than the median trough level during IV treatment presented in VISIBLE 1 (11.1&#xA0;&#x3BC;g/ml).<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> In contrast, the average serum concentrations over time were rather similar (39.8 and 32.2&#xA0;&#x3BC;g/ml, during SC and IV treatment, respectively).<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> Finally, there were no new safety issues observed, other than the incidence of injection&#x2010;site reaction frequencies.<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> However, data on patient experience or satisfaction were not presented in the VISIBLE publications, and studies to investigate the efficacy and safety of switching patients from maintenance IV to maintenance SC vedolizumab treatment in a real&#x2010;world setting are scarce. To our knowledge, there is only one report on the topic, and in that study, the follow&#x2010;up time after the switch was only 12&#x2009;weeks.<xref rid=\"apt16927-bib-0006\" ref-type=\"bibr\">\\n<sup>6</sup>\\n</xref> Given that the half&#x2010;life of the drug is approximately 26&#x2009;days and that the wash&#x2010;out period is several months, such a short follow&#x2010;up time may not be adequate to examine the effectiveness of the SC formulation. Nevertheless, the authors described a 52% increase (<italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.01) in the patients\\' faecal calprotectin levels at the end of their study which was rather unexpected.<xref rid=\"apt16927-bib-0006\" ref-type=\"bibr\">\\n<sup>6</sup>\\n</xref> Thus, further studies are warranted.</p>\\n      <p>There are several potential benefits with SC as compared to IV administration of vedolizumab including a reduced burden of health care resources and increased patient convenience. Potential caveats with SC treatment are increased difficulties to ensure therapy compliance, fewer built&#x2010;in disease follow&#x2010;up visits, possible IV treatment preference and local skin reactions to SC injections.</p>\\n      <p>The aims of this study were to assess efficacy, safety, pharmacokinetics, patient experience, patient satisfaction, and potential cost savings following a switch from IV to SC vedolizumab treatment in patients with inflammatory bowel disease in a real&#x2010;world setting.</p>\\n    </sec>\\n    <sec sec-type=\"methods\" id=\"apt16927-sec-0006\">\\n      <label>2</label>\\n      <title>METHODS</title>\\n      <sec id=\"apt16927-sec-0007\">\\n        <label>2.1</label>\\n        <title>Study design and study population</title>\\n        <p>This was a prospective observational cohort study of a switch from maintenance IV to SC vedolizumab treatment in a population of adult IBD patients. The study was conducted at the Skane University Hospital, Sweden, with a 6&#x2010;month follow&#x2010;up period. Consecutive patients were approached regarding participation. Inclusion criteria comprised signed informed consent; diagnosis of CD, UC or IBD&#x2010;unclassified; and ongoing maintenance treatment with IV vedolizumab (previously received &#x2265;3 doses of IV vedolizumab). Exclusion criteria comprised noticeable difficulties handling an SC injector pen, inability to give informed consent, or inability to comply with study procedures. The study was performed in accordance with the principles of the Declaration of Helsinki. Ethical permission was granted by the regional research ethics committee in Lund, Sweden (DNR 2018/761). All patients provided written informed consent to participation before study entry.</p>\\n        <p>Patients were enrolled between December 2020 and June 2021. The study included a baseline visit, scheduled at the time&#x2010;point when the patient should have received the next dose of IV vedolizumab, and a follow&#x2010;up visit 6&#x2009;months after the switch. A subset of patients, that was the first to be enrolled, could be evaluated also after 12&#xA0;months. Additional visits were scheduled on demand in case of a suspected disease flare or potential side effects. All patients were switched to a dose of 108&#x2009;mg vedolizumab SC every 2&#x2009;weeks regardless of previous dose or dosing interval on IV vedolizumab. All conventional IBD treatments were permitted during the study and changes in the treatment regimen were allowed if clinically indicated. Dose optimization of SC vedolizumab to 108&#x2009;mg weekly was done at the discretion of the treating physician based on a combination of clinical symptoms and biomarker levels. Any changes in treatment regimen throughout the study period were recorded.</p>\\n        <p>Baseline data recorded included diagnosis (CD, UC or IBD&#x2010;unclassified), gender, age at diagnosis, age at inclusion, weight, height, smoking status, time on IV vedolizumab before the switch, IV vedolizumab dose and dosing interval at inclusion, previous and current IBD treatment, disease characteristics according to the Montreal classification, and disease activity at baseline.</p>\\n      </sec>\\n      <sec id=\"apt16927-sec-0008\">\\n        <label>2.2</label>\\n        <title>Study endpoints and definitions</title>\\n        <p>The primary endpoint was change in disease activity defined by faecal calprotectin levels at 6&#x2009;months after the switch to SC vedolizumab treatment. Faecal calprotectin is a sensitive and non&#x2010;subjective measure of disease activity that is not affected by placebo or nocebo effects. It reacts to an early increase in subclinical inflammatory activity and is expected to change earlier than clinical symptom levels in the event of a diminished therapeutic effect.</p>\\n        <p>Secondary endpoints were [all refer to 6&#x2009;months of follow&#x2010;up unless otherwise indicated] (a) change in remission rates defined by a faecal calprotectin &lt;150&#x2009;&#x3BC;g/g and clinical disease activity indices: for CD patient&#x2010;based Harvey Bradshaw Index (HBI)<xref rid=\"apt16927-bib-0007\" ref-type=\"bibr\">\\n<sup>7</sup>\\n</xref>, <xref rid=\"apt16927-bib-0008\" ref-type=\"bibr\">\\n<sup>8</sup>\\n</xref> &#x2264;4 or Patient&#x2010;Reported Outcomes (PRO)2&#x2010;CD &#x2264;11<xref rid=\"apt16927-bib-0009\" ref-type=\"bibr\">\\n<sup>9</sup>\\n</xref> and for UC Simple Clinical Colitis Activity Index (SCCAI)<xref rid=\"apt16927-bib-0010\" ref-type=\"bibr\">\\n<sup>10</sup>\\n</xref> &#x2264;2 or PRO2&#x2010;UC&#xA0;=&#xA0;0.<xref rid=\"apt16927-bib-0009\" ref-type=\"bibr\">\\n<sup>9</sup>\\n</xref> PRO2 scores were applied in accordance with the STRIDE documents.<xref rid=\"apt16927-bib-0009\" ref-type=\"bibr\">\\n<sup>9</sup>\\n</xref> Briefly, the PRO2&#x2010;CD<xref rid=\"apt16927-bib-0011\" ref-type=\"bibr\">\\n<sup>11</sup>\\n</xref> is the sum of the daily soft or liquid stool frequency and abdominal pain (multiplied by the weighting factors 2 and 5, respectively) items from the Crohn&#x2019;s Disease Activity Index, whereas the PRO2&#x2010;UC<xref rid=\"apt16927-bib-0012\" ref-type=\"bibr\">\\n<sup>12</sup>\\n</xref> is the simple sum of the stool frequency and rectal bleeding items from the Mayo score; (b) change in the laboratory biomarker plasma C&#x2010;reactive protein (CRP); (c) change in clinical disease activity defined by the patient&#x2010;based HBI for CD and the SCCAI for UC, as well as symptom levels according to the Patient&#x2010;Reported Outcomes (PRO)&#x2010;2 criteria as described in the STRIDE documents<xref rid=\"apt16927-bib-0009\" ref-type=\"bibr\">\\n<sup>9</sup>\\n</xref>; (d) subgroup analyses of patients that were dose optimised on IV vedolizumab, and patients with perianal CD, respectively; (e) subgroup analysis of patients that completed 12&#xA0;months of follow&#x2010;up, including drug persistence (11 patients that had not completed 12&#xA0;months of follow&#x2010;up but remained on the drug were censored), and evaluation of faecal calprotectin and plasma CRP levels. When all patients had completed the first 6&#x2009;months of follow&#x2010;up, the study was closed and thus not all patients completed 12&#xA0;months of follow&#x2010;up; (f) adverse events and local injection reactions; (g) serum vedolizumab trough levels and relation to faecal calprotectin levels (patients categorised into quartiles based on serum vedolizumab trough levels and median faecal calprotectin levels calculated per quartile), and SC vedolizumab dose optimization rates; (h) patient experience of switching from IV to SC treatment, overall injection experience and patient satisfaction with various aspects of the injector pen [see below for details]; (i) health&#x2010;related quality&#x2010;of&#x2010;life using the Short Health Scale (SHS)<xref rid=\"apt16927-bib-0013\" ref-type=\"bibr\">\\n<sup>13</sup>\\n</xref>, <xref rid=\"apt16927-bib-0014\" ref-type=\"bibr\">\\n<sup>14</sup>\\n</xref> which is a validated four&#x2010;item questionnaire (symptom burden, social function, disease&#x2010;related worry and general well&#x2010;being; each item scored 0&#x2013;5 with an SHS composite score ranging from 0 to 20) and (j) annualised cost savings per patient with SC as compared to IV treatment.</p>\\n        <p>Faecal calprotectin levels were analysed using an enzyme&#x2010;linked immunosorbent assay (ELISA; PhiCal, Calpro AS). Serum vedolizumab trough levels were analysed by a Clinical and Laboratory Standards Institute (CLSI) validated in&#x2010;house developed chemiluminescence ELISA at the Karolinska Institute (Stockholm, Sweden). Both methods are used in clinical routine care and the analyses were performed in clinical laboratories.</p>\\n        <p>Adverse events that occurred after study entry considered related or of possible relation to SC vedolizumab treatment or switch were documented. Local injection reactions including discomfort, pain, burning sensation and erythema; and patient satisfaction with the injector pen, overall injection experience, the experience of switching from IV to SC treatment; were evaluated using structured questionnaires (see Table&#xA0;<xref rid=\"apt16927-tbl-0001\" ref-type=\"table\">1</xref> and Table&#xA0;<xref rid=\"apt16927-supitem-0002\" ref-type=\"supplementary-material\">S1</xref> for details on items, questions asked and response options). The questions and response options were adapted from previously published questionnaires used in similar studies.<xref rid=\"apt16927-bib-0015\" ref-type=\"bibr\">\\n<sup>15</sup>\\n</xref>, <xref rid=\"apt16927-bib-0016\" ref-type=\"bibr\">\\n<sup>16</sup>\\n</xref>, <xref rid=\"apt16927-bib-0017\" ref-type=\"bibr\">\\n<sup>17</sup>\\n</xref>\\n</p>\\n        <table-wrap position=\"float\" id=\"apt16927-tbl-0001\" content-type=\"TABLE\">\\n          <label>TABLE 1</label>\\n          <caption>\\n            <p>Incidence of adverse events and local injection reactions during study</p>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\">\\n            <col align=\"left\" span=\"1\"/>\\n            <col align=\"center\" span=\"1\"/>\\n            <col align=\"center\" span=\"1\"/>\\n            <col align=\"center\" span=\"1\"/>\\n            <thead valign=\"bottom\">\\n              <tr style=\"border-bottom:solid 1px #000000\">\\n                <th align=\"left\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\"/>\\n                <th align=\"center\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">All patients (IBD)</th>\\n                <th align=\"center\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">Crohn&#x2019;s disease</th>\\n                <th align=\"center\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">Ulcerative colitis</th>\\n              </tr>\\n            </thead>\\n            <tbody valign=\"top\">\\n              <tr>\\n                <td colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Local injection reactions (adapted from Dehoratius et al.),<sup>16</sup>\\n<italic toggle=\"yes\">n</italic> (%)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Discomfort</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">None</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">60 (72.3)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">35 (74.5)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">25 (69.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Mild</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">18 (21.7)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">10 (21.3)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8 (22.2)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Moderate</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4 (4.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.3)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (5.6)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Severe</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.8)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Pain</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">None</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">51 (61.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">29 (61.7)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">22 (61.1)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Mild</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">22 (26.5)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">14 (29.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8 (22.2)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Moderate</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">9 (10.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (6.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">6 (16.7)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Severe</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Burning sensation</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">None</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">40 (48.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">22 (46.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">18 (50.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Mild</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">35 (42.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">20 (42.6)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">15 (41.7)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Moderate</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7 (8.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4 (8.5)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (8.3)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Severe</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Erythema</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">None</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">57 (68.7)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">36 (76.6)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">21 (58.3)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Mild</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">16 (19.3)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5 (10.6)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">11 (30.6)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Moderate</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">9 (10.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">6 (12.8)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (8.3)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Severe</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.8)</td>\\n              </tr>\\n              <tr>\\n                <td colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Other adverse events, <italic toggle=\"yes\">n</italic> (%)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Fatigue</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8 (9.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">6 (12.5)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.9)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Headache</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (3.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Nausea</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (3.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (6.3)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Rash</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (3.4)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Arthralgia</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (2.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Clostridium difficile enteritis</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Early satiety</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Herpes labialis</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Hyperhidrosis</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Muscle weakness/faintness</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Nasal congestion</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Nasal ulceration</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Non&#x2010;productive cough</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Paresthesia</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Photosensitivity</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Pruritus</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Sleep disturbance</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Weight loss</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              </tr>\\n              <tr>\\n                <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Xerostomia</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (1.1)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n                <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot id=\"apt16927-ntgp-0002\">\\n            <fn id=\"apt16927-note-0003\">\\n              <p>Abbreviations: IBD, inflammatory bowel disease; <italic toggle=\"yes\">n</italic>, number of patients.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>Annualised treatment costs for IV treatment included the cost of an appointment with a nurse for drug administration and the cost of the drug. Treatment costs of SC treatment included annual drug costs only. The rates of patients that were dose escalated on IV and SC treatment, respectively, were accounted for in the calculation.</p>\\n      </sec>\\n      <sec id=\"apt16927-sec-0009\">\\n        <label>2.3</label>\\n        <title>Statistical analyses</title>\\n        <p>Data are presented as mean values with standard deviation (SD), or median values with interquartile range (IQR) as appropriate. Prism 9 for Mac OS X version 9.3.1 (GraphPad Software, Inc.) was used for statistical analyses and to graph data. The paired&#x2010;samples Student&#x2019;s <italic toggle=\"yes\">t</italic>&#x2010;test alternatively the Wilcoxon matched&#x2010;pair signed&#x2010;rank test was used to compare baseline and follow&#x2010;up data for changes in laboratory biomarkers, disease activity indices and quality&#x2010;of&#x2010;life scores as appropriate depending on data scale type and data distribution. Missing data are shown by presenting numbers of data points in the figures. The complete case analysis method was applied, which together with an account of discontinued patients and data point numbers presented, was deemed to give the most adequate description of the cohort.<xref rid=\"apt16927-bib-0018\" ref-type=\"bibr\">\\n<sup>18</sup>\\n</xref>, <xref rid=\"apt16927-bib-0019\" ref-type=\"bibr\">\\n<sup>19</sup>\\n</xref> The approach was verified by performing sensitivity analyses comprising best&#x2010; and worst&#x2010;case scenario calculations (i.e. missing data equals relapse and remission, respectively), neither of which altered the statistical significance as compared with the complete case analysis.<xref rid=\"apt16927-bib-0019\" ref-type=\"bibr\">\\n<sup>19</sup>\\n</xref> Regarding faecal calprotectin&#x2010;missing data, the missing&#x2010;at&#x2010;random assumption is plausible and the complete case analysis is thus adequate to apply.<xref rid=\"apt16927-bib-0020\" ref-type=\"bibr\">\\n<sup>20</sup>\\n</xref> The Kruskal&#x2013;Wallis test was used to assess differences in faecal calprotectin levels between patient groups stratified by serum vedolizumab trough level quartiles during IV and SC vedolizumab treatment, respectively. The chi&#x2010;square test was used to compare remission rates between groups. Kaplan&#x2013;Meier survival analysis was used to calculate drug persistence. A statistically significant test result was defined by <italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.05.</p>\\n      </sec>\\n    </sec>\\n    <sec sec-type=\"results\" id=\"apt16927-sec-0010\">\\n      <label>3</label>\\n      <title>RESULTS</title>\\n      <p>Eighty&#x2010;nine patients (48 patients with CD, 41 patients with UC and no patients with IBD&#x2010;unclassified) were included in the study. In total, 102 patients were approached regarding participation. Twelve patients declined participation, and one patient did not meet the inclusion criteria (Figure&#xA0;<xref rid=\"apt16927-fig-0001\" ref-type=\"fig\">1</xref>). Baseline patient characteristics, clinical disease activity scores, laboratory biomarkers, concomitant IBD treatment and time on IV vedolizumab are presented in Table&#xA0;<xref rid=\"apt16927-tbl-0002\" ref-type=\"table\">2</xref>. Details on previous IBD treatments and changes during follow&#x2010;up are presented in Table&#xA0;<xref rid=\"apt16927-supitem-0003\" ref-type=\"supplementary-material\">S2</xref>. The median time on IV vedolizumab before the switch was 26.1&#x2009;months (IQR 9.5&#x2013;52.9). The wide IQR illustrates heterogeneity in terms of previous exposure time to vedolizumab. At baseline, four patients received low dose oral prednisolone (1.25&#x2013;10&#xA0;mg daily), and three patients received oral budesonide. Prednisolone could be discontinued in one of these patients. Results refer to 6 months follow&#x2010;up, unless otherwise specified.</p>\\n      <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0001\">\\n        <label>FIGURE 1</label>\\n        <caption>\\n          <p>Flow chart of study design, enrollment of consecutive patients, patients discontinued and reasons for discontinuation during the primary observational follow&#x2010;up period of 6&#x2009;months. Abbreviations: EIM, extraintestinal manifestations; <italic toggle=\"yes\">n</italic>, number of patients</p>\\n        </caption>\\n        <graphic xlink:href=\"APT-55-1389-g002\" position=\"anchor\" id=\"jats-graphic-3\"/>\\n      </fig>\\n      <table-wrap position=\"float\" id=\"apt16927-tbl-0002\" content-type=\"TABLE\">\\n        <label>TABLE 2</label>\\n        <caption>\\n          <p>Demographics and disease characteristics at baseline (study inclusion)</p>\\n        </caption>\\n        <table frame=\"hsides\" rules=\"groups\">\\n          <col align=\"left\" span=\"1\"/>\\n          <col align=\"left\" span=\"1\"/>\\n          <col align=\"left\" span=\"1\"/>\\n          <col align=\"left\" span=\"1\"/>\\n          <thead valign=\"bottom\">\\n            <tr style=\"border-bottom:solid 1px #000000\">\\n              <th align=\"left\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">Baseline demographics and disease characteristics</th>\\n              <th align=\"left\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">All patients (IBD)</th>\\n              <th align=\"left\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">Crohn&#x2019;s disease</th>\\n              <th align=\"left\" valign=\"bottom\" rowspan=\"1\" colspan=\"1\">Ulcerative colitis</th>\\n            </tr>\\n          </thead>\\n          <tbody valign=\"top\">\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">IBD diagnosis, <italic toggle=\"yes\">n</italic> (%)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">89 (100)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">48 (53.9)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">41 (46.1)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Age at baseline (years), Md (range)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">44 (20&#x2013;82)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">46.5 (23&#x2013;82)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">37 (20&#x2013;82)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Age at diagnosis (years), Md (range)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">24 (9&#x2013;76)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">23.5 (9&#x2013;74)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">26 (14&#x2013;76)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Height at baseline (cm), Mn (SD)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">174.2 (&#xB1;11.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">173.2 (&#xB1;11.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">175.5 (&#xB1;11&#x2013;8)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Weight at baseline (kg), Mn (SD)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">79.4 (&#xB1;16.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">77.7 (&#xB1;17.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">81.5 (&#xB1;14.4)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Female:Male ratio, <italic toggle=\"yes\">n</italic> (%)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">43:46 (48.3:51.7)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">25:23 (52.1:47.9)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">18:23 (43.9:56.1)</td>\\n            </tr>\\n            <tr>\\n              <td colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Montreal classification, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Age at diagnosis</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">A1 (&lt;17&#x2009;years)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">10 (11.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7 (14.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (7.3)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">A2 (17&#x2013;40&#x2009;years)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">62 (69.7)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">36 (75)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">26 (63.4)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">A3 (&gt;40&#x2009;years)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">17 (19.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5 (10.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">12 (29.3)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Disease location (Crohn&#x2019;s disease)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">L1 (ileal&#x2009;&#xB1;&#x2009;cecal disease)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">10 (20.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">L2 (colonic)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">12 (25)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">L3 (ileocolonic)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">19 (39.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">L3L4 (ileocolonic and upper gastrointestinal tract)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7 (14.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Disease behaviour (Crohn&#x2019;s disease)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">B1 (uncomplicated)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">28 (58.3)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">B2 (structuring)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">14 (29.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">B3 (penetrating)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">B2B3 (stricturing, penetrating)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5 (10.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">p (perianal)<xref rid=\"apt16927-note-0005\" ref-type=\"table-fn\">\\n<sup>a</sup>\\n</xref>\\n</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">10 (20.9)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Disease extent (ulcerative colitis)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">E1 (proctitis)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5 (12.2)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">E2 (left&#x2010;sided)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">15 (36.6)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">E3 (extensive/pancolitis)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">21 (51.2)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Smoking status, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Never</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">53 (59.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">29 (60.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">24 (58.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Previous</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">29 (32.6)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">13 (27.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">16 (39.0)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Active</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7 (7.9)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">6 (12.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Baseline data</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Faecal calprotectin (&#x3BC;g/g), Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">39.0 (12.5&#x2013;135)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">64.0 (12.5&#x2013;238.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">12.5 (12.5&#x2013;96.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Plasma CRP (mg/L), Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2.0 (2.0&#x2013;2.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2.0 (2.0&#x2013;2.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2.0 (2.0&#x2013;2.0)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Serum vedolizumab trough levels (&#x3BC;g/ml), Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8.1 (5.2&#x2013;14.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8.7 (4.9&#x2013;14.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7.9 (5.3&#x2013;12.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Patient&#x2010;based Harvey Bradshaw Index, Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3.0 (1.0&#x2013;5.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">PRO2&#x2010;CD, Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5.0 (0.5&#x2013;12.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Simple Clinical Colitis Activity Index, Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2.0 (1.0&#x2013;3.0)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">PRO2&#x2010;UC, Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\"/>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0.0 (0.0&#x2013;0.0)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Short Health Scale composite score, Mean (SD)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4.7 (&#xB1;3.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5.1 (&#xB1;3.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4.2 (&#xB1;3.2)</td>\\n            </tr>\\n            <tr>\\n              <td colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">IBD treatment at baseline</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Conventional oral treatment, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5&#x2010;aminosalisylic acid</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">31 (34.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">9 (18.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">22 (53.7)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Azathioprine</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">11 (12.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (6.3)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8 (19.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">6&#x2010;mercaptopurine</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (2.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.9)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Methotrexate</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (2.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.9)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Prednisolone</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4 (4.5)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.9)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Budesonide</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (3.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Topical treatment, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">5&#x2010;aminosalisylic acid</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (3.4)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">3 (7.3)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Corticosteroids<xref rid=\"apt16927-note-0006\" ref-type=\"table-fn\">\\n<sup>b</sup>\\n</xref>\\n</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0.0)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">Concomitant biologic treatment, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Adalimumab</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (2.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n            </tr>\\n            <tr>\\n              <td align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Time on IV vedolizumab (months), Median (IQR)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">26.1 (9.5&#x2013;52.9)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">26.1 (8.7&#x2013;53.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">27.4 (10.8&#x2013;51.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">IV vedolizumab dose</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">300&#x2009;mg, <italic toggle=\"yes\">n</italic> (%)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">87 (97.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">46 (95.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">41 (100)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:15%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">600&#x2009;mg, <italic toggle=\"yes\">n</italic> (%)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (2.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">0 (0)</td>\\n            </tr>\\n            <tr>\\n              <td colspan=\"4\" align=\"left\" valign=\"top\" rowspan=\"1\">IV vedolizumab infusion interval, <italic toggle=\"yes\">n</italic> (%)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8&#x2009;weeks</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">71 (79.8)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">38 (79.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">33 (80.5)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">4&#x2009;weeks</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">9 (10.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">2 (4.2)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">7 (17.1)</td>\\n            </tr>\\n            <tr>\\n              <td style=\"padding-left:10%\" align=\"left\" valign=\"top\" rowspan=\"1\" colspan=\"1\">Other (5&#x2013;7&#x2009;weeks)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">9 (10.1)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">8 (16.7)</td>\\n              <td align=\"char\" char=\"(\" valign=\"top\" rowspan=\"1\" colspan=\"1\">1 (2.4)</td>\\n            </tr>\\n          </tbody>\\n        </table>\\n        <table-wrap-foot id=\"apt16927-ntgp-0003\">\\n          <fn id=\"apt16927-note-0004\">\\n            <p>Abbreviations: CRP, C&#x2010;reactive protein; IBD, inflammatory bowel disease; IQR, interquartile range; IV, intravenous; <italic toggle=\"yes\">n</italic>, number of patients; PRO2&#x2010;CD, Crohn&#x2019;s Disease Activity Index&#x2010;based patient&#x2010;reported outcome for Crohn&#x2019;s disease; PRO2&#x2010;UC, Mayo&#x2010;based patient&#x2010;reported outcome for ulcerative colitis; SD, standard deviation.</p>\\n          </fn>\\n          <fn id=\"apt16927-note-0005\">\\n            <label>\\n<sup>a</sup>\\n</label>\\n            <p>May coexist with B1&#x2010;B3.</p>\\n          </fn>\\n          <fn id=\"apt16927-note-0006\">\\n            <label>\\n<sup>b</sup>\\n</label>\\n            <p>Prednisolone or budesonide.</p>\\n          </fn>\\n        </table-wrap-foot>\\n      </table-wrap>\\n      <sec id=\"apt16927-sec-0011\">\\n        <label>3.1</label>\\n        <title>Changes in disease activity and remission rates 6&#x2009;months after the switch</title>\\n        <p>For the cohort as a whole and the subgroup of CD patients, significant decreases in faecal calprotectin median levels were observed following the switch, whereas no change was seen in UC patients (Figure&#xA0;<xref rid=\"apt16927-fig-0002\" ref-type=\"fig\">2A</xref>). The remission rates as defined by faecal calprotectin remained stable for all three groups (Figure&#xA0;<xref rid=\"apt16927-fig-0002\" ref-type=\"fig\">2B</xref>). A subgroup analysis of faecal calprotectin levels in patients with limited ileal CD showed a median of 145&#x2009;&#x3BC;g/g (IQR 48&#x2013;281) at baseline and 94&#x2009;&#x3BC;g/g (IQR 50.0&#x2013;175.5) at follow&#x2010;up. The corresponding values for the entire CD group were 64.0 (IQR 12.5&#x2013;238.5) &#x3BC;g/g and 49.0&#xA0;&#x3BC;g/g (IQR 12.5&#x2013;161.8), respectively. Analyses of plasma CRP levels did not show any significant changes before compared with after switch for the cohort as a whole, nor in the CD and UC subgroups (data not shown).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0002\">\\n          <label>FIGURE 2</label>\\n          <caption>\\n            <p>Analysis of faecal calprotectin levels and remission rates defined by faecal calprotectin at baseline and 6&#x2009;months after the switch from IV to SC vedolizumab treatment. (A) Faecal calprotectin levels presented as median values with IQR. (B) Proportions of patients in remission as defined by a faecal calprotectin level of &lt;150&#x2009;&#x3BC;g/g. Abbreviations: CD, Crohn&#x2019;s disease; IQR, interquartile range; IV, intravenous; M, months; SC, subcutaneous; UC, ulcerative colitis. *<italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.05</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g007\" position=\"anchor\" id=\"jats-graphic-5\"/>\\n        </fig>\\n        <p>Clinical disease activity in patients with CD, as measured by average patient&#x2010;based HBI and PRO2&#x2010;CD scores, remained unchanged (Figure&#xA0;<xref rid=\"apt16927-fig-0003\" ref-type=\"fig\">3A</xref>). Patients with UC displayed a statistically significant improvement in clinical symptoms according to the SCCAI although the median score remained unchanged, while the PRO2&#x2010;UC score did not show a significant change (Figure&#xA0;<xref rid=\"apt16927-fig-0003\" ref-type=\"fig\">3C</xref>). There were no statistically significant changes in the proportions of patients displaying clinical remission, as defined by patient&#x2010;based HBI &#x2264;4 or PRO2&#x2010;CD &#x2264;11 for patients with CD, and by SCCAI &#x2264;2 or PRO2&#x2010;UC&#xA0;=&#xA0;0 for patients with UC (Figure&#xA0;<xref rid=\"apt16927-fig-0003\" ref-type=\"fig\">3B,D</xref>).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0003\">\\n          <label>FIGURE 3</label>\\n          <caption>\\n            <p>Analysis of clinical disease activity index score levels and remission rates at baseline and 6&#x2009;months after the switch from IV to SC vedolizumab treatment. (A) Patient&#x2010;based HBI and PRO2&#x2010;CD scores for CD patients presented as median values with IQR. (B) Proportions of CD patients in remission as defined by a patient&#x2010;based HBI &#x2264;4 or PRO2&#x2010;CD &#x2264;11. (C) SCCAI and PRO2&#x2010;UC scores for UC patients presented as median values with IQR. (D) Proportions of UC patients in remission as defined by an SCCAI &#x2264;2 or PRO2&#x2010;UC&#xA0;=&#xA0;0. Abbreviations: CD, Crohn&#x2019;s disease; IQR, interquartile range; IV, intravenous; M, months; pHBI, patient&#x2010;based Harvey Bradshaw index; PRO2&#x2010;CD, Crohn&#x2019;s Disease Activity Index&#x2010;based patient&#x2010;reported outcomes&#x2010;2; PRO2&#x2010;UC, Mayo&#x2010;based patient&#x2010;reported outcomes&#x2010;2; SC, subcutaneous; SCCAI, simple clinical colitis activity index; UC, ulcerative colitis. *<italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.05</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g008\" position=\"anchor\" id=\"jats-graphic-7\"/>\\n        </fig>\\n        <p>At baseline, 10 patients had a diagnosis of perianal CD. Three of these had active perianal disease at baseline, and at follow&#x2010;up, this number was two.</p>\\n      </sec>\\n      <sec id=\"apt16927-sec-0012\">\\n        <label>3.2</label>\\n        <title>Subgroup analyses of patients on optimised and standard dosing of <styled-content style=\"fixed-case\" toggle=\"no\">IV</styled-content> vedolizumab</title>\\n        <p>Twenty patients were on optimised IV vedolizumab dosing at baseline. At follow&#x2010;up, there was no significant change in their faecal calprotectin levels, whereas the 69 patients that had been on standard IV vedolizumab dosing showed a small but significant decrease (Figure&#xA0;<xref rid=\"apt16927-fig-0004\" ref-type=\"fig\">4A</xref>). Faecal calprotectin remission rates (Figure&#xA0;<xref rid=\"apt16927-fig-0004\" ref-type=\"fig\">4A</xref>) and plasma CRP median values (data not shown) remained unchanged in both groups. Clinical remission rates remained stable at follow&#x2010;up (Figure&#xA0;<xref rid=\"apt16927-fig-0004\" ref-type=\"fig\">4B,C</xref>) except for the PRO2&#x2010;UC remission rate for UC patients that had been on standard IV vedolizumab dosing, where a statistically significant improvement was seen (Figure&#xA0;<xref rid=\"apt16927-fig-0004\" ref-type=\"fig\">4C</xref>).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0004\">\\n          <label>FIGURE 4</label>\\n          <caption>\\n            <p>Subgroup analysis of faecal calprotectin and clinical disease activity levels at baseline and 6&#x2009;months after the switch from IV to SC vedolizumab treatment for patients on standard versus optimised dosing of IV vedolizumab. (A) Faecal calprotectin levels presented as median values with IQR, and proportions of patients in remission as defined by a faecal calprotectin level of &lt;150&#x2009;&#x3BC;g/g, respectively. (B) Proportions of CD patients in remission as defined by a patient&#x2010;based HBI &#x2264;4 or PRO2&#x2010;CD &#x2264;11. (C) Proportions of UC patients in remission as defined by an SCCAI &#x2264;2 or PRO2&#x2010;UC&#xA0;=&#xA0;0. Abbreviations: CD, Crohn&#x2019;s disease; IQR, interquartile range; IV, intravenous; M, months; pHBI, patient&#x2010;based Harvey Bradshaw index; PRO2&#x2010;CD, Crohn&#x2019;s disease activity index&#x2010;based patient&#x2010;reported outcomes&#x2010;2; PRO2&#x2010;UC, Mayo&#x2010;based patient&#x2010;reported outcomes&#x2010;2; SC, subcutaneous; SCCAI, simple clinical colitis activity index; UC, ulcerative colitis. *<italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.05</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g003\" position=\"anchor\" id=\"jats-graphic-9\"/>\\n        </fig>\\n      </sec>\\n      <sec id=\"apt16927-sec-0013\">\\n        <label>3.3</label>\\n        <title>\\n<styled-content style=\"fixed-case\" toggle=\"no\">SC</styled-content> vedolizumab dose optimization</title>\\n        <p>Dose optimization of SC vedolizumab to 108&#x2009;mg weekly was deemed indicated in 10.1% of patients (6 CD, 3 UC). Three of these (1 CD, 2 UC) belonged to the subgroup of 20 patients (22.5%) that had been on intensified IV vedolizumab dosing before the switch, whereas the other 17 (85%) remained on standard SC dosing. All patients with perianal CD (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;10) remained on treatment, but 3/10 were dose optimised to SC vedolizumab 108&#x2009;mg weekly. No patient required hospitalisation or IV corticosteroid treatment due to disease worsening during the study.</p>\\n      </sec>\\n      <sec id=\"apt16927-sec-0014\">\\n        <label>3.4</label>\\n        <title>Drug persistence and biomarker levels at 12&#xA0;months after the switch</title>\\n        <p>A subset of patients was evaluated at 12&#xA0;months after the switch, in addition to the more comprehensive evaluation after the primary follow&#x2010;up period of 6&#x2009;months. Drug persistence at 6 and 12&#xA0;months were 95.5% (85/89) and 88.5% (69/78), respectively, for the whole cohort (Figure&#xA0;<xref rid=\"apt16927-fig-0005\" ref-type=\"fig\">5</xref>). Reasons for drug discontinuation (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;9) were disease worsening in five patients, change in treatment regimen due to extraintestinal manifestations (present before the switch) in one patient, local injection reaction in one patient and adverse events in two patients (headache and repeated infections). There were no statistically significant changes in plasma CRP levels for the whole cohort (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;50), CD (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;27) or UC (n&#xA0;=&#xA0;23); or in faecal calprotectin levels for the whole cohort (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;20), CD (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;10) or UC (<italic toggle=\"yes\">n</italic>&#xA0;=&#xA0;10), at 12&#xA0;months (data not shown).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0005\">\\n          <label>FIGURE 5</label>\\n          <caption>\\n            <p>Kaplan&#x2013;Meier survival curve for drug persistence after the switch from IV to SC vedolizumab treatment. Events refer to treatment discontinuation. Censored points refer to patients that have not yet completed 12&#xA0;months of follow&#x2010;up</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g004\" position=\"anchor\" id=\"jats-graphic-11\"/>\\n        </fig>\\n      </sec>\\n      <sec id=\"apt16927-sec-0015\">\\n        <label>3.5</label>\\n        <title>Serum vedolizumab concentrations before and after the switch</title>\\n        <p>Median serum vedolizumab trough levels at steady state on IV treatment (i.e. at baseline) were 8.1&#xA0;&#x3BC;g/ml (IQR 5.2&#x2013;14&#x2009;&#x3BC;g/ml) for the whole cohort, 8.7&#xA0;&#x3BC;g/ml (IQR 4.9&#x2013;14.0&#xA0;&#x3BC;g/ml) in CD patients, and 7.9&#xA0;&#x3BC;g/ml (IQR 5.3&#x2013;12.5&#xA0;&#x3BC;g/ml) in UC patients. Median serum vedolizumab trough levels at steady state on SC treatment (i.e. at 6&#x2009;months follow&#x2010;up) were 19.0&#xA0;&#x3BC;g/ml (IQR 13.0&#x2013;23.0&#xA0;&#x3BC;g/ml) for the whole cohort, 19.0&#xA0;&#x3BC;g/ml (IQR 12.0&#x2013;22.8&#xA0;&#x3BC;g/ml) in CD patients, and 18.5&#xA0;&#x3BC;g/ml (IQR 15.0&#x2013;23.8&#xA0;&#x3BC;g/ml) in UC patients. When patients were on IV treatment, we found significantly higher faecal calprotectin levels, primarily among CD patients, in the quartiles with the lowest serum vedolizumab trough levels compared to those with higher serum vedolizumab trough levels (Figure&#xA0;<xref rid=\"apt16927-fig-0006\" ref-type=\"fig\">6A</xref>). This relationship was not observed after patients had been on SC treatment for 6&#xA0;months (Figure&#xA0;<xref rid=\"apt16927-fig-0006\" ref-type=\"fig\">6B</xref>).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0006\">\\n          <label>FIGURE 6</label>\\n          <caption>\\n            <p>Associations between serum vedolizumab trough concentration quartiles (Q1 lowest; Q4 highest) and faecal calprotectin levels during IV and SC treatment for the entire cohort (all patients), and for the subgroups of CD and UC patients. (A) IV vedolizumab treatment. (B) SC vedolizumab treatment. Data are presented as median values with IQR (box), 1.5&#x2009;&#xD7;&#x2009;IQR (whiskers) and outliers. Abbreviations: CD, Crohn&#x2019;s disease; IQR, interquartile range; IV, intravenous; Q, quartile; SC, subcutaneous; UC, ulcerative colitis. *<italic toggle=\"yes\">p</italic>&#x2009;&lt;&#x2009;0.05</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g006\" position=\"anchor\" id=\"jats-graphic-13\"/>\\n        </fig>\\n      </sec>\\n      <sec id=\"apt16927-sec-0016\">\\n        <label>3.6</label>\\n        <title>Quality&#x2010;of&#x2010;life and patient satisfaction regarding the switch and injector pen</title>\\n        <p>We observed no differences in the SHS composite score or separate SHS items (Figure&#xA0;<xref rid=\"apt16927-supitem-0001\" ref-type=\"supplementary-material\">S1</xref>). Patient satisfaction with the injector pen (all eight categories; see Table&#xA0;<xref rid=\"apt16927-supitem-0002\" ref-type=\"supplementary-material\">S1</xref> for details) was high with 94.1%&#x2013;100% of patients responding &#x201C;strongly agree&#x201D;, &#x201C;agree&#x201D; or &#x201C;agree to some extent&#x201D; (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7A</xref>). Overall satisfaction with the injection experience was generally high with 96.4% of the patients reporting being satisfied or very satisfied (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7B</xref>). Generally, patients favoured SC administration over IV (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7C</xref>). Only 2.4&#x2013;9.4% of patients reported a slight preference for IV treatment over SC. Conversely, 55.3% of patients experienced SC treatment as slightly or clearly more effective, and 85.9% slightly or clearly more convenient (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7C</xref>). Regarding overall feeling of security, no preference was the most frequent response (58.8%) and a slight preference for IV treatment was reported by 9.4% of patients (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7C</xref>). Taking all aspects that follow with the given route of administration into account, 83.3% of patients reported a preference for SC over IV treatment, whereas the opposite was true for 2.4% of patients (Figure&#xA0;<xref rid=\"apt16927-fig-0007\" ref-type=\"fig\">7C</xref>).</p>\\n        <fig position=\"float\" fig-type=\"FIGURE\" id=\"apt16927-fig-0007\">\\n          <label>FIGURE 7</label>\\n          <caption>\\n            <p>Patient satisfaction regarding various aspects of handling the vedolizumab injector pen, overall satisfaction with the injection experience, and patient preference comparing various aspects of IV versus SC vedolizumab treatment, based on questionnaires (Table&#xA0;<xref rid=\"apt16927-supitem-0002\" ref-type=\"supplementary-material\">S1</xref>). Data are presented for all patients (entire IBD cohort) collectively. (A) Aspects of handling the vedolizumab injector pen are perceived as easy or difficult to varying degrees. Data are presented as proportions of patients reporting a specific response option ranging from easy to difficult. (B) Satisfaction with the injection experience presented as proportions of patients reporting a specific response option ranging from very satisfied to very dissatisfied. (C) Patient preference comparing IV versus SC treatment in terms of patient&#x2010;perceived therapeutic effect, overall convenience, overall feeling of security and patient preference overall. Data are presented as proportions of patients reporting a specific response option ranging from clear preference for SC treatment to clear preference for IV treatment, with slight preference or no preference as response options in&#x2010;between. Abbreviations: IBD, inflammatory bowel disease; IV, intravenous, SC, subcutaneous</p>\\n          </caption>\\n          <graphic xlink:href=\"APT-55-1389-g005\" position=\"anchor\" id=\"jats-graphic-15\"/>\\n        </fig>\\n      </sec>\\n      <sec id=\"apt16927-sec-0017\">\\n        <label>3.7</label>\\n        <title>Adverse events experienced on <styled-content style=\"fixed-case\" toggle=\"no\">IV</styled-content> and <styled-content style=\"fixed-case\" toggle=\"no\">SC</styled-content> vedolizumab treatment</title>\\n        <p>All reported adverse events are presented in Table&#xA0;<xref rid=\"apt16927-tbl-0001\" ref-type=\"table\">1</xref>. Adverse events, excluding local injection reactions, occurred in 15 (31.3%) of CD patients and 10 (24.4%) of UC patients. The corresponding rates for IV treatment were 27.1% and 22.0%, respectively. Some patients reported several side effects. The most common complaint was fatigue, followed by headache, nausea and rash. No serious adverse events were reported. Data on local skin reactions including discomfort, pain, burning sensation and erythema are presented in Table&#xA0;<xref rid=\"apt16927-tbl-0001\" ref-type=\"table\">1</xref>. The vast majority experienced none or only mild local injection reactions (88.0%&#x2013;94.0% of patients, depending on the type of local injection reaction). Similar numbers were seen among CD and UC patients. Severe local symptoms were reported in only 1.2% of patients for the various subcategories. There was one case of drug discontinuation due to local injection reactions at 12&#xA0;months of follow&#x2010;up, but none during the first 6&#x2009;months.</p>\\n      </sec>\\n      <sec id=\"apt16927-sec-0018\">\\n        <label>3.8</label>\\n        <title>Annualised costs related to <styled-content style=\"fixed-case\" toggle=\"no\">SC</styled-content> as compared with <styled-content style=\"fixed-case\" toggle=\"no\">IV</styled-content> vedolizumab treatment</title>\\n        <p>In Sweden, the current fee for a visit to a registered nurse for administration of an IV infusion is approximately &#x20AC;290; the annual drug cost for IV vedolizumab (standard dosing) is approximately &#x20AC;13,700; and the annual drug cost for SC vedolizumab (standard dosing) is approximately &#x20AC;13,800. During IV vedolizumab treatment, 22.5% of patients required dose optimization (one infusion of 300&#x2009;mg every 4&#x2013;7&#x2009;weeks or 600&#x2009;mg every 8&#x2009;weeks), and during SC vedolizumab treatment 10.1% were dose optimised to 108&#x2009;mg of SC vedolizumab once weekly. Taking these factors into account, the annualised cost of maintenance treatment with SC vedolizumab was 15.0% lower than for maintenance treatment with IV vedolizumab.</p>\\n      </sec>\\n    </sec>\\n    <sec sec-type=\"discussion\" id=\"apt16927-sec-0019\">\\n      <label>4</label>\\n      <title>DISCUSSION</title>\\n      <p>The phase III VISIBLE studies investigated de novo treatment with SC vedolizumab. However, studies on switching patients that are on established maintenance treatment with IV vedolizumab to SC treatment are largely lacking. We report on a switch from IV to SC vedolizumab maintenance treatment in 89 adult IBD patients in a real&#x2010;world setting with a follow&#x2010;up time of 6&#x2009;months and for a subgroup 12&#xA0;months. Our results show that the levels of therapeutic efficacy, quality&#x2010;of&#x2010;life and adverse events were highly similar before as compared to after the switch with a high degree of drug persistence, and that the patients were in general very satisfied with being transferred to self&#x2010;administered SC treatment.</p>\\n      <p>Faecal calprotectin levels showed a statistically significant decrease for the cohort as a whole and for CD patients, while levels remained unchanged for UC patients. However, absolute levels were low and the observed decreases may not be clinically relevant. On the other hand, subclinical changes in faecal calprotectin levels are considered to precede changes in clinical disease activity<xref rid=\"apt16927-bib-0021\" ref-type=\"bibr\">\\n<sup>21</sup>\\n</xref>, <xref rid=\"apt16927-bib-0022\" ref-type=\"bibr\">\\n<sup>22</sup>\\n</xref>, <xref rid=\"apt16927-bib-0023\" ref-type=\"bibr\">\\n<sup>23</sup>\\n</xref>, <xref rid=\"apt16927-bib-0024\" ref-type=\"bibr\">\\n<sup>24</sup>\\n</xref> and decreases of this type may further stabilise a state of clinical remission. Drug persistence was high with 95.5% of patients remaining on treatment after 6&#x2009;months, and 88.5% after 12&#xA0;months. These numbers are in line with those reported for IV vedolizumab treatment, ranging from 60&#x2013;95% after 12&#xA0;months.<xref rid=\"apt16927-bib-0025\" ref-type=\"bibr\">\\n<sup>25</sup>\\n</xref>, <xref rid=\"apt16927-bib-0026\" ref-type=\"bibr\">\\n<sup>26</sup>\\n</xref>, <xref rid=\"apt16927-bib-0027\" ref-type=\"bibr\">\\n<sup>27</sup>\\n</xref>\\n</p>\\n      <p>Our evaluation of the outcome of the switch included thorough investigations of clinical disease activity, applying two activity indices for CD (patient&#x2010;based HBI and PRO2&#x2010;CD) and two for UC (SCCAI and PRO2&#x2010;UC), analysed by both median values and by proportions of patients in remission. All of these analyses corroborated the faecal calprotectin data, showing either unchanged disease activity levels after the switch in both CD and UC patients, or as in the case of SCCAI levels, a statistically significant improvement. For the 10 patients with perianal CD, the patient&#x2010;based HBI questionnaire was of particular interest since it included separate questions regarding active perianal fistula, perianal abscesses and anal fissures. At baseline, 3/10 had an active perianal disease but after the switch the number was 2/10 at follow&#x2010;up. From the literature, it seems that vedolizumab may have some therapeutic effect on perianal CD in a subset of patients, but that the effectiveness overall is moderate.<xref rid=\"apt16927-bib-0028\" ref-type=\"bibr\">\\n<sup>28</sup>\\n</xref>, <xref rid=\"apt16927-bib-0029\" ref-type=\"bibr\">\\n<sup>29</sup>\\n</xref>, <xref rid=\"apt16927-bib-0030\" ref-type=\"bibr\">\\n<sup>30</sup>\\n</xref>, <xref rid=\"apt16927-bib-0031\" ref-type=\"bibr\">\\n<sup>31</sup>\\n</xref> Our results do not contradict this view, but one should be cautious regarding conclusions given the low number of patients with perianal CD.</p>\\n      <p>We also performed a subgroup analysis of patients with limited ileal CD, which showed measurable levels of faecal calprotectin with a numerical decrease after the switch. This confirms that faecal calprotectin was an adequate readout parameter also for this subset of CD patients, which has been debated but several recent studies have shown that faecal calprotectin is a sensitive measure of disease activity also in cases with limited ileal disease.<xref rid=\"apt16927-bib-0032\" ref-type=\"bibr\">\\n<sup>32</sup>\\n</xref>, <xref rid=\"apt16927-bib-0033\" ref-type=\"bibr\">\\n<sup>33</sup>\\n</xref>, <xref rid=\"apt16927-bib-0034\" ref-type=\"bibr\">\\n<sup>34</sup>\\n</xref>, <xref rid=\"apt16927-bib-0035\" ref-type=\"bibr\">\\n<sup>35</sup>\\n</xref>\\n</p>\\n      <p>The SC dose of 108&#x2009;mg every 2&#x2009;weeks was chosen by the manufacturer with the intent to provide patients with similar average serum concentrations at steady state, as the IV dose of 300&#x2009;mg every 8&#x2009;weeks.<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref> However, it is unclear whether average serum concentrations directly translate into levels of therapeutic efficacy. In addition, it is possible that the altered pharmacokinetics that comes with SC administration affect the various mechanisms of action of vedolizumab (i.e. those suggested to take place in the circulation compared to within tissues) in different ways.<xref rid=\"apt16927-bib-0001\" ref-type=\"bibr\">\\n<sup>1</sup>\\n</xref>, <xref rid=\"apt16927-bib-0002\" ref-type=\"bibr\">\\n<sup>2</sup>\\n</xref>, <xref rid=\"apt16927-bib-0003\" ref-type=\"bibr\">\\n<sup>3</sup>\\n</xref> Although the VISIBLE studies gave us an indication as to what serum levels are common with SC vedolizumab at standard dose, the studies did not address which levels are therapeutically optimal. In our study, serum vedolizumab trough concentrations at steady state were approximately twice as high during SC as compared with IV treatment. These findings are in line with the VISIBLE studies<xref rid=\"apt16927-bib-0004\" ref-type=\"bibr\">\\n<sup>4</sup>\\n</xref>, <xref rid=\"apt16927-bib-0005\" ref-type=\"bibr\">\\n<sup>5</sup>\\n</xref> and the study by Ventress et al.<xref rid=\"apt16927-bib-0006\" ref-type=\"bibr\">\\n<sup>6</sup>\\n</xref> Our results suggest an inverse relationship between serum vedolizumab trough levels and faecal calprotectin levels with vedolizumab given IV. However, after 6&#x2009;months with SC vedolizumab at standard dose, this correlation was not seen. This change was primarily observed in CD patients, which also displayed a statistically significant decrease in faecal calprotectin levels after having switched to SC treatment. Our subgroup analyses of patients that had been on optimised IV dosing did not show any signs of disease worsening in terms of remission rates, clinical index scores, biomarker levels or drug persistence, after the switch to standard SC dosing. Interestingly, patients on standard IV dosing showed a statistically significant improvement in faecal calprotectin levels on SC treatment, while other outcome measures remained unchanged. Taken together, these results suggest that some patients were underdosed when being on standard IV dosing and that they were more adequately dosed (or potentially overdosed at the group level) on SC standard dosing.</p>\\n      <p>Ventress et al. suggested that the first dose of SC vedolizumab should be given 28&#x2009;days after the last IV dose. This was based on the assumption that the serum drug concentrations observed in the VISIBLE studies are therapeutically the most appropriate (although this has not been studied) and that the drug levels should be kept at or above this limit.<xref rid=\"apt16927-bib-0006\" ref-type=\"bibr\">\\n<sup>6</sup>\\n</xref> With IV vedolizumab, patients\\' drug levels are below this limit during the entire second half of the 8&#x2010;week dosing interval. There is no evidence that the limited time that serum concentrations are below the SC serum steady&#x2010;state levels in the VISIBLE studies increases the risk of relapse, nor for dose&#x2010;dependent toxicity, if the first SC dose is given in close proximity to the last IV dose.<xref rid=\"apt16927-bib-0036\" ref-type=\"bibr\">\\n<sup>36</sup>\\n</xref>, <xref rid=\"apt16927-bib-0037\" ref-type=\"bibr\">\\n<sup>37</sup>\\n</xref> Thus, with current knowledge and with support from our data we would argue that the first SC dose may be administered when the next IV dose would have been given, or earlier due to potential practical aspects.</p>\\n      <p>In our cohort, the rates of adverse events were similar before and after the switch, and no serious adverse events were reported. Some of the reported symptoms, including fatigue, headache, nausea and arthralgia, were transient and lasted 1&#x2013;2&#x2009;days after injection. The time to the maximum serum concentration after administration of vedolizumab subcutaneously is on average 7&#x2009;days with a variation between 3&#x2013;14&#x2009;days.<xref rid=\"apt16927-bib-0036\" ref-type=\"bibr\">\\n<sup>36</sup>\\n</xref> Such transient reactions are thus not likely to be an effect of the drug per se but more likely representing nonpharmacological potentially immune&#x2010;mediated adverse effects,<xref rid=\"apt16927-bib-0038\" ref-type=\"bibr\">\\n<sup>38</sup>\\n</xref>, <xref rid=\"apt16927-bib-0039\" ref-type=\"bibr\">\\n<sup>39</sup>\\n</xref> alternatively representing a nocebo effect.<xref rid=\"apt16927-bib-0040\" ref-type=\"bibr\">\\n<sup>40</sup>\\n</xref> Investigating local injection reactions, moderate discomfort, pain or burning sensations were reported by 5%&#x2013;11% of patients, and corresponding severe reactions by 1% of the patients. Conversely, 88%&#x2013;94% reported none or only mild local injection reactions. These results are in line with the VISIBLE studies as well as with data for other SC biologics.<xref rid=\"apt16927-bib-0041\" ref-type=\"bibr\">\\n<sup>41</sup>\\n</xref> SC vedolizumab contains citrate which has been pointed out to be causing pain, but studies that have addressed this issue underscore that citrate is merely one of several factors that may affect potential pain sensation at SC injection and that some of the studies attributing pain at the injection site to citrate are difficult to interpret since citrate was one of several factors modified.<xref rid=\"apt16927-bib-0042\" ref-type=\"bibr\">\\n<sup>42</sup>\\n</xref>, <xref rid=\"apt16927-bib-0043\" ref-type=\"bibr\">\\n<sup>43</sup>\\n</xref>, <xref rid=\"apt16927-bib-0044\" ref-type=\"bibr\">\\n<sup>44</sup>\\n</xref> Other factors that may be equally important in this context are other buffers commonly used such as phosphate and histidine, the buffer concentration, injected volume, solution temperature, pH, osmolality, needle gauge, injector device, injection speed, injection technique and low body weight.<xref rid=\"apt16927-bib-0042\" ref-type=\"bibr\">\\n<sup>42</sup>\\n</xref>, <xref rid=\"apt16927-bib-0043\" ref-type=\"bibr\">\\n<sup>43</sup>\\n</xref>, <xref rid=\"apt16927-bib-0044\" ref-type=\"bibr\">\\n<sup>44</sup>\\n</xref>\\n</p>\\n      <p>We also investigated various aspects of the patients\\' experience with the injector pen and the switch from IV to SC treatment. Overall patients found the injector pen to be user&#x2010;friendly and they were very satisfied with switching to SC treatment, which was reflected in all aspects explored. However, this dataset can also be used to illuminate the group of patients, albeit small (2%&#x2013;9%), that preferred IV infusions. Thus, SC administration may not be the best option for all patients.<xref rid=\"apt16927-bib-0045\" ref-type=\"bibr\">\\n<sup>45</sup>\\n</xref> One caveat with SC treatment is that it may be more difficult to ensure patient compliance.<xref rid=\"apt16927-bib-0046\" ref-type=\"bibr\">\\n<sup>46</sup>\\n</xref>, <xref rid=\"apt16927-bib-0047\" ref-type=\"bibr\">\\n<sup>47</sup>\\n</xref> Hence, for patients where compliance historically has been a problem or if risk factors for non&#x2010;adherence are present, IV therapy may be advisable.<xref rid=\"apt16927-bib-0048\" ref-type=\"bibr\">\\n<sup>48</sup>\\n</xref>\\n</p>\\n      <p>Evaluations of health&#x2010;related quality&#x2010;of&#x2010;life using the SHS instrument<xref rid=\"apt16927-bib-0013\" ref-type=\"bibr\">\\n<sup>13</sup>\\n</xref>, <xref rid=\"apt16927-bib-0014\" ref-type=\"bibr\">\\n<sup>14</sup>\\n</xref> showed no statistically significant differences after the switch, but there was a slight numerical trend towards improved overall quality&#x2010;of&#x2010;life as well as better symptom&#x2010;related and social function&#x2010;related quality&#x2010;of&#x2010;life in patients with CD. These findings underscore the high level of satisfaction regarding the switch.</p>\\n      <p>The annualised cost of SC vedolizumab maintenance treatment was calculated to be 15.0% lower than for IV maintenance treatment. Another structural benefit was that nurse resources were liberated for other work tasks. This was especially valuable in times of a pandemic when the number of nurses at the outpatient clinic had to be diminished to enable staffing of Covid&#x2010;19 wards. In addition, avoiding hospital visits in this context was desirable to prevent transmission of the virus.</p>\\n      <p>This study had some important limitations. Firstly, there was no control group that was continued on IV treatment. Secondly, patients were not evaluated endoscopically. Lastly, anti&#x2010;drug antibodies were not measured.</p>\\n      <p>In conclusion, this study shows that a switch from IV to SC vedolizumab maintenance treatment can be done with maintained efficacy, safety and tolerability, including in patients on optimised IV vedolizumab dosing. In addition, patient satisfaction regarding the switch was overall high, although for a small proportion of patients IV treatment may be advisable. The appropriate window for serum vedolizumab concentration to target for combined optimal efficacy, patient convenience and cost&#x2010;effectiveness during SC maintenance treatment, is still unclear and should be addressed in future studies.</p>\\n    </sec>\\n    <sec id=\"apt16927-sec-0024\">\\n      <title>AUTHOR CONTRIBUTIONS</title>\\n      <p>VB contributed with acquisition, analysis and interpretation of data, as well as study design and writing the manuscript. JH was involved in study design, data analysis and data interpretation. DK was involved in study design and data interpretation. JM contributed with the detailed planning of the study including conceptualization and design, analysis and interpretation of data. All authors contributed intellectually to the work carried out within the framework of this study, critically revised the manuscript and approved the final version.</p>\\n    </sec>\\n    <sec id=\"apt16927-sec-0021\">\\n      <title>AUTHORSHIP</title>\\n      <p>\\n<italic toggle=\"yes\">Guarantor of the article:</italic> Jan Marsal.</p>\\n    </sec>\\n    <sec sec-type=\"supplementary-material\">\\n      <title>Supporting information</title>\\n      <supplementary-material id=\"apt16927-supitem-0001\" position=\"float\" content-type=\"local-data\">\\n        <caption>\\n          <p>\\nFigureS 1\\n</p>\\n        </caption>\\n        <media xlink:href=\"APT-55-1389-s002.pdf\">\\n          <caption>\\n            <p>Click here for additional data file.</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n      <supplementary-material id=\"apt16927-supitem-0002\" position=\"float\" content-type=\"local-data\">\\n        <caption>\\n          <p>\\nTableS 1\\n</p>\\n        </caption>\\n        <media xlink:href=\"APT-55-1389-s001.pdf\">\\n          <caption>\\n            <p>Click here for additional data file.</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n      <supplementary-material id=\"apt16927-supitem-0003\" position=\"float\" content-type=\"local-data\">\\n        <caption>\\n          <p>\\nTableS 2\\n</p>\\n        </caption>\\n        <media xlink:href=\"APT-55-1389-s003.pdf\">\\n          <caption>\\n            <p>Click here for additional data file.</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n    </sec>\\n  </body>\\n  <back>\\n    <ack id=\"apt16927-sec-0020\">\\n      <title>ACKNOWLEDGEMENTS</title>\\n      <p>We would especially like to thank research nurses Ida Kapusta and Ann Tornberg at the Gastroenterology Outpatient Clinic at Skane University Hospital for their excellent work in managing patient contact and communication throughout the study as well as for being instrumental in the data capturing process. We would also like to thank the staff at the same outpatient clinic for facilitating this project and for all the hard work during the pandemic.</p>\\n      <p>\\n<italic toggle=\"yes\">Declaration of personal interests:</italic> DK has received speaker honoraria from Norgine. JH has received speaker honoraria from Takeda and has served as a consultant for Janssen&#x2010;Cilag. JM has served as a speaker, consultant or advisory board member for AbbVie, Bayer, Bristol&#x2010;Myers Squibb, Hospira, Janssen&#x2010;Cilag, Merck Sharp &amp; Dohme, Pfizer, Sandoz, Takeda and Union Chimique Belge, and has received grant support from AbbVie, Calpro AS, Fresenius Kabi, Pfizer, SVAR Life Science and Takeda (not for this study).</p>\\n      <p>\\n<italic toggle=\"yes\">Declaration of funding interests:</italic> This work was made possible through the financial support from the Healthcare Region of Southern Sweden, and by grants to researchers in the public health care from the Swedish government (ALFSKANE&#x2010;539811) to Jan Marsal.</p>\\n    </ack>\\n    <sec sec-type=\"data-availability\" id=\"apt16927-sec-0023\">\\n      <title>DATA AVAILABILITY STATEMENT</title>\\n      <p>The data underlying this article will be shared on reasonable request to the corresponding author.</p>\\n    </sec>\\n    <ref-list content-type=\"cited-references\" id=\"apt16927-bibl-0001\">\\n      <title>REFERENCES</title>\\n      <ref id=\"apt16927-bib-0001\">\\n        <label>1</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0001\">\\n<string-name>\\n<surname>Luzentales&#x2010;Simpson</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Pang</surname>\\n<given-names>YCF</given-names>\\n</string-name>, <string-name>\\n<surname>Zhang</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>Sousa</surname>\\n<given-names>JA</given-names>\\n</string-name>, <string-name>\\n<surname>Sly</surname>\\n<given-names>LM</given-names>\\n</string-name>. <article-title>Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases</article-title>. <source>Front Cell Dev Biol</source>. <year>2021</year>;<volume>9</volume>:<elocation-id>612830</elocation-id>.<pub-id pub-id-type=\"pmid\">33614645</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0002\">\\n        <label>2</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0002\">\\n<string-name>\\n<surname>Wyant</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Fedyk</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Abhyankar</surname>\\n<given-names>B</given-names>\\n</string-name>. <article-title>An overview of the mechanism of action of the monoclonal antibody vedolizumab</article-title>. <source>J Crohns Colitis</source>. <year>2016</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1437</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type=\"pmid\">27252400</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0003\">\\n        <label>3</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0003\">\\n<string-name>\\n<surname>Zeissig</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Rosati</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Dowds</surname>\\n<given-names>CM</given-names>\\n</string-name>, <string-name>\\n<surname>Aden</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Bethge</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Schulte</surname>\\n<given-names>B</given-names>\\n</string-name>, et al. <article-title>Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease</article-title>. <source>Gut</source>. <year>2019</year>;<volume>68</volume>(<issue>1</issue>):<fpage>25</fpage>&#x2013;<lpage>39</lpage>.<pub-id pub-id-type=\"pmid\">29730603</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0004\">\\n        <label>4</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0004\">\\n<string-name>\\n<surname>Sandborn</surname>\\n<given-names>WJ</given-names>\\n</string-name>, <string-name>\\n<surname>Baert</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Danese</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Krznari&#x107;</surname>\\n<given-names>&#x17D;</given-names>\\n</string-name>, <string-name>\\n<surname>Kobayashi</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Yao</surname>\\n<given-names>X</given-names>\\n</string-name>, et al. <article-title>Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis</article-title>. <source>Gastroenterology</source>. <year>2020</year>;<volume>158</volume>(<issue>3</issue>):<fpage>562</fpage>&#x2013;<lpage>572 e512</lpage>.<pub-id pub-id-type=\"pmid\">31470005</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0005\">\\n        <label>5</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0005\">\\n<string-name>\\n<surname>Vermeire</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>D&#x2019;Haens</surname>\\n<given-names>G</given-names>\\n</string-name>, <string-name>\\n<surname>Baert</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Danese</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Kobayashi</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Loftus</surname>\\n<given-names>EV</given-names>\\n<suffix>Jr</suffix>\\n</string-name>, et al. <article-title>Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn&#x2019;s disease: results from the VISIBLE 2 randomised trial</article-title>. <source>J Crohns Colitis</source>. <year>2022</year>;<volume>16</volume>(<issue>1</issue>):<fpage>27</fpage>&#x2013;<lpage>38</lpage>.<pub-id pub-id-type=\"pmid\">34402887</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0006\">\\n        <label>6</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0006\">\\n<string-name>\\n<surname>Ventress</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Young</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Rahmany</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Harris</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Bettey</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Smith</surname>\\n<given-names>T</given-names>\\n</string-name>, et al. <article-title>Transitioning from intRavenous to subcutAneous VEdolizumab in patients with infLammatory bowEl diSeaSe (TRAVELESS)</article-title>. <source>J Crohns Colitis</source>. <year>2021</year>; <fpage>jjab224</fpage>.</mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0007\">\\n        <label>7</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0007\">\\n<string-name>\\n<surname>Bjorkesten</surname>\\n<given-names>CG</given-names>\\n</string-name>, <string-name>\\n<surname>Nieminen</surname>\\n<given-names>U</given-names>\\n</string-name>, <string-name>\\n<surname>Turunen</surname>\\n<given-names>U</given-names>\\n</string-name>, <string-name>\\n<surname>Arkkila</surname>\\n<given-names>P</given-names>\\n</string-name>, <string-name>\\n<surname>Sipponen</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Farkkila</surname>\\n<given-names>M</given-names>\\n</string-name>. <article-title>Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti&#x2010;TNF&#x2010;treated luminal Crohn&#x2019;s disease</article-title>. <source>Scand J Gastroenterol</source>. <year>2012</year>;<volume>47</volume>(<issue>5</issue>):<fpage>528</fpage>&#x2013;<lpage>37</lpage>.<pub-id pub-id-type=\"pmid\">22356594</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0008\">\\n        <label>8</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0008\">\\n<string-name>\\n<surname>Harvey</surname>\\n<given-names>RF</given-names>\\n</string-name>, <string-name>\\n<surname>Bradshaw</surname>\\n<given-names>JM</given-names>\\n</string-name>. <article-title>A simple index of Crohn&#x2019;s&#x2010;disease activity</article-title>. <source>Lancet</source>. <year>1980</year>;<volume>1</volume>(<issue>8167</issue>):<fpage>514</fpage>.<pub-id pub-id-type=\"pmid\">6102236</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0009\">\\n        <label>9</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0009\">\\n<string-name>\\n<surname>Turner</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Ricciuto</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>Lewis</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>D\\'Amico</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Dhaliwal</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Griffiths</surname>\\n<given-names>AM</given-names>\\n</string-name>, et al. <article-title>STRIDE&#x2010;II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat&#x2010;to&#x2010;target strategies in IBD</article-title>. <source>Gastroenterology</source>. <year>2021</year>;<volume>160</volume>(<issue>5</issue>):<fpage>1570</fpage>&#x2013;<lpage>83</lpage>.<pub-id pub-id-type=\"pmid\">33359090</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0010\">\\n        <label>10</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0010\">\\n<string-name>\\n<surname>Walmsley</surname>\\n<given-names>RS</given-names>\\n</string-name>, <string-name>\\n<surname>Ayres</surname>\\n<given-names>RC</given-names>\\n</string-name>, <string-name>\\n<surname>Pounder</surname>\\n<given-names>RE</given-names>\\n</string-name>, <string-name>\\n<surname>Allan</surname>\\n<given-names>RN</given-names>\\n</string-name>. <article-title>A simple clinical colitis activity index</article-title>. <source>Gut</source>. <year>1998</year>;<volume>43</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>32</lpage>.<pub-id pub-id-type=\"pmid\">9771402</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0011\">\\n        <label>11</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0011\">\\n<string-name>\\n<surname>Khanna</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Zou</surname>\\n<given-names>G</given-names>\\n</string-name>, <string-name>\\n<surname>D&#x2019;Haens</surname>\\n<given-names>G</given-names>\\n</string-name>, et al. <article-title>A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn&#x2019;s disease activity</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2015</year>;<volume>41</volume>(<issue>1</issue>):<fpage>77</fpage>&#x2013;<lpage>86</lpage>.<pub-id pub-id-type=\"pmid\">25348809</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0012\">\\n        <label>12</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0012\">\\n<string-name>\\n<surname>Jairath</surname>\\n<given-names>V</given-names>\\n</string-name>, <string-name>\\n<surname>Khanna</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Zou</surname>\\n<given-names>GY</given-names>\\n</string-name>, <string-name>\\n<surname>Stitt</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Mosli</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Vandervoort</surname>\\n<given-names>MK</given-names>\\n</string-name>, et al. <article-title>Development of interim patient&#x2010;reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2015</year>;<volume>42</volume>(<issue>10</issue>):<fpage>1200</fpage>&#x2013;<lpage>10</lpage>.<pub-id pub-id-type=\"pmid\">26388424</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0013\">\\n        <label>13</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0013\">\\n<string-name>\\n<surname>Hjortswang</surname>\\n<given-names>H</given-names>\\n</string-name>, <string-name>\\n<surname>Jarnerot</surname>\\n<given-names>G</given-names>\\n</string-name>, <string-name>\\n<surname>Curman</surname>\\n<given-names>B</given-names>\\n</string-name>, et al. <article-title>The short health scale: a valid measure of subjective health in ulcerative colitis</article-title>. <source>Scand J Gastroenterol</source>. <year>2006</year>;<volume>41</volume>(<issue>10</issue>):<fpage>1196</fpage>&#x2013;<lpage>203</lpage>.<pub-id pub-id-type=\"pmid\">16990205</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0014\">\\n        <label>14</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0014\">\\n<string-name>\\n<surname>Stjernman</surname>\\n<given-names>H</given-names>\\n</string-name>, <string-name>\\n<surname>Granno</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Jarnerot</surname>\\n<given-names>G</given-names>\\n</string-name>, et al. <article-title>Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn&#x2019;s disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2008</year>;<volume>14</volume>(<issue>1</issue>):<fpage>47</fpage>&#x2013;<lpage>52</lpage>.<pub-id pub-id-type=\"pmid\">17828783</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0015\">\\n        <label>15</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0015\">\\n<string-name>\\n<surname>Callis Duffin</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Bukhalo</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Bobonich</surname>\\n<given-names>MA</given-names>\\n</string-name>, <string-name>\\n<surname>Shrom</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Zhao</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Kershner</surname>\\n<given-names>J</given-names>\\n</string-name>, et al. <article-title>Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open&#x2010;label clinical trial, including patient&#x2010;reported experience</article-title>. <source>Med Devices (Auckl)</source>. <year>2016</year>;<volume>9</volume>:<fpage>361</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">27785115</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0016\">\\n        <label>16</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0016\">\\n<string-name>\\n<surname>Dehoratius</surname>\\n<given-names>RJ</given-names>\\n</string-name>, <string-name>\\n<surname>Brent</surname>\\n<given-names>LH</given-names>\\n</string-name>, <string-name>\\n<surname>Curtis</surname>\\n<given-names>JR</given-names>\\n</string-name>, <string-name>\\n<surname>Ellis</surname>\\n<given-names>LA</given-names>\\n</string-name>, <string-name>\\n<surname>Tang</surname>\\n<given-names>KL</given-names>\\n</string-name>. <article-title>Satisfaction with subcutaneous golimumab and its auto&#x2010;injector among rheumatoid arthritis patients with inadequate response to adalimumab or etanercept</article-title>. <source>Patient</source>. <year>2018</year>;<volume>11</volume>(<issue>3</issue>):<fpage>361</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">29427176</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0017\">\\n        <label>17</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0017\">\\n<string-name>\\n<surname>Tischer</surname>\\n<given-names>B</given-names>\\n</string-name>, <string-name>\\n<surname>Mehl</surname>\\n<given-names>A</given-names>\\n</string-name>. <article-title>Patients\\' and nurses\\' preferences for autoinjectors for rheumatoid arthritis: results of a European survey</article-title>. <source>Patient Prefer Adherence</source>. <year>2018</year>;<volume>12</volume>:<fpage>1413</fpage>&#x2013;<lpage>24</lpage>.<pub-id pub-id-type=\"pmid\">30122906</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0018\">\\n        <label>18</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0018\">\\n<string-name>\\n<surname>Papp</surname>\\n<given-names>KA</given-names>\\n</string-name>, <string-name>\\n<surname>Fonjallaz</surname>\\n<given-names>P</given-names>\\n</string-name>, <string-name>\\n<surname>Casset&#x2010;Semanaz</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Krueger</surname>\\n<given-names>JG</given-names>\\n</string-name>, <string-name>\\n<surname>Wittkowski</surname>\\n<given-names>KM</given-names>\\n</string-name>. <article-title>Analytical approaches to reporting long&#x2010;term clinical trial data</article-title>. <source>Curr Med Res Opin</source>. <year>2008</year>;<volume>24</volume>(<issue>7</issue>):<fpage>2001</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type=\"pmid\">18534049</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0019\">\\n        <label>19</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0019\">\\n<string-name>\\n<surname>Thabane</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Mbuagbaw</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Zhang</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Samaan</surname>\\n<given-names>Z</given-names>\\n</string-name>, <string-name>\\n<surname>Marcucci</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Ye</surname>\\n<given-names>C</given-names>\\n</string-name>, et al. <article-title>A tutorial on sensitivity analyses in clinical trials: the what, why, when and how</article-title>. <source>BMC Med Res Methodol</source>. <year>2013</year>;<volume>13</volume>:<fpage>92</fpage>.<pub-id pub-id-type=\"pmid\">23855337</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0020\">\\n        <label>20</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0020\">\\n<string-name>\\n<surname>Fu</surname>\\n<given-names>EL</given-names>\\n</string-name>, <string-name>\\n<surname>van Diepen</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Xu</surname>\\n<given-names>Y</given-names>\\n</string-name>, <string-name>\\n<surname>Trevisan</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Dekker</surname>\\n<given-names>FW</given-names>\\n</string-name>, <string-name>\\n<surname>Zoccali</surname>\\n<given-names>C</given-names>\\n</string-name>, et al. <article-title>Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them</article-title>. <source>Clin Kidney J</source>. <year>2021</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1317</fpage>&#x2013;<lpage>26</lpage>.<pub-id pub-id-type=\"pmid\">33959262</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0021\">\\n        <label>21</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0021\">\\n<string-name>\\n<surname>De Vos</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Louis</surname>\\n<given-names>EJ</given-names>\\n</string-name>, <string-name>\\n<surname>Jahnsen</surname>\\n<given-names>J</given-names>\\n</string-name>, et al. <article-title>Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy</article-title>. <source>Inflamm Bowel Dis</source>. <year>2013</year>;<volume>19</volume>(<issue>10</issue>):<fpage>2111</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type=\"pmid\">23883959</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0022\">\\n        <label>22</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0022\">\\n<string-name>\\n<surname>Mao</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Xiao</surname>\\n<given-names>YL</given-names>\\n</string-name>, <string-name>\\n<surname>Gao</surname>\\n<given-names>X</given-names>\\n</string-name>, <string-name>\\n<surname>Chen</surname>\\n<given-names>BL</given-names>\\n</string-name>, <string-name>\\n<surname>He</surname>\\n<given-names>Y</given-names>\\n</string-name>, <string-name>\\n<surname>Yang</surname>\\n<given-names>L</given-names>\\n</string-name>, et al. <article-title>Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta&#x2010;analysis of prospective studies</article-title>. <source>Inflamm Bowel Dis</source>. <year>2012</year>;<volume>18</volume>(<issue>10</issue>):<fpage>1894</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">22238138</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0023\">\\n        <label>23</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0023\">\\n<string-name>\\n<surname>Molander</surname>\\n<given-names>P</given-names>\\n</string-name>, <string-name>\\n<surname>Farkkila</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Ristimaki</surname>\\n<given-names>A</given-names>\\n</string-name>, et al. <article-title>Does fecal calprotectin predict short&#x2010;term relapse after stopping TNFalpha&#x2010;blocking agents in inflammatory bowel disease patients in deep remission?</article-title>\\n<source>J Crohns Colitis</source>. <year>2015</year>;<volume>9</volume>(<issue>1</issue>):<fpage>33</fpage>&#x2013;<lpage>40</lpage>.<pub-id pub-id-type=\"pmid\">25052347</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0024\">\\n        <label>24</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0024\">\\n<string-name>\\n<surname>Tibble</surname>\\n<given-names>JA</given-names>\\n</string-name>, <string-name>\\n<surname>Sigthorsson</surname>\\n<given-names>G</given-names>\\n</string-name>, <string-name>\\n<surname>Bridger</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Fagerhol</surname>\\n<given-names>MK</given-names>\\n</string-name>, <string-name>\\n<surname>Bjarnason</surname>\\n<given-names>I</given-names>\\n</string-name>. <article-title>Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease</article-title>. <source>Gastroenterology</source>. <year>2000</year>;<volume>119</volume>(<issue>1</issue>):<fpage>15</fpage>&#x2013;<lpage>22</lpage>.<pub-id pub-id-type=\"pmid\">10889150</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0025\">\\n        <label>25</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0025\">\\n<string-name>\\n<surname>Eriksson</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Marsal</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Bergemalm</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Vigren</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Bj&#xF6;rk</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Eberhardson</surname>\\n<given-names>M</given-names>\\n</string-name>, et al. <article-title>Long&#x2010;term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for inflammatory bowel disease (SWIBREG)</article-title>. <source>Scand J Gastroenterol</source>. <year>2017</year>;<volume>52</volume>(<issue>6&#x2013;7</issue>):<fpage>722</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">28362144</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0026\">\\n        <label>26</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0026\">\\n<string-name>\\n<surname>Eriksson</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Rundquist</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Lykiardopoulos</surname>\\n<given-names>V</given-names>\\n</string-name>, <string-name>\\n<surname>Udumyan</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Karl&#xE9;n</surname>\\n<given-names>P</given-names>\\n</string-name>, <string-name>\\n<surname>Grip</surname>\\n<given-names>O</given-names>\\n</string-name>, <string-name>\\n<surname>S&#xF6;derman</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Almer</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Hertervig</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Marsal</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Gunnarsson</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Malmgren</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Delin</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Strid</surname>\\n<given-names>H</given-names>\\n</string-name>, <string-name>\\n<surname>Sj&#xF6;berg</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>&#xD6;berg</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Bergemalm</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Hjortswang</surname>\\n<given-names>H</given-names>\\n</string-name>, <string-name>\\n<surname>Halfvarson</surname>\\n<given-names>J</given-names>\\n</string-name>, <collab collab-type=\"authors\">The SWIBREG SVEAH Study Group</collab>\\n<article-title>Real&#x2010;world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study</article-title>. <source>Therap Adv Gastroenterol</source>\\n<year>2021</year>;<volume>14</volume>:<fpage>1</fpage>&#x2013;<lpage>15</lpage>.</mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0027\">\\n        <label>27</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0027\">\\n<string-name>\\n<surname>Reinglas</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Gonczi</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Verdon</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Bessissow</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Afif</surname>\\n<given-names>W</given-names>\\n</string-name>, <string-name>\\n<surname>Wild</surname>\\n<given-names>G</given-names>\\n</string-name>, et al. <article-title>Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center</article-title>. <source>Dig Dis Sci</source>. <year>2020</year>;<volume>65</volume>(<issue>7</issue>):<fpage>2046</fpage>&#x2013;<lpage>53</lpage>.<pub-id pub-id-type=\"pmid\">31813132</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0028\">\\n        <label>28</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0028\">\\n<string-name>\\n<surname>Ayoub</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Odenwald</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Micic</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Dalal</surname>\\n<given-names>SR</given-names>\\n</string-name>, <string-name>\\n<surname>Pekow</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Cohen</surname>\\n<given-names>RD</given-names>\\n</string-name>, et al. <article-title>Vedolizumab for perianal fistulizing Crohn&#x2019;s disease: systematic review and meta&#x2010;analysis</article-title>. <source>Intest Res</source>. <year>2022</year>;<fpage>1</fpage>&#x2013;<lpage>14</lpage>.<pub-id pub-id-type=\"pmid\">35135074</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0029\">\\n        <label>29</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0029\">\\n<string-name>\\n<surname>Chapuis&#x2010;Biron</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name>\\n<surname>Bourrier</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>Nachury</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Nancey</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Bouhnik</surname>\\n<given-names>Y</given-names>\\n</string-name>, <string-name>\\n<surname>Serrero</surname>\\n<given-names>M</given-names>\\n</string-name>, et al. <article-title>Vedolizumab for perianal Crohn&#x2019;s disease: a multicentre cohort study in 151 patients</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>51</volume>(<issue>7</issue>):<fpage>719</fpage>&#x2013;<lpage>27</lpage>.<pub-id pub-id-type=\"pmid\">32080886</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0030\">\\n        <label>30</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0030\">\\n<string-name>\\n<surname>Feagan</surname>\\n<given-names>BG</given-names>\\n</string-name>, <string-name>\\n<surname>Schwartz</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Danese</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Rubin</surname>\\n<given-names>DT</given-names>\\n</string-name>, <string-name>\\n<surname>Lissoos</surname>\\n<given-names>TW</given-names>\\n</string-name>, <string-name>\\n<surname>Xu</surname>\\n<given-names>J</given-names>\\n</string-name>, et al. <article-title>Efficacy of vedolizumab in Fistulising Crohn&#x2019;s disease: exploratory analyses of data from GEMINI 2</article-title>. <source>J Crohns Colitis</source>. <year>2018</year>;<volume>12</volume>(<issue>5</issue>):<fpage>621</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type=\"pmid\">29471381</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0031\">\\n        <label>31</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0031\">\\n<string-name>\\n<surname>Schwartz</surname>\\n<given-names>DA</given-names>\\n</string-name>, <string-name>\\n<surname>Peyrin&#x2010;Biroulet</surname>\\n<given-names>L</given-names>\\n</string-name>, <string-name>\\n<surname>Lasch</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Adsul</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>Danese</surname>\\n<given-names>S</given-names>\\n</string-name>. <article-title>Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn&#x2019;s disease: ENTERPRISE study</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2021</year>;S1542&#x2010;3565(21)01042&#x2010;9.</mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0032\">\\n        <label>32</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0032\">\\n<string-name>\\n<surname>Buisson</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>Mak</surname>\\n<given-names>WY</given-names>\\n</string-name>, <string-name>\\n<surname>Andersen</surname>\\n<given-names>MJ</given-names>\\n</string-name>, et al. <article-title>Fecal calprotectin is highly effective to detect endoscopic ulcerations in Crohn&#x2019;s disease regardless of disease location</article-title>. <source>Inflamm Bowel Dis</source>. <year>2021</year>;<volume>27</volume>(<issue>7</issue>):<fpage>1008</fpage>&#x2013;<lpage>16</lpage>.<pub-id pub-id-type=\"pmid\">33107563</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0033\">\\n        <label>33</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0033\">\\n<string-name>\\n<surname>Iwamoto</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Matsuoka</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Motobayashi</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Takenaka</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Kuno</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Tanaka</surname>\\n<given-names>K</given-names>\\n</string-name>, et al. <article-title>Prediction of disease activity of Crohn&#x2019;s disease through fecal calprotectin evaluated by balloon&#x2010;assisted endoscopy</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2018</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1984</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">29889986</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0034\">\\n        <label>34</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0034\">\\n<string-name>\\n<surname>Jung</surname>\\n<given-names>ES</given-names>\\n</string-name>, <string-name>\\n<surname>Lee</surname>\\n<given-names>SP</given-names>\\n</string-name>, <string-name>\\n<surname>Kae</surname>\\n<given-names>SH</given-names>\\n</string-name>, <string-name>\\n<surname>Kim</surname>\\n<given-names>JH</given-names>\\n</string-name>, <string-name>\\n<surname>Kim</surname>\\n<given-names>HS</given-names>\\n</string-name>, <string-name>\\n<surname>Jang</surname>\\n<given-names>HJ</given-names>\\n</string-name>. <article-title>Diagnostic accuracy of fecal calprotectin for the detection of small bowel Crohn&#x2019;s disease through capsule endoscopy: an updated meta&#x2010;analysis and systematic review</article-title>. <source>Gut Liver</source>. <year>2021</year>;<volume>15</volume>(<issue>5</issue>):<fpage>732</fpage>&#x2013;<lpage>41</lpage>.<pub-id pub-id-type=\"pmid\">33361549</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0035\">\\n        <label>35</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0035\">\\n<string-name>\\n<surname>Kopylov</surname>\\n<given-names>U</given-names>\\n</string-name>, <string-name>\\n<surname>Yung</surname>\\n<given-names>DE</given-names>\\n</string-name>, <string-name>\\n<surname>Engel</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Avni</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Battat</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Ben&#x2010;Horin</surname>\\n<given-names>S</given-names>\\n</string-name>, et al. <article-title>Fecal calprotectin for the prediction of small&#x2010;bowel Crohn&#x2019;s disease by capsule endoscopy: a systematic review and meta&#x2010;analysis</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2016</year>;<volume>28</volume>(<issue>10</issue>):<fpage>1137</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type=\"pmid\">27415156</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0036\">\\n        <label>36</label>\\n        <mixed-citation publication-type=\"miscellaneous\" id=\"apt16927-cit-0036\">\\n<article-title>Entyvio (vedolizumab) &#x2010; Summary of product characteristics (SPC)</article-title>. European Medicines Agency (EMA). <ext-link xlink:href=\"https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf\" ext-link-type=\"uri\">https://www.ema.europa.eu/en/documents/product&#x2010;information/entyvio&#x2010;epar&#x2010;product&#x2010;information_en.pdf</ext-link>. Accessed February 1, 2022.</mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0037\">\\n        <label>37</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0037\">\\n<string-name>\\n<surname>Colombel</surname>\\n<given-names>JF</given-names>\\n</string-name>, <string-name>\\n<surname>Sands</surname>\\n<given-names>BE</given-names>\\n</string-name>, <string-name>\\n<surname>Rutgeerts</surname>\\n<given-names>P</given-names>\\n</string-name>, <string-name>\\n<surname>Sandborn</surname>\\n<given-names>W</given-names>\\n</string-name>, <string-name>\\n<surname>Danese</surname>\\n<given-names>S</given-names>\\n</string-name>, <string-name>\\n<surname>D\\'Haens</surname>\\n<given-names>G</given-names>\\n</string-name>, et al. <article-title>The safety of vedolizumab for ulcerative colitis and Crohn&#x2019;s disease</article-title>. <source>Gut</source>. <year>2017</year>;<volume>66</volume>(<issue>5</issue>):<fpage>839</fpage>&#x2013;<lpage>51</lpage>.<pub-id pub-id-type=\"pmid\">26893500</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0038\">\\n        <label>38</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0038\">\\n<string-name>\\n<surname>Johnson</surname>\\n<given-names>DE</given-names>\\n</string-name>. Biotherapeutics: <article-title>Challenges and opportunities for predictive toxicology of monoclonal antibodies</article-title>. <source>Int J Mol Sci</source>\\n<year>2018</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0039\">\\n        <label>39</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0039\">\\n<string-name>\\n<surname>Patel</surname>\\n<given-names>SV</given-names>\\n</string-name>, <string-name>\\n<surname>Khan</surname>\\n<given-names>DA</given-names>\\n</string-name>. <article-title>Adverse reactions to biologic therapy</article-title>. <source>Immunol Allergy Clin North Am</source>. <year>2017</year>;<volume>37</volume>(<issue>2</issue>):<fpage>397</fpage>&#x2013;<lpage>412</lpage>.<pub-id pub-id-type=\"pmid\">28366484</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0040\">\\n        <label>40</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0040\">\\n<string-name>\\n<surname>Fleischmann</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Jairath</surname>\\n<given-names>V</given-names>\\n</string-name>, <string-name>\\n<surname>Mysler</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Nicholls</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name>\\n<surname>Declerck</surname>\\n<given-names>P</given-names>\\n</string-name>. <article-title>Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?</article-title>\\n<source>Rheumatol Ther</source>. <year>2020</year>;<volume>7</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2013;<lpage>64</lpage>.<pub-id pub-id-type=\"pmid\">31950442</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0041\">\\n        <label>41</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0041\">\\n<string-name>\\n<surname>Thomaidou</surname>\\n<given-names>E</given-names>\\n</string-name>, <string-name>\\n<surname>Ramot</surname>\\n<given-names>Y</given-names>\\n</string-name>. <article-title>Injection site reactions with the use of biological agents</article-title>. <source>Dermatol Ther</source>. <year>2019</year>;<volume>32</volume>(<issue>2</issue>):<elocation-id>e12817</elocation-id>.<pub-id pub-id-type=\"pmid\">30637967</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0042\">\\n        <label>42</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0042\">\\n<string-name>\\n<surname>Shi</surname>\\n<given-names>GH</given-names>\\n</string-name>, <string-name>\\n<surname>Pisupati</surname>\\n<given-names>K</given-names>\\n</string-name>, <string-name>\\n<surname>Parker</surname>\\n<given-names>JG</given-names>\\n</string-name>, <string-name>\\n<surname>Corvari</surname>\\n<given-names>VJ</given-names>\\n</string-name>, <string-name>\\n<surname>Payne</surname>\\n<given-names>CD</given-names>\\n</string-name>, <string-name>\\n<surname>Xu</surname>\\n<given-names>W</given-names>\\n</string-name>, et al. <article-title>Subcutaneous injection site pain of formulation matrices</article-title>. <source>Pharm Res</source>. <year>2021</year>;<volume>38</volume>(<issue>5</issue>):<fpage>779</fpage>&#x2013;<lpage>93</lpage>.<pub-id pub-id-type=\"pmid\">33942212</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0043\">\\n        <label>43</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0043\">\\n<string-name>\\n<surname>St Clair&#x2010;Jones</surname>\\n<given-names>A</given-names>\\n</string-name>, <string-name>\\n<surname>Prignano</surname>\\n<given-names>F</given-names>\\n</string-name>, <string-name>\\n<surname>Goncalves</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Paul</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Sewerin</surname>\\n<given-names>P</given-names>\\n</string-name>. <article-title>Understanding and Minimising injection&#x2010;site pain following subcutaneous Administration of Biologics: a narrative review</article-title>. <source>Rheumatol Ther</source>. <year>2020</year>;<volume>7</volume>(<issue>4</issue>):<fpage>741</fpage>&#x2013;<lpage>57</lpage>.<pub-id pub-id-type=\"pmid\">33206343</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0044\">\\n        <label>44</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0044\">\\n<string-name>\\n<surname>Usach</surname>\\n<given-names>I</given-names>\\n</string-name>, <string-name>\\n<surname>Martinez</surname>\\n<given-names>R</given-names>\\n</string-name>, <string-name>\\n<surname>Festini</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name>\\n<surname>Peris</surname>\\n<given-names>JE</given-names>\\n</string-name>. <article-title>Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site</article-title>. <source>Adv Ther</source>. <year>2019</year>;<volume>36</volume>(<issue>11</issue>):<fpage>2986</fpage>&#x2013;<lpage>96</lpage>.<pub-id pub-id-type=\"pmid\">31587143</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0045\">\\n        <label>45</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0045\">\\n<string-name>\\n<surname>Allen</surname>\\n<given-names>PB</given-names>\\n</string-name>, <string-name>\\n<surname>Lindsay</surname>\\n<given-names>H</given-names>\\n</string-name>, <string-name>\\n<surname>Tham</surname>\\n<given-names>TC</given-names>\\n</string-name>. <article-title>How do patients with inflammatory bowel disease want their biological therapy administered?</article-title>\\n<source>BMC Gastroenterol</source>. <year>2010</year>;<volume>10</volume>:<fpage>1</fpage>.<pub-id pub-id-type=\"pmid\">20064220</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0046\">\\n        <label>46</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0046\">\\n<string-name>\\n<surname>van der Have</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name>\\n<surname>Oldenburg</surname>\\n<given-names>B</given-names>\\n</string-name>, <string-name>\\n<surname>Kaptein</surname>\\n<given-names>AA</given-names>\\n</string-name>, <string-name>\\n<surname>Jansen</surname>\\n<given-names>JM</given-names>\\n</string-name>, <string-name>\\n<surname>Scheffer</surname>\\n<given-names>RCH</given-names>\\n</string-name>, <string-name>\\n<surname>van Tuyl</surname>\\n<given-names>BA</given-names>\\n</string-name>, et al. <article-title>Non&#x2010;adherence to anti&#x2010;TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study</article-title>. <source>J Crohns Colitis</source>. <year>2016</year>;<volume>10</volume>(<issue>5</issue>):<fpage>549</fpage>&#x2013;<lpage>55</lpage>.<pub-id pub-id-type=\"pmid\">26738757</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0047\">\\n        <label>47</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0047\">\\n<string-name>\\n<surname>Wentworth</surname>\\n<given-names>BJ</given-names>\\n</string-name>, <string-name>\\n<surname>Buerlein</surname>\\n<given-names>RCD</given-names>\\n</string-name>, <string-name>\\n<surname>Tuskey</surname>\\n<given-names>AG</given-names>\\n</string-name>, <string-name>\\n<surname>Overby</surname>\\n<given-names>MA</given-names>\\n</string-name>, <string-name>\\n<surname>Smolkin</surname>\\n<given-names>ME</given-names>\\n</string-name>, <string-name>\\n<surname>Behm</surname>\\n<given-names>BW</given-names>\\n</string-name>. <article-title>Nonadherence to biologic therapies in inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2018</year>;<volume>24</volume>(<issue>9</issue>):<fpage>2053</fpage>&#x2013;<lpage>61</lpage>.<pub-id pub-id-type=\"pmid\">29668917</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"apt16927-bib-0048\">\\n        <label>48</label>\\n        <mixed-citation publication-type=\"journal\" id=\"apt16927-cit-0048\">\\n<string-name>\\n<surname>Shah</surname>\\n<given-names>NB</given-names>\\n</string-name>, <string-name>\\n<surname>Haydek</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Slaughter</surname>\\n<given-names>J</given-names>\\n</string-name>, <string-name>\\n<surname>Ashton</surname>\\n<given-names>JR</given-names>\\n<suffix>Jr</suffix>\\n</string-name>, <string-name>\\n<surname>Zuckerman</surname>\\n<given-names>AD</given-names>\\n</string-name>, <string-name>\\n<surname>Wong</surname>\\n<given-names>R</given-names>\\n</string-name>, et al. <article-title>Risk factors for medication nonadherence to self&#x2010;injectable biologic therapy in adult patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2020</year>;<volume>26</volume>(<issue>2</issue>):<fpage>314</fpage>&#x2013;<lpage>20</lpage>.<pub-id pub-id-type=\"pmid\">31671188</pub-id></mixed-citation>\\n      </ref>\\n    </ref-list>\\n  </back>\\n</article>\\n<article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" dtd-version=\"1.3\" xml:lang=\"en\" article-type=\"research-article\">\\n  <?properties open_access?>\\n  <processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\">\\n    <restricted-by>pmc</restricted-by>\\n  </processing-meta>\\n  <front>\\n    <journal-meta>\\n      <journal-id journal-id-type=\"nlm-ta\">J Crohns Colitis</journal-id>\\n      <journal-id journal-id-type=\"iso-abbrev\">J Crohns Colitis</journal-id>\\n      <journal-id journal-id-type=\"publisher-id\">eccojc</journal-id>\\n      <journal-title-group>\\n        <journal-title>Journal of Crohn\\'s &amp; Colitis</journal-title>\\n      </journal-title-group>\\n      <issn pub-type=\"ppub\">1873-9946</issn>\\n      <issn pub-type=\"epub\">1876-4479</issn>\\n      <publisher>\\n        <publisher-name>Oxford University Press</publisher-name>\\n        <publisher-loc>UK</publisher-loc>\\n      </publisher>\\n    </journal-meta>\\n    <article-meta>\\n      <article-id pub-id-type=\"pmid\">35301512</article-id>\\n      <article-id pub-id-type=\"pmc\">9426668</article-id>\\n      <article-id pub-id-type=\"doi\">10.1093/ecco-jcc/jjac036</article-id>\\n      <article-id pub-id-type=\"publisher-id\">jjac036</article-id>\\n      <article-categories>\\n        <subj-group subj-group-type=\"heading\">\\n          <subject>Original Articles</subject>\\n        </subj-group>\\n        <subj-group subj-group-type=\"category-taxonomy-collection\">\\n          <subject>AcademicSubjects/MED00260</subject>\\n        </subj-group>\\n      </article-categories>\\n      <title-group>\\n        <article-title>Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn&#x2019;s Disease: Results from the Phase 2 HUBBLE Study</article-title>\\n      </title-group>\\n      <contrib-group>\\n        <contrib contrib-type=\"author\" corresp=\"yes\">\\n          <name>\\n            <surname>Hyams</surname>\\n            <given-names>Jeffrey S</given-names>\\n          </name>\\n          <aff>\\n<institution>Connecticut Children&#x2019;s Medical Center</institution>, <addr-line>Hartford, CT</addr-line>, <country country=\"US\">USA</country></aff>\\n          <xref rid=\"c1\" ref-type=\"corresp\"/>\\n          <!--Jhyams@connecticutchildrens.org-->\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Turner</surname>\\n            <given-names>Dan</given-names>\\n          </name>\\n          <aff>\\n<institution>Shaare Zedek Medical Center, The Hebrew University of Jerusalem</institution>, <addr-line>Jerusalem</addr-line>, <country country=\"IL\">Israel</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Cohen</surname>\\n            <given-names>Stanley A</given-names>\\n          </name>\\n          <aff>\\n<institution>Children&#x2019;s Center for Digestive Health Care</institution>, <addr-line>Atlanta, GA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Szakos</surname>\\n            <given-names>Erzs&#xE9;bet</given-names>\\n          </name>\\n          <aff>\\n<institution>Borsod-A-Z County Central University Teaching Hospital, Velkey Laszlo Paediatric Health Centre, University of Miskolc</institution>, <addr-line>Miskolc</addr-line>, <country country=\"HU\">Hungary</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Kowalska-Duplaga</surname>\\n            <given-names>Kinga</given-names>\\n          </name>\\n          <aff>\\n<institution>Department of Paediatrics, Gastroenterology and Nutrition, Jagiellonian University Medical College</institution>, <addr-line>Krak&#xF3;w</addr-line>, <country country=\"PL\">Poland</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Ruemmele</surname>\\n            <given-names>Frank</given-names>\\n          </name>\\n          <aff>\\n<institution>Universit&#xE9; de Paris, APHP, H&#xF4;pital Necker Enfants Malades, Paediatric Gastroenterology</institution>, <addr-line>Paris</addr-line>, <country country=\"FR\">France</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Croft</surname>\\n            <given-names>Nicholas M</given-names>\\n          </name>\\n          <aff>\\n<institution>Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London and The Royal London Children&#x2019;s Hospital, Barts Health NHS Trust</institution>, <addr-line>London</addr-line>, <country country=\"GB\">UK</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Korczowski</surname>\\n            <given-names>Bartosz</given-names>\\n          </name>\\n          <aff>\\n<institution>Department of Paediatrics and Paediatric Gastroenterology, University of Rzesz&#xF3;w</institution>, <addr-line>Rzesz&#xF3;w</addr-line>, <country country=\"PL\">Poland</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Lawrence</surname>\\n            <given-names>Promise</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Bhatia</surname>\\n            <given-names>Siddharth</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Kadali</surname>\\n            <given-names>Harisha</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Chen</surname>\\n            <given-names>Chunlin</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n          <xref rid=\"fn-0001\" ref-type=\"author-notes\"/>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Sun</surname>\\n            <given-names>Wan</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n          <xref rid=\"fn-0001\" ref-type=\"author-notes\"/>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Rosario</surname>\\n            <given-names>Maria</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n          <xref rid=\"fn-0001\" ref-type=\"author-notes\"/>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Kabilan</surname>\\n            <given-names>Senthil</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Treem</surname>\\n            <given-names>William</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Rossiter</surname>\\n            <given-names>Guillermo</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n        </contrib>\\n        <contrib contrib-type=\"author\">\\n          <name>\\n            <surname>Lirio</surname>\\n            <given-names>Richard A</given-names>\\n          </name>\\n          <aff>\\n<institution>Takeda</institution>, <addr-line>Cambridge, MA</addr-line>, <country country=\"US\">USA</country></aff>\\n          <xref rid=\"fn-0001\" ref-type=\"author-notes\"/>\\n        </contrib>\\n      </contrib-group>\\n      <author-notes>\\n        <corresp id=\"c1\">Corresponding author: Jeffrey S. Hyams, Connecticut Children&#x2019;s Medical Center, Hartford, CT, USA. Tel: <phone>+1 860 545 9532</phone>; Email: <email>Jhyams@connecticutchildrens.org</email></corresp>\\n        <fn id=\"fn-0001\">\\n          <p>Employees of Takeda at the time of this research.</p>\\n        </fn>\\n      </author-notes>\\n      <pub-date pub-type=\"collection\">\\n        <month>8</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <pub-date pub-type=\"epub\" iso-8601-date=\"2022-03-17\">\\n        <day>17</day>\\n        <month>3</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <pub-date pub-type=\"pmc-release\">\\n        <day>17</day>\\n        <month>3</month>\\n        <year>2022</year>\\n      </pub-date>\\n      <volume>16</volume>\\n      <issue>8</issue>\\n      <fpage>1243</fpage>\\n      <lpage>1254</lpage>\\n      <history>\\n        <date date-type=\"received\">\\n          <day>11</day>\\n          <month>10</month>\\n          <year>2021</year>\\n        </date>\\n        <date date-type=\"rev-recd\">\\n          <day>10</day>\\n          <month>2</month>\\n          <year>2022</year>\\n        </date>\\n        <date date-type=\"accepted\">\\n          <day>16</day>\\n          <month>3</month>\\n          <year>2022</year>\\n        </date>\\n        <date date-type=\"corrected-typeset\">\\n          <day>26</day>\\n          <month>4</month>\\n          <year>2022</year>\\n        </date>\\n      </history>\\n      <permissions>\\n        <copyright-statement>&#xA9; The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn&#x2019;s and Colitis Organisation.</copyright-statement>\\n        <copyright-year>2022</copyright-year>\\n        <license>\\n          <ali:license_ref xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" specific-use=\"textmining\" content-type=\"ccbylicense\">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>\\n          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by/4.0/\">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>\\n        </license>\\n      </permissions>\\n      <self-uri xlink:href=\"jjac036.pdf\"/>\\n      <abstract>\\n        <title>Abstract</title>\\n        <sec id=\"s1\">\\n          <title>Background and Aims</title>\\n          <p>To date, there are no systematic pharmacokinetic [PK] data on vedolizumab in paediatric inflammatory bowel disease [IBD]. We report results from HUBBLE, a dose-ranging, phase 2 trial evaluating the PK, safety and efficacy of intravenous vedolizumab for paediatric IBD.</p>\\n        </sec>\\n        <sec id=\"s2\">\\n          <title>Methods</title>\\n          <p>Enrolled patients [aged 2&#x2013;17 years] with moderate to severe ulcerative colitis [UC] or Crohn&#x2019;s disease [CD] and body weight &#x2265;10 kg were randomized by weight to receive low- or high-dose vedolizumab [&#x2265;30 kg, 150 or 300 mg; &lt;30 kg, 100 or 200 mg] on Day 1 and Weeks 2, 6 and 14. Week 14 assessments included PK, clinical response and exposure&#x2013;response relationship. Safety and immunogenicity were assessed.</p>\\n        </sec>\\n        <sec id=\"s3\">\\n          <title>Results</title>\\n          <p>Randomized patients weighing &#x2265;30 kg [UC, <italic toggle=\"yes\">n</italic> = 25; CD, <italic toggle=\"yes\">n</italic> = 24] and &lt;30 kg [UC, <italic toggle=\"yes\">n</italic> = 19; CD, <italic toggle=\"yes\">n</italic> = 21] had a baseline mean [standard deviation] age of 13.5 [2.5] and 7.6 [3.2] years, respectively. In almost all indication and weight groups, area under the concentration curve and average concentration increased ~2-fold from low to high dose; the trough concentration was higher in each high-dose arm compared with the low-dose arms. At Week 14, clinical response occurred in 40.0&#x2013;69.2% of patients with UC and 33.3&#x2013;63.6% with CD in both weight groups. Clinical responders with UC generally had higher trough concentration vs non-responders, while this trend was not observed in CD. Fourteen per cent [12/88] of patients had treatment-related adverse events and 6.8% [6/88] had anti-drug antibodies.</p>\\n        </sec>\\n        <sec id=\"s4\">\\n          <title>Conclusions</title>\\n          <p>Vedolizumab exposure increased in an approximate dose-proportional manner. No clear dose&#x2013;response relationship was observed in this limited cohort. No new safety signals were identified.</p>\\n        </sec>\\n      </abstract>\\n      <abstract abstract-type=\"graphical\">\\n        <title>Graphical Abstract</title>\\n        <p>\\n<fig position=\"float\" id=\"ga1\"><label>Graphical Abstract</label><graphic xlink:href=\"jjac036f0004\" position=\"float\"/></fig>\\n</p>\\n      </abstract>\\n      <kwd-group>\\n        <kwd>Endoscopy</kwd>\\n        <kwd>clinical trials</kwd>\\n        <kwd>paediatrics</kwd>\\n      </kwd-group>\\n      <funding-group>\\n        <award-group award-type=\"grant\">\\n          <funding-source>\\n<institution-wrap><institution>Takeda Foundation</institution><institution-id institution-id-type=\"DOI\">10.13039/100016925</institution-id></institution-wrap>\\n</funding-source>\\n        </award-group>\\n      </funding-group>\\n      <counts>\\n        <page-count count=\"12\"/>\\n      </counts>\\n    </article-meta>\\n  </front>\\n  <body>\\n    <sec id=\"s5\">\\n      <title>1. Introduction</title>\\n      <p>Paediatric ulcerative colitis [UC] and Crohn&#x2019;s disease [CD] share many features with the adult forms of the illnesses. However, children with UC and CD also have age-related complications related to growth, development, nutrition, bone mineral density accretion and psychosocial needs.<sup><xref rid=\"CIT0001\" ref-type=\"bibr\">1</xref></sup> Unlike biological therapy in adults, where weight-based dosing is linear, in young children with a body weight &lt;30 kg, a higher dose per kilogram may be required to achieve similar trough concentration levels.<sup><xref rid=\"CIT0002\" ref-type=\"bibr\">2</xref></sup> This highlights the importance of dose-ranging studies in paediatric inflammatory bowel disease [IBD] to determine the optimal dose in all paediatric age groups.</p>\\n      <p>The IBD treatment landscape has improved for children and adults since the development of biological therapy world-wide. In the USA, for example, several biologics are approved by the US Food and Drug Administration [FDA] for adults, two of which are also available for children. Intravenous [IV] infliximab [REMICADE, Janssen Biotech, Inc.] was the first to receive FDA approval for adults with UC and CD, and later for paediatric patients with IBD;<sup><xref rid=\"CIT0003\" ref-type=\"bibr\">3</xref></sup> subsequently, subcutaneous [SC] adalimumab [HUMIRA, AbbVie, Inc.] was FDA-approved for both adult and paediatric patients with UC and CD.<sup><xref rid=\"CIT0004\" ref-type=\"bibr\">4</xref></sup> IV and SC ustekinumab [STELARA, Janssen Biotech, Inc.] are FDA-approved for use only in adult, but not paediatric patients with UC and CD [currently in phase 3 trials in paediatric patients with CD and UC].<sup><xref rid=\"CIT0005\" ref-type=\"bibr\">5</xref></sup> Oral tofacitinib [XELJANZ, Pfizer, Inc.] and SC golimumab [SIMPONI, Janssen Biotech] are both FDA-approved for adult patients with UC, whereas phase 3 trials in paediatric patients with UC are ongoing.<sup><xref rid=\"CIT0006\" ref-type=\"bibr\">6</xref>,<xref rid=\"CIT0007\" ref-type=\"bibr\">7</xref></sup> IV vedolizumab [ENTYVIO, Takeda Pharmaceuticals U.S.A., Inc.] is indicated for adults with moderately to severely active UC and CD,<sup><xref rid=\"CIT0008\" ref-type=\"bibr\">8</xref></sup> and paediatric phase 3 trials in UC<sup><xref rid=\"CIT0009\" ref-type=\"bibr\">9</xref></sup> and CD<sup><xref rid=\"CIT0010\" ref-type=\"bibr\">10</xref></sup> are now underway. Real-world studies evaluating off-label use of biologics, such as ustekinumab<sup><xref rid=\"CIT0011\" ref-type=\"bibr\">11</xref>,<xref rid=\"CIT0012\" ref-type=\"bibr\">12</xref></sup> and vedolizumab,<sup><xref rid=\"CIT0013\" ref-type=\"bibr\">13&#x2013;15</xref></sup> in the paediatric population suggest positive outcomes, but the safety and efficacy findings await confirmation from clinical trial data.</p>\\n      <p>In previous adult studies of IV vedolizumab, positive exposure&#x2013;response relationships for clinical response and remission were demonstrated, and these relationships appeared to be steeper in patients with UC than in those with CD.<sup><xref rid=\"CIT0016\" ref-type=\"bibr\">16</xref></sup> However, an effective and safe dose of IV vedolizumab in children has yet to be determined. Data from a previously developed population pharmacokinetic [PK] model based on vedolizumab phase 3 study results in adult patients with UC or CD were used to select the dose and weight groups evaluated in this paediatric study.<sup><xref rid=\"CIT0017\" ref-type=\"bibr\">17</xref></sup> Here, we now report results of HUBBLE, a paediatric phase 2 study of IV vedolizumab, a gut-selective monoclonal anti-&#x3B1;<sub>4</sub>&#x3B2;<sub>7</sub>-integrin antibody evaluating PK, safety and efficacy of IV vedolizumab in paediatric patients with UC and CD.</p>\\n    </sec>\\n    <sec id=\"s6\">\\n      <title>2. Methods</title>\\n      <sec id=\"s7\">\\n        <title>2.1. Study population</title>\\n        <p>This study enrolled male and female paediatric patients [aged 2&#x2013;17 years; body weight &#x2265;10 kg] with moderate to severe UC or CD who failed to respond or were intolerant to corticosteroids, immunomodulators and/or tumour necrosis factor [TNF] antagonists. Moderately to severely active UC was defined as a complete Mayo score of 6&#x2013;12, a total of Mayo subscores of stool frequency and rectal bleeding of &#x2265;4, and an endoscopy subscore of &#x2265;2.<sup><xref rid=\"CIT0018\" ref-type=\"bibr\">18</xref></sup> Moderately to severely active CD was defined as a simple endoscopic score for CD [SES-CD] of &#x2265;7, the CD activity index [CDAI] components of average daily abdominal pain score of &gt;1, and total number of liquid/very soft stools &gt;10 for the 7 days before the first dose of study drug.<sup><xref rid=\"CIT0019\" ref-type=\"bibr\">19</xref>,<xref rid=\"CIT0020\" ref-type=\"bibr\">20</xref></sup> Patients were excluded for previous exposure to approved or investigational anti-integrins, positive progressive multifocal leukoencephalopathy [PML] subjective symptom checklist, and current or anticipated surgical intervention for UC or CD. See the <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Methods</xref> for complete inclusion and exclusion criteria.</p>\\n      </sec>\\n      <sec id=\"s8\">\\n        <title>2.2. Study design</title>\\n        <p>HUBBLE [NCT03138655; EudraCT #2017-002231-41] was an international, phase 2, randomized, dose-ranging study. Patients with body weight &#x2265;30 kg were enrolled at nine US and 14 non-US sites, and those weighing &lt;30 kg were enrolled at seven US and 16 non-US sites. Patients were randomized 1:1 by body weight to receive a low or high IV vedolizumab dose [&#x2265;30 kg, 150 or 300 mg; &lt;30 kg, 100 or 200 mg] on Day 1 and at Weeks 2, 6 and 14 [<xref rid=\"sup2\" ref-type=\"supplementary-material\">Supplementary Figure 1</xref>]. An interactive web response system was used for patient randomization and for dispensing medication ID number of the investigational drug. The high and low doses were selected on the basis of simulations performed using a population PK model derived from IV vedolizumab adult phase 3 data.<sup><xref rid=\"CIT0017\" ref-type=\"bibr\">17</xref></sup> Randomization was stratified by previous exposure/failure to TNF&#x3B1; antagonist therapy or na&#xEF;vety to TNF&#x3B1; antagonist therapy, by indication [UC or CD] and by body weight group [&#x2265;30 or &lt;30 kg]. Patients randomized to low-dose IV vedolizumab who did not show any clinical response were escalated to a high dose at Week 14. At Week 22, patients with clinical response could continue vedolizumab treatment in an extension study.</p>\\n        <p>Oral 5-aminosalicylic acid [5-ASA], immunomodulators and corticosteroids [CS] were permitted during the study. Oral 5-ASA and immunomodulators had to be maintained at a constant dose throughout the first 14 weeks of the study. CS could be maintained at a maximum dose of &#x2264;50 mg/day of prednisone [or equivalent steroid] or could be tapered down from the maximum dose under a specific protocol [see <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Methods</xref> for more details on permitted medications and the CS tapering protocol].</p>\\n      </sec>\\n      <sec id=\"s9\">\\n        <title>2.3. Study endpoints and assessments</title>\\n        <sec id=\"s10\">\\n          <title>2.3.1. PK and immunogenicity</title>\\n          <p>The primary endpoints evaluated were PK parameters at Week 14 including area under the serum concentration curve [AUC], average concentration [<italic toggle=\"yes\">C</italic><sub>avg</sub>] and observed serum concentration at the end of the dosing interval [<italic toggle=\"yes\">C</italic><sub>trough</sub>]. Blood samples for PK assessment were collected post-dose on Day 1 and at Weeks 1 and 2, between Weeks 2 and 6, at Weeks 6, 10, 14 and 22, and at the final safety visit 18 weeks after the last dose of the study.</p>\\n          <p>Vedolizumab serum concentrations were measured using a validated sandwich enzyme-linked immunosorbent assay, as previously described.<sup><xref rid=\"CIT0017\" ref-type=\"bibr\">17</xref></sup> Immunogenicity of vedolizumab was measured on the basis of the development of anti-drug antibodies [ADAs]. Blood samples were obtained within 30 min before dosing on Day 1 and at Weeks 2, 6, 14 and 22/early termination visit, and at any unscheduled visit for a patient who experienced a serious adverse event [AE] or disease exacerbation. Serum titres of ADAs were determined using a validated drug-tolerant electrochemiluminescence assay.<sup><xref rid=\"CIT0021\" ref-type=\"bibr\">21</xref></sup></p>\\n        </sec>\\n        <sec id=\"s11\">\\n          <title>2.3.2. Efficacy</title>\\n          <p>Disease activity was assessed at screening and during the study for efficacy using the Mayo and paediatric UC activity index [PUCAI] scores in UC, and the CDAI, paediatric CD activity index [PCDAI] and SES-CD scores in CD.<sup><xref rid=\"CIT0018\" ref-type=\"bibr\">18&#x2013;20</xref></sup> For the clinical components of the scores, patients with UC or CD, or their parents/legal guardians made daily entries into a diary, and laboratory results [CD only] were collected during screening and the study period. Flexible sigmoidoscopy/colonoscopy assessed by a central reader was used to assess the endoscopic component of the Mayo score in patients with UC and the SES-CD score in patients with CD.</p>\\n          <p>Secondary efficacy endpoints included the proportion of patients with UC who achieved clinical response at Week 14&#x2014;defined as a reduction in complete Mayo score of &#x2265;3 points and &#x2265;30% reduction from baseline, with an accompanying decrease in rectal bleeding subscore of &#x2265;1 point or absolute rectal bleeding subscore of &#x2264;1 point&#x2014;and in CD as a &#x2265;70-point decrease from baseline in CDAI score.</p>\\n          <p>Exploratory efficacy endpoints at Week 14 included: enhanced clinical response rate based on CDAI [&#x2265;100-point decrease from baseline in score]; clinical response rate based on a composite of SES-CD [&#x2265;50% reduction from baseline in score or score of 0&#x2013;2] plus CDAI [decrease in average daily abdominal pain score of &gt;0.25]; clinical response rate based on paediatric measures of PUCAI [&#x2265;20-point decrease from baseline in score] and PCDAI [&#x2265;15-point decrease from baseline in score and maximum total score of &#x2264;30]; clinical remission rates based on each of the adult and paediatric measures [see definitions of clinical remission in <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Methods</xref>]; and mean changes from baseline in faecal calprotectin.</p>\\n        </sec>\\n        <sec id=\"s12\">\\n          <title>2.3.3. Vedolizumab exposure&#x2013;response relationship</title>\\n          <p>The IV vedolizumab exposure&#x2013;response relationship was assessed at Week 14. This relationship was explored by evaluating <italic toggle=\"yes\">C</italic><sub>trough</sub> by clinical response in each treatment group, for each indication and weight group separately. <italic toggle=\"yes\">C</italic><sub>trough</sub> by clinical responsiveness was defined as a &#x2265;3-point decrease and &#x2265;30% reduction from baseline in complete Mayo score for UC, and a &#x2265;70-point decrease from baseline in CDAI score for CD. According to paediatric measures, <italic toggle=\"yes\">C</italic><sub>trough</sub> by clinical responsiveness was defined as a &#x2265;20-point decrease from baseline in PUCAI score for UC and &#x2265;15-point decrease from baseline in PCDAI score for CD.</p>\\n        </sec>\\n        <sec id=\"s13\">\\n          <title>2.3.4. Safety</title>\\n          <p>Safety assessments of all AEs and serious AEs that occurred throughout the study were conducted. AEs were categorized according to the <italic toggle=\"yes\">Medical Dictionary for Regulatory Activities</italic> [MedDRA; versions 22.0 and 23.0U].</p>\\n        </sec>\\n      </sec>\\n      <sec id=\"s14\">\\n        <title>2.4. Statistical analyses</title>\\n        <sec id=\"s15\">\\n          <title>2.4.1. Overview</title>\\n          <p>The full analysis set [FAS] and safety analysis set included all patients who received at least one dose of study drug according to the treatment they were randomized to receive or treatment that they actually received, respectively. The PK set was defined as all patients who received at least one dose of study drug and had at least one measurable concentration of vedolizumab. All statistical analyses were conducted using SAS version 9.2 or higher.</p>\\n        </sec>\\n        <sec id=\"s16\">\\n          <title>2.4.2. Sample size calculation</title>\\n          <p>The planned sample size was 80 patients including 40 with a body weight of &#x2265;30 kg and 40 with a body weight of 10 to &lt;30 kg. Randomization caps were implemented to ensure that the sample size for each dose regimen was a minimum of nine patients with UC and nine patients with CD per weight group. A sample size of nine patients was expected to have &#x2265;80% power to establish 95% confidence intervals [CIs] that were between 60% and 140% of the geometric mean estimates for total clearance after IV vedolizumab administration for each dose, indication and weight group, assuming the inter-patient variability for clearance in the paediatric population was similar to that in the adult population [% coefficient of variation &#x2264;36.6%]. The sample size was based on industry guidance and was not adjusted for anticipated dropouts.<sup><xref rid=\"CIT0022\" ref-type=\"bibr\">22</xref>,<xref rid=\"CIT0023\" ref-type=\"bibr\">23</xref></sup> The planned sample size was intended to allow for descriptive analysis of exposure and efficacy for each indication and dosing group.</p>\\n        </sec>\\n        <sec id=\"s17\">\\n          <title>2.4.3. Primary and secondary efficacy analyses</title>\\n          <p>All proportion-based efficacy endpoints are summarized by indication [UC or CD], weight group and treatment group. The point estimate, 95% Jeffrey&#x2019;s interval and 95% CI based on Clopper&#x2013;Pearson method are presented. Patients with any component of a scale missing were considered to be non-responders for that particular endpoint, scale and time point.</p>\\n        </sec>\\n        <sec id=\"s18\">\\n          <title>2.4.4. PK and immunogenicity analyses</title>\\n          <p>Descriptive statistics were used to summarize serum concentrations of vedolizumab over time and all PK parameters according to dose and weight groups; <italic toggle=\"yes\">C</italic><sub>trough</sub> was also summarized according to response status. The PK parameters were derived by compartmental and/or non-compartmental approaches. This study was not designed or powered for hypothesis testing or comparing different groups.</p>\\n          <p>The proportions of patients who were confirmed as ADA positive (persistent [positive ADA on at least two consecutive samples] or transient) or negative were summarized by weight group and treatment group for each indication separately in the FAS. Missing ADA data were not imputed.</p>\\n        </sec>\\n      </sec>\\n      <sec sec-type=\"data-availability\" id=\"s19\">\\n        <label>2.5.</label>\\n        <title>Data availability</title>\\n        <p>The datasets, including the redacted study protocol, redacted statistical analysis plan and individual participants&#x2019; data supporting the results reported in this article, will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Data are available upon request via application at <ext-link xlink:href=\"https://search.vivli.org\" ext-link-type=\"uri\">https://search.vivli.org</ext-link>.</p>\\n      </sec>\\n      <sec id=\"s20\">\\n        <label>2.6.</label>\\n        <title>Study ethics and consent</title>\\n        <p>The patient, or the patient&#x2019;s legally acceptable representative, signed and dated an informed consent/assent form and patient authorization form [if applicable] prior to entering the study. The study was approved by the Institutional Review Board [or equivalent] at each participating centre.</p>\\n      </sec>\\n    </sec>\\n    <sec id=\"s21\">\\n      <title>3. Results</title>\\n      <sec id=\"s22\">\\n        <title>3.1. Study population</title>\\n        <p>There were no differences in demographic characteristics between patients with UC and CD [<xref rid=\"T1\" ref-type=\"table\">Table 1</xref>]. There were some apparent differences between dose groups in baseline disease characteristics but comparisons are limited by the small sample size [<xref rid=\"T2\" ref-type=\"table\">Table 2</xref>].</p>\\n        <table-wrap position=\"float\" id=\"T1\">\\n          <label>Table 1.</label>\\n          <caption>\\n            <p>Baseline demographic characteristics in patients with UC or CD</p>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" width=\"100%\" border=\"1\">\\n            <colgroup span=\"1\">\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th align=\"left\" rowspan=\"3\" colspan=\"1\"/>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">UC</th>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">CD</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 25]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 19]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 24]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 21]</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 13]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 9]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 11]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Age, years</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12.4 [2.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.9 [2.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.0 [3.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.0 [3.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.4 [2.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">14.3 [2.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.4 [3.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.1 [2.7]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">14.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6.5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">15.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.5</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Age categories, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Children, 2&#x2013;11 years<sup>a</sup></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [30.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [16.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [90.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [88.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [25.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [16.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [81.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [90.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Adolescents, 12&#x2013;17 years</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [69.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [83.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [10.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [11.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [75.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [83.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [18.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [10.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Sex, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Male</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [61.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [60.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [55.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [33.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [75.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [63.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [50.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Female</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [38.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [40.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [44.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [66.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [25.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [36.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [50.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Height, cm</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">153.1 [17.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">160.0 [13.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">119.6 [23.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">122.4 [18.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">157.9 [15.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">158.0 [10.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">120.6 [20.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">124.7 [13.9]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">156.0 [128.0&#x2013;176.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">159.7 [138.3&#x2013;185.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">118.0 [82.7&#x2013;146.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">125.8 [84.9&#x2013;143.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">162.7 [134.3&#x2013;182.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">155.9 [141.9&#x2013;181.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">128.0 [83.5&#x2013;146.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">130.0 [96.5&#x2013;137.6]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Body weight, kg</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">46.2 [12.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">54.0 [14.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">22.4 [6.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">23.2 [6.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">51.5 [13.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">45.9 [10.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">22.1 [6.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">23.4 [5.1]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">47.6 [30.3&#x2013;75.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">52.9 [32.0&#x2013;78.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">22.7 [12.8&#x2013;29.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">25.4 [10.2&#x2013;29.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">47.7 [31.4&#x2013; 79.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">41.4 [33.9&#x2013;68.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">24.1 [12.0&#x2013;29.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">24.5 [14.3&#x2013;30.0]</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"T1Fn1\">\\n              <p>CD, Crohn&#x2019;s disease; SD, standard deviation; UC, ulcerative colitis; VDZ, vedolizumab.</p>\\n            </fn>\\n            <fn id=\"T1Fn2\">\\n              <p>The youngest patient in the &#x2265;30 kg category was aged 8 years at enrolment.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <table-wrap position=\"float\" id=\"T2\">\\n          <label>Table 2.</label>\\n          <caption>\\n            <p>Baseline disease characteristics in patients with [A] UC or [B] CD</p>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" width=\"100%\" border=\"1\">\\n            <colgroup span=\"1\">\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">A</th>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"2\" colspan=\"1\"/>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">UC</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 25]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 19]</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">Characteristic</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 13]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 9]</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Disease duration</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD], years<sup>a</sup></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.0 [2.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.7 [2.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.2 [2.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.6 [2.7]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Faecal calprotectin</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;&gt;500 &#x3BC;g/g, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12 [92.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [75.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [80.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [77.8]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range], &#x3BC;g/g</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2517.0 [410.0&#x2013;10 654.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1466.0 [147.0&#x2013;2996.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1193.5 [48.0&#x2013;5546.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1824.0 [10.0&#x2013;10 685.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">C-reactive protein</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD], mg/L</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.5 [4.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6.2 [11.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.2 [15.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6.9 [7.1]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range], mg/L</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0.4 [0.2&#x2013;15.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1.9 [0.2&#x2013;39.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.3 [0.2&#x2013;50.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3.3 [0.2&#x2013;19.3]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Anti-TNF antagonist history, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Na&#xEF;ve</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [61.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [80.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [77.8]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Exposed/failed</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [38.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [20.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [22.2]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Complete Mayo score</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.4 [1.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.5 [2.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.9 [1.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9.0 [1.4]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.0 [4.0&#x2013;10.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.0 [6.0&#x2013;12.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8.5 [6.0&#x2013;11.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9.0 [7.0&#x2013;11.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">PUCAI score</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">46.5 [16.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">50.4 [19.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">56.0 [8.10]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">54.4 [13.1]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">50.0 [5.0&#x2013;70.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">42.5 [25.0&#x2013;80.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">55.0 [45.0&#x2013;70.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">50.0 [40.0&#x2013;80.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Mayo endoscopic subscore</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Severe, score of 3, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [15.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [41.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [60.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [44.4]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Concomitant medication use,<xref rid=\"T2Fn3\" ref-type=\"table-fn\"><sup>b</sup></xref><italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Corticosteroids</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Immunomodulators</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2</td>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">B</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"2\" colspan=\"1\"/>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">CD</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 24]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 21]</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">Characteristic</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 11]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Disease duration</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD], years<sup>a</sup></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3.7 [2.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4.4 [2.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.0 [1.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2.2 [2.4]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Faecal calprotectin</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;&gt;500 &#x3BC;g/g, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [66.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [83.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [90.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [80.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range], &#x3BC;g/g</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1257.5 [408.0&#x2013;10 737.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1421.0 [22.0&#x2013;2922.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1495.0 [483.0&#x2013;4578.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1155.0 [162.0&#x2013;18 978]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">C-reactive protein</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD], mg/L</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">21.8 [32.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.5 [33.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">17.1 [40.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">27.2 [46.5]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range], mg/L</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3.3 [0.2&#x2013;103.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">18.0 [0.2&#x2013;99.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1.8 [0.2&#x2013;135.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.9 [0.2&#x2013;142.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Anti-TNF agonist history, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Na&#xEF;ve</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [25.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [25.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [54.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [40.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Exposed/failed</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [75.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [75.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [45.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [60.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">CDAI total score</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">213.9 [113.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">250.7 [49.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">258.2 [57.9]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">220.2 [120.1]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">163.8 [117.0&#x2013;492.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">271.0 [172.0&#x2013;307.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">265.8 [129.0&#x2013;354.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">203.7 [89.0&#x2013;426.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">PCDAI score</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">28.4 [10.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">35.0 [9.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">32.5 [10.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.0 [10.8]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Median [range]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.0 [15.0&#x2013;45.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">36.3 [23.0&#x2013;50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">35.0 [5.0&#x2013;45.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">27.5 [18.0&#x2013;48.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">SES-CD score</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Patients, <italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mean [SD]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12.9 [5.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">16.6 [6.1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11.2 [8.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.9 [5.7]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Severe, score of &gt;15, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [33.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [50.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [27.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [30.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Concomitant medication use,<xref rid=\"T2Fn3\" ref-type=\"table-fn\"><sup>b</sup></xref><italic toggle=\"yes\">n</italic></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Corticosteroids</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Immunomodulators</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"T2Fn1\">\\n              <p>CD, Crohn&#x2019;s disease; CDAI, Crohn&#x2019;s disease activity index; PCDAI, paediatric Crohn&#x2019;s disease activity index; PUCAI, paediatric ulcerative colitis activity index; SD, standard deviation; SES-CD, simple endoscopic score for Crohn&#x2019;s disease; TNF, tumour necrosis factor; UC, ulcerative colitis; VDZ, vedolizumab.</p>\\n            </fn>\\n            <fn id=\"T2Fn2\">\\n              <p>Disease duration was defined as the date from first diagnosis to date of informed consent.</p>\\n            </fn>\\n            <fn id=\"T2Fn3\">\\n              <p>Concomitant medications were those given prior or during the screening period and ongoing at informed consent and/or post-baseline/Day 1.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>Patient disposition in the study is shown in <xref rid=\"F1\" ref-type=\"fig\">Figure 1</xref>. Twelve [27.3%] of 44 patients with UC and ten [22.2%] of 45 patients with CD discontinued from the study. There was no difference in the discontinuation rate between weight groups. Compliance [number of completed infusions out of a total of four infusions] was 99% for patients weighing &#x2265;30 kg and 98% for those &lt;30 kg, with an overall mean (standard deviation [SD]) of 3.7 [0.7] and 3.7 [0.9] infusions completed [total amount of study drug infused] respectively.</p>\\n        <fig position=\"float\" id=\"F1\">\\n          <label>Figure 1.</label>\\n          <caption>\\n            <p>Patient disposition. AE, adverse event; CD, Crohn&#x2019;s disease; TNF, tumour necrosis factor; UC, ulcerative colitis. <sup>a</sup>Randomization stratified by previous exposure/failure to TNF antagonist therapy or na&#xEF;vety to TNF antagonist therapy, by indication [UC or CD] and by weight group [&#x2265;30 kg, or 10 to &lt;30 kg]. <sup>b</sup>Includes one patient who received dose escalation to 300 mg vedolizumab at Week 14. <sup>c</sup>Includes five patients who received dose escalation to 300 mg vedolizumab at Week 14. <sup>d</sup>Worsening disease [<italic toggle=\"yes\">n</italic> = 8] and lymphopenia considered associated with azathioprine use [<italic toggle=\"yes\">n</italic> = 1]. <sup>e</sup>This patient was randomized but not treated with study drug. <sup>f</sup>Lack of efficacy [<italic toggle=\"yes\">n</italic> = 1] and no improvement of disease [<italic toggle=\"yes\">n</italic> = 1]. <sup>g</sup>Based on clinical response criteria. <sup>h</sup>Worsening disease [UC or CD; <italic toggle=\"yes\">n</italic> = 5] and <italic toggle=\"yes\">Clostridium difficile</italic> infection and procedural intestinal perforation in one patient with UC [<italic toggle=\"yes\">n</italic> = 1]. <sup>i</sup>Worsening disease and transition to other treatment option [<italic toggle=\"yes\">n</italic> = 1], patient needed enteral nutrition [<italic toggle=\"yes\">n</italic> = 1] and worsening CD [<italic toggle=\"yes\">n</italic> = 1].</p>\\n          </caption>\\n          <graphic xlink:href=\"jjac036f0001\" position=\"float\"/>\\n        </fig>\\n      </sec>\\n      <sec id=\"s23\">\\n        <title>3.2. PK and immunogenicity</title>\\n        <p>In these paediatric patients with moderately to severely active UC and CD, vedolizumab serum exposure increased in an approximately dose-proportional manner for both weight groups. Consistently higher <italic toggle=\"yes\">C</italic><sub>trough</sub> at Week 14 were observed in the high-dose groups, and Week 14 <italic toggle=\"yes\">C</italic><sub>avg</sub> increased ~2-fold over the dose range from 150 to 300 mg in patients weighing &#x2265;30 kg and from 100 to 200 mg in patients &lt;30 kg [<xref rid=\"F2\" ref-type=\"fig\">Figure 2</xref>]. Mean [SD] <italic toggle=\"yes\">C</italic><sub>trough</sub> for all patients [combined CD and UC] was 10.4 [13.8] and 14.7 [15.7] &#xB5;g/mL in patients weighing &#x2265;30 kg and 9.0 [8.4] and 10.5 [10.5] &#xB5;g/mL in those weighing &lt;30 kg in the low- and high-dose groups, respectively.</p>\\n        <fig position=\"float\" id=\"F2\">\\n          <label>Figure 2.</label>\\n          <caption>\\n            <p>Pharmacokinetic parameters of VDZ AUC, <italic toggle=\"yes\">C</italic><sub>avg</sub> and <italic toggle=\"yes\">C</italic><sub>trough</sub> at Week 14 in patients with [A] ulcerative colitis and [B] Crohn&#x2019;s disease [pharmacokinetic analysis set]. <italic toggle=\"yes\">N</italic> = 88; one patient was randomized but not treated. The pharmacokinetic analysis set was defined as all patients who received at least one dose of VDZ and had at least one measurable concentration of VDZ. AUC, area under the serum concentration curve; <italic toggle=\"yes\">C</italic><sub>avg</sub>, average concentration; <italic toggle=\"yes\">C</italic><sub>trough</sub>, observed serum concentration at the end of the dosing interval; CV, coefficient of variation; IQR, interquartile range; SD, standard deviation; VDZ, vedolizumab; WK, Week.</p>\\n          </caption>\\n          <graphic xlink:href=\"jjac036f0002\" position=\"float\"/>\\n        </fig>\\n        <p>In paediatric patients weighing &#x2265;30 kg, vedolizumab Week 14 serum concentrations and derived PK parameters [particularly <italic toggle=\"yes\">C</italic><sub>trough</sub> but less so AUC or <italic toggle=\"yes\">C</italic><sub>avg</sub>] were higher for patients with UC compared with patients with CD. This difference was not observed for patients weighing &lt;30 kg.</p>\\n        <p>Six [6.8%] of 88 patients were ADA-positive. Three patients [all with UC] were persistently ADA-positive [with two or more consecutive confirmed positive samples]. Among patients weighing &#x2265;30 kg, 12.0% [3/25] with UC [all in the 150 mg group] were ADA-positive at any time during the study and 8.7% [2/23] with CD were ADA-positive [both patients were in the 300 mg group]. Among patients weighing &lt;30 kg, 5.3% [1/19] with UC [100 mg group] were ADA-positive but no patients with CD were ADA-positive. Overall, there was no apparent trend suggesting that positive ADA status had a negative impact on PK parameters or achievement of clinical response at Week 14. However, interpretation of this is limited due to the small number of patients who were positive for ADA.</p>\\n        <p>There was no trend showing that co-administration of immunomodulators was associated with a decrease in ADA rate in patients weighing &#x2265;30 kg for both UC and CD. The impact of immunomodulators on immunogenicity in patients weighing &lt;30 kg could not be evaluated because there was only one positive ADA case in this group.</p>\\n      </sec>\\n      <sec id=\"s24\">\\n        <title>3.3. Efficacy and exposure&#x2013;response</title>\\n        <p>According to adult measures, clinical response rates across weight and dose groups at Week 14 ranged from 40.0 to 69.2% in patients with UC [based on a reduction in complete Mayo score of &#x2265;3 points and &#x2265;30% from baseline] and from 33.3 to 63.6% in patients with CD [based on a &#x2265;70-point decrease from baseline in CDAI score] [<xref rid=\"T3\" ref-type=\"table\">Table 3</xref>]. The enhanced clinical response rates [&#x2265;100-point decrease from baseline in CDAI score] at Week 14 ranged from 25.0% to 63.6% in patients with CD [<xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 1</xref>]. Clinical response [based on a composite of improvements in CDAI abdominal pain/stool subscores and SES-CD score] occurred at lower rates than the other clinical endpoints in patients with CD [<xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 2</xref>].</p>\\n        <table-wrap position=\"float\" id=\"T3\">\\n          <label>Table 3.</label>\\n          <caption>\\n            <p>Clinical response rates among patients with UC or CD [based on complete Mayo<xref rid=\"T3Fn3\" ref-type=\"table-fn\"><sup>a</sup></xref> or CDAI<xref rid=\"T3Fn4\" ref-type=\"table-fn\"><sup>b</sup></xref> scores] at Week 14 [full analysis set]</p>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" width=\"100%\" border=\"1\">\\n            <colgroup span=\"1\">\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th align=\"left\" rowspan=\"3\" colspan=\"1\"/>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">UC</th>\\n                <th align=\"left\" colspan=\"4\" rowspan=\"1\">CD</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 25]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 19]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 23]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 21]</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 13]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 9]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">150 mg VDZ [<italic toggle=\"yes\">n</italic> = 11]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">300 mg VDZ [<italic toggle=\"yes\">n</italic> = 12]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">100 mg VDZ [<italic toggle=\"yes\">n</italic> = 11]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">200 mg VDZ [<italic toggle=\"yes\">n</italic> = 10]</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Responder, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [69.2]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [41.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [40.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [66.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [45.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [33.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [63.6]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [40.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Jeffreys 95% CI<xref rid=\"T3Fn5\" ref-type=\"table-fn\"><sup>c</sup></xref></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">42.3&#x2013;88.6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">18.0&#x2013;68.8</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">15.3&#x2013;69.6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">34.8&#x2013;89.6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">20.0&#x2013;73.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12.5&#x2013;61.2</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">34.8&#x2013;86.3</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">15.3&#x2013;69.6</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Exact 95% CI<xref rid=\"T3Fn6\" ref-type=\"table-fn\"><sup>d</sup></xref></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">38.6&#x2013;90.9</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">15.2&#x2013;72.3</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12.2&#x2013;73.8</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">29.9&#x2013;92.5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">16.7&#x2013;76.6</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9.9&#x2013;65.1</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.8&#x2013;89.1</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">12.2&#x2013;73.8</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Non-responder, <italic toggle=\"yes\">n</italic> [%]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [30.8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [58.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [60.0]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [33.3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [54.5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">8 [66.7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [36.4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [60.0]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Jeffreys 95% CI<xref rid=\"T3Fn5\" ref-type=\"table-fn\"><sup>c</sup></xref></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">11.4&#x2013;57.7</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">31.2&#x2013;82.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.4&#x2013;84.7</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10.4&#x2013;65.2</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">27.0&#x2013;80.0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">38.8&#x2013;87.5</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">13.7&#x2013;65.2</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">30.4&#x2013;84.7</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Exact 95% CI<xref rid=\"T3Fn6\" ref-type=\"table-fn\"><sup>d</sup></xref></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9.1&#x2013;61.4</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">27.7&#x2013;84.8</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">26.2&#x2013;87.8</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7.5&#x2013;70.1</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">23.4&#x2013;83.3</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">34.9&#x2013;90.1</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10.9&#x2013;69.2</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">26.2&#x2013;87.8</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"T3Fn1\">\\n              <p>The full analysis set included all patients who received at least one dose of study drug according to the treatment they were randomized to receive.</p>\\n            </fn>\\n            <fn id=\"T3Fn2\">\\n              <p>CD, Crohn&#x2019;s disease; CDAI, Crohn&#x2019;s disease activity index; CI, confidence interval; UC, ulcerative colitis; VDZ, vedolizumab.</p>\\n            </fn>\\n            <fn id=\"T3Fn3\">\\n              <p>Clinical response, based on the complete Mayo score, was defined as a reduction in complete Mayo score of &#x2265;3 points and &#x2265;30% reduction from baseline with an accompanying decrease in rectal bleeding subscore of &#x2265;1 point or absolute rectal bleeding subscore of &#x2264;1 point; calculation was based on the GEMINI approach. Any patient with missing data for determination of clinical response status was counted as a non-responder. Patients with missing data at Week 14: body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 2 in 150 mg VDZ, <italic toggle=\"yes\">n</italic> = 2 in 300 mg VDZ]; body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 3 in 100 mg VDZ, <italic toggle=\"yes\">n</italic> = 1 in 200 mg VDZ].</p>\\n            </fn>\\n            <fn id=\"T3Fn4\">\\n              <p>Clinical response, based on the CDAI score, was defined as a &#x2265;70-point reduction from baseline in CDAI score. Any patient with missing data for determination of response status was counted as a non responder. Patients with missing data at Week 14: body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 1 in 150 mg VDZ, <italic toggle=\"yes\">n</italic> = 2 in 300 mg VDZ]; body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 3 in 100 mg VDZ, <italic toggle=\"yes\">n</italic> = 4 in 200 mg VDZ].</p>\\n            </fn>\\n            <fn id=\"T3Fn5\">\\n              <p>Calculated using Jeffreys method. Jeffreys interval is a Bayesian credible interval obtained using the non-informative Jeffreys prior.</p>\\n            </fn>\\n            <fn id=\"T3Fn6\">\\n              <p>The exact 95% CI was constructed on the basis of the Clopper&#x2013;Pearson method.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>According to paediatric measures, clinical response rates across weight and dose groups at Week 14 ranged from 50.0 to 80.0% in patients with UC [based on a &#x2265;20-point decrease from baseline in PUCAI score] and from 45.5 to 54.5% in patients with CD [based on a &#x2265;15-point decrease in PCDAI score] [<xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 3</xref>].</p>\\n        <p>In the evaluation of vedolizumab exposure&#x2013;response, in patients with UC, generally a higher <italic toggle=\"yes\">C</italic><sub>trough</sub> was observed in patients who achieved clinical response at Week 14 compared with patients who did not achieve clinical response in each dose arm according to complete Mayo and PUCAI scores. This trend was not observed in patients with CD, based on CDAI and PCDAI scores [adult measures are shown in <xref rid=\"F3\" ref-type=\"fig\">Figure 3</xref> and paediatric measures in <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 4</xref>].</p>\\n        <fig position=\"float\" id=\"F3\">\\n          <label>Figure 3.</label>\\n          <caption>\\n            <p>VDZ exposure at Week 14 according to clinical responsiveness in patients with [A] ulcerative colitis and [B] Crohn&#x2019;s disease [pharmacokinetic analysis set]. The exposure&#x2013;response relationship was based on reduction in complete Mayo score of &#x2265;3 points and &#x2265;30% from baseline for patients with ulcerative colitis and a &#x2265;70-point decrease in Crohn&#x2019;s disease activity index score from baseline for patients with Crohn&#x2019;s disease. The pharmacokinetic analysis set was defined as all patients who received at least one dose of VDZ and had at least one measurable concentration of VDZ. <italic toggle=\"yes\">C</italic><sub>trough</sub>, observed serum concentration at the end of the dosing interval; IQR, interquartile range; SD, standard deviation; VDZ, vedolizumab; WK, Week.</p>\\n          </caption>\\n          <graphic xlink:href=\"jjac036f0003\" position=\"float\"/>\\n        </fig>\\n        <p>Clinical remission rates at Week 14 according to adult and paediatric measures are reported in <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Tables 5 and 6</xref>, respectively. In patients with UC, clinical remission rates across weight and dose groups at Week 14 ranged from 20.0 to 38.5% on Mayo and from 30.0 to 61.5% on PUCAI. In patients with CD, clinical remission rates across weight and dose groups at Week 14 ranged from 50.0 to 63.6% on CDAI and from 16.7 to 54.5% on PCDAI. Faecal calprotectin levels at baseline were highly variable, with change during treatment seen across most dosing and weight groups in UC and CD [<xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 7</xref>].</p>\\n      </sec>\\n      <sec id=\"s25\">\\n        <title>3.4. Safety</title>\\n        <p>The overall duration of exposure to vedolizumab was a median of 99.0 days in both weight groups with a range of 98.0&#x2013;100.5 days. The incidence of AEs was similar between both disease indications in both weight groups: among patients with UC and CD, at least one AE was experienced by 80.0% and 91.3% of patients weighing &#x2265;30 kg, respectively, and 84.2% and 90.5% of patients weighing &lt;30 kg, respectively; most AEs were considered mild and not related to study drug [<xref rid=\"T4\" ref-type=\"table\">Table 4</xref>]. Of the 22 patients who discontinued, 15 discontinued due to AEs; of these, 13 were due to AEs of worsening UC or CD. Headache was the most commonly reported AE in the &#x2265;30 kg group and abdominal pain was the most frequently reported AE in the &lt;30 kg group. In patients with UC, headaches affected &lt;10% of patients in the &#x2265;30 kg group and 10.5% of patients in the &lt;30 kg group. In patients with CD, headaches affected 21.7% of patients in the &#x2265;30 kg group and &lt;10% of patients in the &lt;30 kg group. Abdominal pain affected &lt;10% of patients with UC and CD in the &#x2265;30 kg group and 21.1% of patients with UC and 28.6% of patients with CD in the &lt;30 kg group [all AEs that occurred in &#x2265;10% of patients are reported in <xref rid=\"sup1\" ref-type=\"supplementary-material\">Supplementary Table 8</xref>]. Most AEs of abdominal pain were mild to moderate in intensity and not related to study drug; they were possibly related to underlying disease pathology. Infections and infestations occurred in 48.0% of patients with UC and 47.8% of patients with CD in the &#x2265;30 kg group (most were reported as viral infections [10.4% of total UC and CD patients] or ear infections, nasopharyngitis, pharyngitis or upper respiratory tract infection [6.3% each of total UC and CD patients]), and 36.8% and 28.6% in patients with UC and CD, respectively, in the &lt;30 kg group [only upper respiratory tract infection, respiratory tract infection and viral infections were reported in more than one patient]. There were no cases of PML during the study.</p>\\n        <table-wrap position=\"float\" id=\"T4\">\\n          <label>Table 4.</label>\\n          <caption>\\n            <p>Overview of AEs<xref rid=\"T4Fn3\" ref-type=\"table-fn\"><sup>a</sup></xref><sup>,</sup><xref rid=\"T4Fn4\" ref-type=\"table-fn\"><sup>b</sup></xref> among patients with UC or CD [safety analysis set]</p>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" width=\"100%\" border=\"1\">\\n            <colgroup span=\"1\">\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n              <col align=\"left\" span=\"1\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th align=\"left\" rowspan=\"2\" colspan=\"1\">Patients, <italic toggle=\"yes\">n</italic> [%] [AEs, <italic toggle=\"yes\">n</italic>]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &#x2265;30 kg [<italic toggle=\"yes\">n</italic> = 48]</th>\\n                <th align=\"left\" colspan=\"2\" rowspan=\"1\">Body weight &lt;30 kg [<italic toggle=\"yes\">n</italic> = 40]</th>\\n              </tr>\\n              <tr>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">UC [<italic toggle=\"yes\">n</italic> = 25]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">CD [<italic toggle=\"yes\">n</italic> = 23]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">UC [<italic toggle=\"yes\">n</italic> = 19]</th>\\n                <th align=\"left\" rowspan=\"1\" colspan=\"1\">CD [<italic toggle=\"yes\">n</italic> = 21]</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">AEs by relation to study drug</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">20 [80.0] [64]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">21 [91.3] [106]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">16 [84.2] [61]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">19 [90.5] [90]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Related</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [12.0] [4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [17.4] [15]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [5.3] [1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [19.0] [6]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Not related</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">17 [68.0] [60]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">17 [73.9] [91]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">16 [84.2] [60]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">19 [90.5] [84]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">AEs by severity</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\"/>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Mild</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [36.0] [41]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [39.1] [70]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [52.6] [24]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">17 [81.0] [54]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Moderate</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [28.0] [18]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [30.4] [21]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">10 [52.6] [29]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">9 [42.9] [28]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Severe</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [16.0] [5]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [21.7] [15]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">4 [21.1] [8]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [23.8] [8]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Leading to study drug discontinuation</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [4.0] [1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [13.0] [3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [15.8] [4]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">2 [9.5] [2]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Serious AEs</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [20.0] [7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">6 [26.1] [12]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [26.3] [12]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [33.3] [13]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Related</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [4.3] [1]<xref rid=\"T4Fn5\" ref-type=\"table-fn\"><sup>c</sup></xref></td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Not related</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [20.0] [7]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [21.7] [11]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">5 [26.3] [12]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">7 [33.3] 13]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x2003;Leading to study drug discontinuation</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [4.3] [1]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">3 [15.8] [3]</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">1 [4.8] [1]</td>\\n              </tr>\\n              <tr>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">Deaths</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n                <td align=\"left\" rowspan=\"1\" colspan=\"1\">0</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"T4Fn1\">\\n              <p>Relatedness, severity and seriousness of AEs are not mutually exclusive terms and patients could be counted in multiple categories. The safety analysis set was defined as all patients who received at least one dose of study drug according to the treatment they actually received.</p>\\n            </fn>\\n            <fn id=\"T4Fn2\">\\n              <p>AE, adverse event; CD, Crohn&#x2019;s disease; UC, ulcerative colitis; VDZ, vedolizumab.</p>\\n            </fn>\\n            <fn id=\"T4Fn3\">\\n              <p>An AE was defined as an event whose date of onset occurred on or after the first dose of study drug through Week 22 for patients entering the extension study, or through the final safety visit 18 weeks after their last dose of study drug for those who did not enter the extension study.</p>\\n            </fn>\\n            <fn id=\"T4Fn4\">\\n              <p>Patients with one or more AEs within a level of <italic toggle=\"yes\">Medical Dictionary for Regulatory Activities</italic> [version 23.0U] term were counted only once in that level.</p>\\n            </fn>\\n            <fn id=\"T4Fn5\">\\n              <p>A single serious AE of viral infection in a patient with CD in the dose-escalation group was considered related to vedolizumab treatment but no change was made to study medication.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>Serious AEs occurred in 20% of patients with UC and 26.1% of patients with CD in the &#x2265;30 kg group and 26.3% and 33.3%, respectively, in the &lt;30 kg group [<xref rid=\"T4\" ref-type=\"table\">Table 4</xref>]. A single serious AE of viral infection in a patient with CD in the dose-escalation group was considered related to vedolizumab treatment, but no change was made to study medication. No deaths occurred during the study.</p>\\n        <p>The criteria applied for the identification of hypersensitivity included standardized MedDRA queries of anaphylactic/anaphylactoid shock conditions [broad], angio-oedema [broad] and hypersensitivity [broad]. Among patients weighing &#x2265;30 kg, ten [20.8%] reported hypersensitivity AEs. Although most were mild or moderate, there was one severe hypersensitivity AE [erythema nodosum] which was described as non-serious, unrelated to treatment, and not requiring any change to the dose of study medication, and two hypersensitivity AEs that were assessed as being related to treatment [asthma and hypersensitivity]. Among patients weighing &lt;30 kg, hypersensitivity AEs were reported for four [10%], all of which were mild or moderate in intensity; none were assessed as being related to treatment. None of the hypersensitivity AEs were reported as serious AEs, and no cases of anaphylaxis or infusion-related reactions were reported in either cohort. One patient with hypersensitivity reactions was persistently positive for ADA and was positive for neutralizing ADA. There was no relationship between persistent ADA and hypersensitivity reaction.</p>\\n      </sec>\\n    </sec>\\n    <sec id=\"s26\">\\n      <title>4. Discussion</title>\\n      <p>In this study, vedolizumab PK parameters were evaluated in a paediatric UC and CD population. The exposure in paediatric patients reported in this study [<italic toggle=\"yes\">C</italic><sub>trough</sub> levels of 9.0&#x2013;14.7 &#xB5;g/mL] can be considered efficacious and within the range of therapeutic levels in adult patients after standard IV induction doses, based on PK data and modelling from previous adult phase 3 studies.<sup><xref rid=\"CIT0017\" ref-type=\"bibr\">17</xref>,<xref rid=\"CIT0024\" ref-type=\"bibr\">24</xref>,<xref rid=\"CIT0025\" ref-type=\"bibr\">25</xref></sup> In paediatric patients with moderately to severely active UC and CD, vedolizumab serum exposure increased in an approximately dose-proportional manner for both weight groups, and achieved concentrations similar to those of adults from the previous GEMINI trials. Consistently higher <italic toggle=\"yes\">C</italic><sub>trough</sub> concentrations at Week 14 were observed in the high-dose groups.</p>\\n      <p>In addition, vedolizumab serum concentrations and derived PK parameters at Week 14 were higher for paediatric patients weighing &#x2265;30 kg with UC compared with patients with CD, whereas this difference was not observed for patients weighing &lt;30 kg. However, there was variability in exposure observed across the study population, which was more apparent in <italic toggle=\"yes\">C</italic><sub>trough</sub> than <italic toggle=\"yes\">C</italic><sub>avg</sub>. Indeed, the difference between these UC and CD groups was much more apparent for <italic toggle=\"yes\">C</italic><sub>trough</sub> levels, whereas <italic toggle=\"yes\">C</italic><sub>avg</sub> levels were generally more comparable, suggesting broadly similar PK characteristics between the patients with UC and CD.</p>\\n      <p>The vedolizumab exposure&#x2013;response relationship results showed that in patients with UC, <italic toggle=\"yes\">C</italic><sub>trough</sub> at Week 14 was generally higher in responders than in non-responders in both treatment arms for both weight groups. However, due to the small sample size, these data do not clearly show that higher dosing in patients with UC was associated with superior clinical outcomes. In patients with CD, there was no clear trend for a higher <italic toggle=\"yes\">C</italic><sub>trough</sub> in responders for both weight groups. No firm conclusion can be drawn regarding the exposure&#x2013;response relationship in patients with UC or CD due to the small sample size. In patients with UC weighing &#x2265;30 kg, response rates were generally greater in the low-dose vs high-dose group, with somewhat overlapping 95% CIs, whereas the high-dose group was favoured over the low-dose group in those weighing &lt;30 kg. This may be due to slight differences in baseline disease characteristics such as higher baseline Mayo score, Mayo endoscopic subscore and C-reactive protein level in the high-dose group of patients with UC weighing &#x2265;30 kg, as well as the higher proportion of patients with severe baseline PUCAI scores in the high-dose group. The baseline disease characteristics in patients with UC weighing &lt;30 kg were generally similar between dose groups. There were no clear differences in efficacy among dose groups in the patients with CD.</p>\\n      <p>The current paediatric UC population in this study and adult population in the GEMINI 1 study had similar disease severity and similar prior exposure to TNF antagonist drugs at baseline.<sup><xref rid=\"CIT0024\" ref-type=\"bibr\">24</xref></sup> However, with regard to CD, baseline CDAI scores were higher in adults [GEMINI 2]<sup><xref rid=\"CIT0025\" ref-type=\"bibr\">25</xref></sup> but baseline median faecal calprotectin and C-reactive protein levels were higher in the children in this study, and a greater proportion of children had been previously exposed to TNF&#x3B1; antagonist therapy. It is important to note that CDAI is a disease activity score for adults with CD, which makes translatability to the paediatric population difficult; however, this scoring index has also been previously used for regulatory purposes. It is interesting to compare the current results in children vs those previously reported for adults in the GEMINI trials, although it should be noted that vedolizumab exposure and clinical response were assessed at different time points in HUBBLE [Week 14] vs GEMINI 1 and 2 [Week 6]. Overall, the current PK parameters and the dose-proportional increase in serum concentration levels in paediatric patients were consistent with previous data shown in adults across the same dose range. Vedolizumab treatment with 150 and 300 mg IV doses [&#x2265;30 kg group] and 100 and 200 mg IV doses [&lt;30 kg group] in paediatric patients with UC or CD resulted in similar clinical responses at Week 14 to those observed in adults in the previous phase 3 studies of IV vedolizumab [300 mg] during induction therapy [Week 6].<sup><xref rid=\"CIT0024\" ref-type=\"bibr\">24</xref>,<xref rid=\"CIT0025\" ref-type=\"bibr\">25</xref></sup> In the phase 3 GEMINI 1 study, clinical response was achieved by 47.1% of adults with UC who were evaluated at Week 6 of induction therapy [300 mg IV vedolizumab]. In contrast, at Week 14 of the current study, clinical response was achieved in 56.0% of children with UC weighing &#x2265;30 kg [150 and 300 mg IV vedolizumab] and in 52.6% of children with UC weighing &lt;30 kg [100 and 200 mg IV vedolizumab].<sup><xref rid=\"CIT0024\" ref-type=\"bibr\">24</xref></sup> In the phase 3 GEMINI 2 study, a reduction of CDAI score by &#x2265;100 points was achieved by 31.4% of adults with CD who were evaluated at Week 6 of induction therapy [300 mg IV vedolizumab].<sup><xref rid=\"CIT0025\" ref-type=\"bibr\">25</xref></sup> In contrast, at Week 14 of the current study, a reduction of CDAI score by &#x2265;100 points was achieved in 30.4% of children with CD weighing &#x2265;30 kg [150 and 300 mg IV vedolizumab] and in 47.6% of children with CD weighing &lt;30 kg [100 and 200 mg IV vedolizumab]. Although fixed dosing in this phase 2 paediatric study appeared to be adequate compared with the adult trials, further study is needed on maintenance dosing strategies in the paediatric population, especially in the lowest weight group of &lt;30 kg.</p>\\n      <p>Vedolizumab was generally safe and well tolerated when administered at either 150 and 300 mg in paediatric patients weighing &#x2265;30 kg or at 100 and 200 mg in patients weighing &lt;30 kg, with a comparable safety profile in both weight groups. The overall safety profile observed in this study is generally consistent with the known safety profile of vedolizumab in adults and with the common symptoms of IBD.<sup><xref rid=\"CIT0024\" ref-type=\"bibr\">24&#x2013;26</xref></sup></p>\\n      <p>This study has some limitations. It was not designed or powered for comparing between-group differences in PK parameters, but for descriptive analysis of exposure and efficacy within each indication and dosing group. Any potential inaccuracies in pre-dose sampling time and in a study of this sample size would lead to variability in the PK parameters, in particular <italic toggle=\"yes\">C</italic><sub>trough</sub> levels, although <italic toggle=\"yes\">C</italic><sub>avg</sub> would be less affected. The small number of paediatric patients, especially in the youngest age group, precluded concrete interpretation of comparisons between disease indication, weight group and/or dose group for baseline characteristics, safety and clinical response. Additionally, Mayo and CDAI scores were not designed to assess clinical response in children; however, at the time of this phase 2 trial, these measures were recommended by regulatory agencies to enable comparison of paediatric results to previous adult data. Future paediatric IBD studies will probably use paediatric measures [PUCAI and PCDAI] or the SES-CD.</p>\\n      <p>In conclusion, vedolizumab serum exposure increased in an approximately dose-proportional manner in this paediatric population, and vedolizumab exposure, clinical response and safety were considered similar in children relative to adult patients in historical studies. The results from the HUBBLE study, in conjunction with adult data from the GEMINI studies, have been used to determine ideal dosing schedules for further studies in paediatric patients.</p>\\n    </sec>\\n    <sec sec-type=\"supplementary-material\">\\n      <title>Supplementary Material</title>\\n      <supplementary-material id=\"sup1\" position=\"float\" content-type=\"local-data\">\\n        <label>jjac036_suppl_Supplementary_Data</label>\\n        <media xlink:href=\"jjac036_suppl_supplementary_data.docx\">\\n          <caption>\\n            <p>Click here for additional data file.</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n      <supplementary-material id=\"sup2\" position=\"float\" content-type=\"local-data\">\\n        <label>jjac036_suppl_Supplementary_Figure_S1</label>\\n        <media xlink:href=\"jjac036_suppl_supplementary_figure_s1.jpeg\">\\n          <caption>\\n            <p>Click here for additional data file.</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n    </sec>\\n  </body>\\n  <back>\\n    <ack id=\"a1\">\\n      <title>Acknowledgments</title>\\n      <p>We thank all the patients and their caregivers who took part in the HUBBLE study, as well as Parul Gulati and the HUBBLE study investigators and sites [NCT03138655; EudraCT #2017-002231-41].</p>\\n    </ack>\\n    <sec id=\"s28\">\\n      <title>Conference Presentation</title>\\n      <p>Parts of these data were presented at the 2021 Digestive Disease Week, May 21&#x2013;23, 2021, virtual congress, Poster Su497, and the 2021 World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, June 2&#x2013;5, 2021, virtual congress, Poster G-ePwP-064.</p>\\n    </sec>\\n    <sec id=\"s29\">\\n      <title>Funding</title>\\n      <p>This work was supported by Takeda. Under the direction of the authors, medical writing support was provided by Daniella A. Babu, PhD, and Eleanor Ling, PhD, of Excel Medical Affairs, funded by Takeda.</p>\\n    </sec>\\n    <sec id=\"s30\">\\n      <title>Conflict of Interest</title>\\n      <p>J.S.H. has served on advisory boards for AbbVie, Eli Lilly and Janssen and as a consultant for Allergan, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Takeda and Thetis. D.T. has served as a consultant for and has received research support, royalties or honoraria from AbbVie, Atlantic Health, Bristol Myers Squibb, Celgene, Eli Lilly, Ferring, Hospital for Sick Children, Janssen, Pfizer, Roche, Shire, Takeda and ThermoFisher. S.A.C. has received research support from Abbvie, Janssen, Lilly, Takeda, BMS, Kate Farms and Arena, and has received consultation fees from Janssen and Kate Farms. E.S. reports no conflicts of interest. K.K.-D. has served as a consultant and has received research support from AbbVie and Takeda. F.R. has served on advisory boards and has received grants/research support or lecture fees from AbbVie, Biogen, Celgene, Centocor, Danone, Janssen, Mead Johnson, Merck Sharp &amp; Dohme, Nestl&#xE9; Health Science, Nestl&#xE9; Nutrition Institute, Nutricia, Pfizer, Shire, Takeda and Therakos. N.M.C. has received research support and consultancy and speaker fees, all paid to institutional accounts, from AbbVie, Allergan, AstraZeneca, Janssen, Eli Lilly, Pfizer, Shire and Takeda. B.K. has received research support from Takeda. P.L., S.B., H.K., S.K., W.T. and G.R. are employees of and hold stock/options in Takeda. C.C., W.S., M.R. and R.A.L. were employees of Takeda at the time of this research.</p>\\n    </sec>\\n    <sec id=\"s31\">\\n      <title>Author Contributions</title>\\n      <p>M.R., C.C., W.S. and R.A.L. were involved in the conception and design of the study. J.S.H., D.T., S.A.C., E.S., K.K-D., F.R. and N.M.C. performed the data collection. R.A.L. performed the data analysis. All authors interpreted the data, revised the manuscript critically for intellectual content, and gave final approval for it to be published.</p>\\n    </sec>\\n    <ref-list id=\"r1\">\\n      <title>References</title>\\n      <ref id=\"CIT0001\">\\n        <label>1.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Turner</surname>\\n<given-names>D</given-names>\\n</string-name>, <string-name><surname>Ruemmele</surname><given-names>FM</given-names></string-name>, <string-name><surname>Orlanski-Meyer</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Management of paediatric ulcerative colitis, part 1: ambulatory care &#x2013; an evidence-based guideline from European Crohn&#x2019;s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2018</year>;<volume>67</volume>:<fpage>257</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type=\"pmid\">30044357</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0002\">\\n        <label>2.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Turner</surname>\\n<given-names>D.</given-names>\\n</string-name>\\n</person-group>\\n<article-title>Particularities of IBD trials in children.</article-title>\\n<source>Curr Pharm Des</source>\\n<year>2019</year>;<volume>25</volume>:<fpage>69</fpage>&#x2013;<lpage>72</lpage>.<pub-id pub-id-type=\"pmid\">30848191</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0003\">\\n        <label>3.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>Janssen Biotech, Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">REMICADE (infliximab) for injection, for intravenous use. Prescribing information</italic>\\n</comment>. <ext-link xlink:href=\"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf\" ext-link-type=\"uri\">https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf</ext-link>. Accessed <comment>February 26, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0004\">\\n        <label>4.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>AbbVie Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">HUMIRA</italic>\\n<sup>\\n<italic toggle=\"yes\">&#xAE;</italic>\\n</sup>\\n<italic toggle=\"yes\">(adalimumab) injection, for subcutaneous use. Prescribing information.</italic>\\n</comment>\\n<ext-link xlink:href=\"https://www.rxabbvie.com/pdf/humira.pdf\" ext-link-type=\"uri\">https://www.rxabbvie.com/pdf/humira.pdf</ext-link>. Accessed <comment>February 26, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0005\">\\n        <label>5.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>Janssen Biotech, Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">STELARA</italic>\\n<sup>\\n<italic toggle=\"yes\">&#xAE;</italic>\\n</sup>\\n<italic toggle=\"yes\">(ustekinumab) injection, for subcutaneous or intravenous use. Prescribing information</italic>\\n</comment>. <ext-link xlink:href=\"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf\" ext-link-type=\"uri\">https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf</ext-link>. Accessed <comment>February 26, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0006\">\\n        <label>6.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>Pfizer Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">XELJANZ&#xAE; (oral tofacitinib). Prescribing information</italic>\\n</comment>. <ext-link xlink:href=\"http://labeling.pfizer.com/ShowLabeling.aspx?id=959\" ext-link-type=\"uri\">http://labeling.pfizer.com/ShowLabeling.aspx?id=959</ext-link>. Accessed <comment>February 26, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0007\">\\n        <label>7.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>Janssen Biotech, Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">SIMPONI (golimumab) injection, for subcutaneous use. Prescribing information</italic>\\n</comment>. <ext-link xlink:href=\"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf\" ext-link-type=\"uri\">https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf</ext-link>. Accessed <comment>April 29, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0008\">\\n        <label>8.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>Takeda Pharmaceuticals America, Inc.</collab>\\n<comment>\\n<italic toggle=\"yes\">ENTYVIO (intravenous vedolizumab) for injection, for intravenous use. Prescribing information</italic>\\n</comment>\\n<ext-link xlink:href=\"https://general.takedapharm.com/ENTYVIOPI\" ext-link-type=\"uri\">https://general.takedapharm.com/ENTYVIOPI</ext-link>. Accessed <comment>February 26, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0009\">\\n        <label>9.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>ClinicalTrials.gov.</collab>\\n<comment>\\n<italic toggle=\"yes\">A study of vedolizumab in children and teenagers with moderate to severe ulcerative colitis</italic>\\n</comment>. <ext-link xlink:href=\"https://clinicaltrials.gov/ct2/show/record/NCT04779307?term=NCT04779307&amp;draw=2&amp;rank=1\" ext-link-type=\"uri\">https://clinicaltrials.gov/ct2/show/record/NCT04779307?term=NCT04779307&amp;draw=2&amp;rank=1</ext-link>. Accessed <comment>September 30, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0010\">\\n        <label>10.</label>\\n        <mixed-citation publication-type=\"other\">\\n<collab>ClinicalTrials.gov.</collab>\\n<comment>\\n<italic toggle=\"yes\">A study of vedolizumab in children and teenagers with moderate to severe Crohn&#x2019;s disease</italic>\\n</comment>. <ext-link xlink:href=\"https://clinicaltrials.gov/ct2/show/NCT04779320?term=NCT04779320&amp;draw=2&amp;rank=1\" ext-link-type=\"uri\">https://clinicaltrials.gov/ct2/show/NCT04779320?term=NCT04779320&amp;draw=2&amp;rank=1</ext-link>. Accessed <comment>September 30, 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0011\">\\n        <label>11.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Dayan</surname>\\n<given-names>JR</given-names>\\n</string-name>, <string-name><surname>Dolinger</surname><given-names>M</given-names></string-name>, <string-name><surname>Benkov</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center.</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2019</year>;<volume>69</volume>:<fpage>61</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type=\"pmid\">31058718</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0012\">\\n        <label>12.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Bishop</surname>\\n<given-names>C</given-names>\\n</string-name>, <string-name><surname>Simon</surname><given-names>H</given-names></string-name>, <string-name><surname>Suskind</surname><given-names>D</given-names></string-name>, <string-name><surname>Lee</surname><given-names>D</given-names></string-name>, <string-name><surname>Wahbeh</surname><given-names>G.</given-names></string-name></person-group>\\n<article-title>Ustekinumab in pediatric Crohn disease patients.</article-title>\\n<source>J Pediatr Gastroenterol Nutr</source>\\n<year>2016</year>;<volume>63</volume>:<fpage>348</fpage>&#x2013;<lpage>51</lpage>.<pub-id pub-id-type=\"pmid\">26854655</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0013\">\\n        <label>13.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Singh</surname>\\n<given-names>N</given-names>\\n</string-name>, <string-name><surname>Rabizadeh</surname><given-names>S</given-names></string-name>, <string-name><surname>Jossen</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease.</article-title><source>Inflamm Bowel Dis</source><year>2016</year>;<volume>22</volume>:<fpage>2121</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type=\"pmid\">27542130</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0014\">\\n        <label>14.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Conrad</surname>\\n<given-names>MA</given-names>\\n</string-name>, <string-name><surname>Stein</surname><given-names>RE</given-names></string-name>, <string-name><surname>Maxwell</surname><given-names>EC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Vedolizumab therapy in severe pediatric inflammatory bowel disease.</article-title><source>Inflamm Bowel Dis</source><year>2016</year>;<volume>22</volume>:<fpage>2425</fpage>&#x2013;<lpage>31</lpage>.<pub-id pub-id-type=\"pmid\">27598742</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0015\">\\n        <label>15.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Schneider</surname>\\n<given-names>AM</given-names>\\n</string-name>, <string-name><surname>Weghuber</surname><given-names>D</given-names></string-name>, <string-name><surname>Hetzer</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Vedolizumab use after failure of TNF-&#x3B1; antagonists in children and adolescents with inflammatory bowel disease.</article-title><source>BMC Gastroenterol</source><year>2018</year>;<volume>18</volume>:<fpage>140</fpage>.<pub-id pub-id-type=\"pmid\">30219028</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0016\">\\n        <label>16.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Rosario</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name><surname>Milch</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab.</article-title><source>Clin Pharmacokinet</source><year>2017</year>;<volume>56</volume>:<fpage>1287</fpage>&#x2013;<lpage>301</lpage>.<pub-id pub-id-type=\"pmid\">28523450</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0017\">\\n        <label>17.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Rosario</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name><surname>Gastonguay</surname><given-names>MR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Population pharmacokinetics&#x2013;pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn&#x2019;s disease.</article-title><source>Aliment Pharmacol Ther</source><year>2015</year>;<volume>42</volume>:<fpage>188</fpage>&#x2013;<lpage>202</lpage>.<pub-id pub-id-type=\"pmid\">25996351</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0018\">\\n        <label>18.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Schroeder</surname>\\n<given-names>KW</given-names>\\n</string-name>, <string-name><surname>Tremaine</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Ilstrup</surname><given-names>DM.</given-names></string-name></person-group>\\n<article-title>Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.</article-title>\\n<source>N Engl J Med</source>\\n<year>1987</year>;<volume>317</volume>:<fpage>1625</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type=\"pmid\">3317057</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0019\">\\n        <label>19.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Best</surname>\\n<given-names>WR</given-names>\\n</string-name>, <string-name><surname>Becktel</surname><given-names>JM</given-names></string-name>, <string-name><surname>Singleton</surname><given-names>JW</given-names></string-name>, <string-name><surname>Kern</surname><given-names>F</given-names>, <suffix>Jr</suffix></string-name></person-group>. <article-title>Development of a Crohn&#x2019;s disease activity index. National Cooperative Crohn&#x2019;s Disease Study.</article-title><source>Gastroenterology</source><year>1976</year>;<volume>70</volume>:<fpage>439</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type=\"pmid\">1248701</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0020\">\\n        <label>20.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Daperno</surname>\\n<given-names>M</given-names>\\n</string-name>, <string-name><surname>D&#x2019;Haens</surname><given-names>G</given-names></string-name>, <string-name><surname>Van Assche</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and validation of a new, simplified endoscopic activity score for Crohn&#x2019;s disease: the SES-CD.</article-title><source>Gastrointest Endosc</source><year>2004</year>;<volume>60</volume>:<fpage>505</fpage>&#x2013;<lpage>12</lpage>.<pub-id pub-id-type=\"pmid\">15472670</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0021\">\\n        <label>21.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Wyant</surname>\\n<given-names>T</given-names>\\n</string-name>, <string-name><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name><surname>Lirio</surname><given-names>RA</given-names></string-name>, <string-name><surname>Rosario</surname><given-names>M.</given-names></string-name></person-group>\\n<article-title>Vedolizumab immunogenicity with long-term or interrupted treatment of patients with inflammatory bowel disease.</article-title>\\n<source>J Clin Pharmacol</source>\\n<year>2021</year>;<volume>61</volume>:<fpage>1174</fpage>&#x2013;<lpage>81</lpage>.<pub-id pub-id-type=\"pmid\">33908636</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0022\">\\n        <label>22.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Wang</surname>\\n<given-names>Y</given-names>\\n</string-name>, <string-name><surname>Jadhav</surname><given-names>PR</given-names></string-name>, <string-name><surname>Lala</surname><given-names>M</given-names></string-name>, <string-name><surname>Gobburu</surname><given-names>JV.</given-names></string-name></person-group>\\n<article-title>Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies.</article-title>\\n<source>J Clin Pharmacol</source>\\n<year>2012</year>;<volume>52</volume>:<fpage>1601</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type=\"pmid\">22162537</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0023\">\\n        <label>23.</label>\\n        <mixed-citation publication-type=\"book\">\\n<collab>Food and Drug Administration.</collab>\\n<comment>\\n<italic toggle=\"yes\">Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products</italic>\\n</comment>. <publisher-name>US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)</publisher-name>. <ext-link xlink:href=\"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-and-biological-products\" ext-link-type=\"uri\">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-and-biological-products</ext-link>. Accessed <comment>December 2021</comment>.</mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0024\">\\n        <label>24.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Feagan</surname>\\n<given-names>BG</given-names>\\n</string-name>, <string-name><surname>Rutgeerts</surname><given-names>P</given-names></string-name>, <string-name><surname>Sands</surname><given-names>BE</given-names></string-name>, <etal>et al</etal></person-group>; <collab>GEMINI 1 Study Group.</collab><article-title> Vedolizumab as induction and maintenance therapy for ulcerative colitis.</article-title><source>N Engl J Med</source><year>2013</year>;<volume>369</volume>:<fpage>699</fpage>&#x2013;<lpage>710</lpage>.<pub-id pub-id-type=\"pmid\">23964932</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0025\">\\n        <label>25.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Sandborn</surname>\\n<given-names>WJ</given-names>\\n</string-name>, <string-name><surname>Feagan</surname><given-names>BG</given-names></string-name>, <string-name><surname>Rutgeerts</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>; <collab>GEMINI 2 Study Group.</collab><article-title> Vedolizumab as induction and maintenance therapy for Crohn&#x2019;s disease.</article-title><source>N Engl J Med</source><year>2013</year>;<volume>369</volume>:<fpage>711</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type=\"pmid\">23964933</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"CIT0026\">\\n        <label>26.</label>\\n        <mixed-citation publication-type=\"journal\">\\n<person-group person-group-type=\"author\">\\n<string-name>\\n<surname>Sands</surname>\\n<given-names>BE</given-names>\\n</string-name>, <string-name><surname>Feagan</surname><given-names>BG</given-names></string-name>, <string-name><surname>Rutgeerts</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of vedolizumab induction therapy for patients with Crohn&#x2019;s disease in whom tumor necrosis factor antagonist treatment failed.</article-title><source>Gastroenterology</source><year>2014</year>;<volume>147</volume>:<fpage>618</fpage>&#x2013;<lpage>27.e3</lpage>.<pub-id pub-id-type=\"pmid\">24859203</pub-id></mixed-citation>\\n      </ref>\\n    </ref-list>\\n  </back>\\n</article>\\n</pmc-articleset>'"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import requests\n",
    "from Bio import Entrez\n",
    "from bs4 import BeautifulSoup\n",
    "import boto3\n",
    "\n",
    "#client = boto3.client('lambda')\n",
    "\n",
    "# Provide your email address to the Entrez API\n",
    "Entrez.email = 'your_email@example.com'\n",
    "\n",
    "fetch_handle = Entrez.efetch(db='pmc', id=[9178865, 9322578, 9426668], rettype='xml', retmode='text')\n",
    "fetch_handle.read()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "'1:  Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis\\nLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya\\nBMC Gastroenterol. 2022; 22: 291.  Published online 2022 Jun 8. doi:\\xa010.1186/s12876-022-02347-1\\nPMCID: PMC9178865\\n\\n2:  Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease\\nViktoria Bergqvist, Johanna Holmgren, Daniel Klintman, Jan Marsal\\nAliment Pharmacol Ther. 2022 Jun; 55(11): 1389–1401.  Published online 2022 Apr 25. doi:\\xa010.1111/apt.16927\\nPMCID: PMC9322578\\n\\n3:  Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study\\nJeffrey S Hyams, Dan Turner, Stanley A Cohen, Erzsébet Szakos, Kinga Kowalska-Duplaga, Frank Ruemmele, Nicholas M Croft, Bartosz Korczowski, Promise Lawrence, Siddharth Bhatia, Harisha Kadali, Chunlin Chen, Wan Sun, Maria Rosario, Senthil Kabilan, William Treem, Guillermo Rossiter, Richard A Lirio\\nJ Crohns Colitis. 2022 Aug; 16(8): 1243–1254.  Published online 2022 Mar 17. doi:\\xa010.1093/ecco-jcc/jjac036\\nPMCID: PMC9426668\\n\\n'\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import requests\n",
    "from Bio import Entrez\n",
    "from bs4 import BeautifulSoup\n",
    "import boto3\n",
    "from datetime import datetime\n",
    "\n",
    "# client = boto3.client('lambda')\n",
    "\n",
    "def lambda_handler(event, context):\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/pmc/?term={event['search']}\"\n",
    "\n",
    "    # Send a GET request to the URL\n",
    "    response = requests.get(url)\n",
    "\n",
    "    # Create a BeautifulSoup object to parse the HTML content\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "\n",
    "    # Find all the \"dd\" elements\n",
    "    dd_elements = soup.find_all(\"dd\")\n",
    "\n",
    "    pmc_ids = []\n",
    "\n",
    "    # Iterate over each \"dd\" element\n",
    "    for dd in dd_elements:\n",
    "        # Check if the text starts with \"PMC\"\n",
    "        if dd.text.startswith(\"PMC\"):\n",
    "            # Remove the \"<dd>\" and \"</dd>\" tags and append the PMC ID\n",
    "            pmc_id = dd.text.replace(\"<dd>\", \"\").replace(\"</dd>\", \"\").strip()\n",
    "            pmc_ids.append(pmc_id)\n",
    "            pmc_set = set(pmc_ids)\n",
    "\n",
    "    # Provide your email address to the Entrez API\n",
    "    Entrez.email = 'your_email@example.com'\n",
    "\n",
    "    fetch_handle = Entrez.efetch(db='pmc', id=pmc_set, rettype='json', retmode='text')\n",
    "\n",
    "    output = fetch_handle.read()\n",
    "\n",
    "    # Splitting the output into individual paper entries\n",
    "    articles = output.split('\\n\\n')\n",
    "\n",
    "    # Regular expression patterns for extracting information\n",
    "    title_pattern = r'\\d+: (.*?)[\\n,.]'\n",
    "    authors_pattern = r'\\n(.*?)\\n'\n",
    "    date_pattern = r'Published online (\\d{4} [A-Za-z]+ \\d{1,2})\\.'\n",
    "    doi_pattern = r\"doi:\\xa0(\\S+)\"\n",
    "    pmcid_pattern = r\"PMCID: (\\S+)\"\n",
    "    \n",
    "    paper_list = []\n",
    "\n",
    "    # Extracting the information from each paper\n",
    "    for article in articles[:-1]:  # Exclude the last empty element\n",
    "        \n",
    "        #dictionary for this paper:\n",
    "        paper = {}   \n",
    "        \n",
    "        title_match = re.findall(title_pattern, article)\n",
    "        paper['title'] = title_match[0] if title_match else None\n",
    "        \n",
    "        authors_match = re.findall(authors_pattern, article)\n",
    "        paper['authors'] = authors_match[0] if authors_match else None\n",
    "        \n",
    "        date_match = re.findall(date_pattern, article)\n",
    "        paper['date'] = date_match[0] if date_match else None\n",
    "        \n",
    "        if paper['date']:\n",
    "            date_obj = datetime.strptime(paper['date'], '%Y %b %d')\n",
    "            paper['date'] = date_obj.strftime('%Y/%m/%d')\n",
    "        else:\n",
    "            paper['date'] = '0000/00/00'  # Assign a default value for sorting\n",
    "        \n",
    "        doi_match = re.findall(doi_pattern, article)\n",
    "        paper['doi'] = doi_match[0] if doi_match else None\n",
    "        \n",
    "        pmcid_match = re.findall(pmcid_pattern, article)\n",
    "        paper['pmcid'] = pmcid_match[0] if pmcid_match else None\n",
    "        paper['pdflink'] = f\"https://www.ncbi.nlm.nih.gov/pmc/articles/{paper['pmcid']}/pdf\"\n",
    "\n",
    "        paper_list.append(paper)\n",
    "        \n",
    "    json_response = {\n",
    "        'statusCode': 200,\n",
    "        'body': {\n",
    "            'papers': sorted(paper_list, key=lambda x: x['date'], reverse=True)\n",
    "        }\n",
    "    }\n",
    "    return json_response\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'statusCode': 200,\n",
       " 'body': {'papers': [{'title': ' Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis',\n",
       "    'authors': 'Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya',\n",
       "    'date': '2022/06/08',\n",
       "    'doi': '10.1186/s12876-022-02347-1',\n",
       "    'pmcid': 'PMC9178865',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178865/pdf'},\n",
       "   {'title': ' Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease',\n",
       "    'authors': 'Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman, Jan Marsal',\n",
       "    'date': '2022/04/25',\n",
       "    'doi': '10.1111/apt.16927',\n",
       "    'pmcid': 'PMC9322578',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322578/pdf'},\n",
       "   {'title': ' Pharmacokinetics',\n",
       "    'authors': 'Jeffrey S Hyams, Dan Turner, Stanley A Cohen, Erzsébet Szakos, Kinga Kowalska-Duplaga, Frank Ruemmele, Nicholas M Croft, Bartosz Korczowski, Promise Lawrence, Siddharth Bhatia, Harisha Kadali, Chunlin Chen, Wan Sun, Maria Rosario, Senthil Kabilan, William Treem, Guillermo Rossiter, Richard A Lirio',\n",
       "    'date': '2022/03/17',\n",
       "    'doi': '10.1093/ecco-jcc/jjac036',\n",
       "    'pmcid': 'PMC9426668',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426668/pdf'},\n",
       "   {'title': ' Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease',\n",
       "    'authors': 'Timothy Wyant, Lili Yang, Richard A. Lirio, Maria Rosario',\n",
       "    'date': '2021/07/14',\n",
       "    'doi': '10.1002/jcph.1877',\n",
       "    'pmcid': 'PMC8456828',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456828/pdf'},\n",
       "   {'title': ' Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease',\n",
       "    'authors': 'John Gubatan, Samuel J S Rubin, Lawrence Bai, Yeneneh Haileselassie, Steven Levitte, Tatiana Balabanis, Akshar Patel, Arpita Sharma, Sidhartha R Sinha, Aida Habtezion',\n",
       "    'date': '2021/06/28',\n",
       "    'doi': '10.1093/ecco-jcc/jjab114',\n",
       "    'pmcid': 'PMC8684474',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684474/pdf'},\n",
       "   {'title': ' Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials',\n",
       "    'authors': 'Timothy Wyant, Lili Yang, Maria Rosario',\n",
       "    'date': '2020/11/16',\n",
       "    'doi': '10.1208/s12248-020-00518-0',\n",
       "    'pmcid': 'PMC7669784',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669784/pdf'},\n",
       "   {'title': ' Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety',\n",
       "    'authors': 'Michaeline McGuinty, Jonathan B Angel, Curtis L Cooper, Juthaporn Cowan, Paul A MacPherson, Ashok Kumar, Sanjay Murthy, Richmond Sy, Michelle Dennehy, Nancy Tremblay, Siddappa N Byrareddy, D William Cameron',\n",
       "    'date': '2020/10/08',\n",
       "    'doi': '10.1136/bmjopen-2020-041359',\n",
       "    'pmcid': 'PMC7545629',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545629/pdf'},\n",
       "   {'title': ' Evaluation of the Developmental Toxicity of Vedolizumab',\n",
       "    'authors': 'David Crawford, Mitchell Friedman',\n",
       "    'date': '2019/07/31',\n",
       "    'doi': '10.1177/1091581819864105',\n",
       "    'pmcid': 'PMC6749749',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749749/pdf'},\n",
       "   {'title': ' A product review of vedolizumab in inflammatory bowel disease',\n",
       "    'authors': 'Robert Battat, Parambir S. Dulai, Vipul Jairath, Niels Vande Casteele',\n",
       "    'date': '2019/05/07',\n",
       "    'doi': '10.1080/21645515.2019.1591139',\n",
       "    'pmcid': 'PMC6816403',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816403/pdf'},\n",
       "   {'title': ' A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study',\n",
       "    'authors': 'Fraser Cummings, Daniel R. Gaya, Scott Levison, Sreedhar Subramanian, Glynn Owen, Anna Rathmell, Fiona Glen, Dirk Demuth, Simon Meadowcroft, Peter M. Irving',\n",
       "    'date': '2019/03/01',\n",
       "    'doi': '10.1097/MD.0000000000014681',\n",
       "    'pmcid': 'PMC6831399',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831399/pdf'},\n",
       "   {'title': ' Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease',\n",
       "    'authors': 'Ryan C Ungaro, Andres Yarur, Jacqueline Jossen, Becky L Phan, Ezra Chefitz, Priya Sehgal, Kanika Kamal, Alexandra Bruss, Poonam Beniwal-Patel, Caroline Fox, Amir Patel, Bayda Bahur, Anjali Jain, Daniel Stein, Snehal Naik, Marla C Dubinsky',\n",
       "    'date': '2019/02/13',\n",
       "    'doi': '10.1093/ecco-jcc/jjz041',\n",
       "    'pmcid': 'PMC7185193',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185193/pdf'},\n",
       "   {'title': ' Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation',\n",
       "    'authors': 'Mark T. Osterman, Maria Rosario, Karen Lasch, Morris Barocas, Jayson D. Wilbur, Nathanael L. Dirks, Marc R. Gastonguay',\n",
       "    'date': '2019/01/20',\n",
       "    'doi': '10.1111/apt.15113',\n",
       "    'pmcid': 'PMC6590294',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590294/pdf'},\n",
       "   {'title': ' Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis',\n",
       "    'authors': 'William J Sandborn, Jean-Frédéric Colombel, Remo Panaccione, Parambir S Dulai, Maria Rosario, Charlie Cao, Morris Barocas, Karen Lasch',\n",
       "    'date': '2018/10/04',\n",
       "    'doi': '10.1093/ecco-jcc/jjy149',\n",
       "    'pmcid': 'PMC6357899',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357899/pdf'},\n",
       "   {'title': ' Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials',\n",
       "    'authors': 'Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake, Simon P L Travis',\n",
       "    'date': '2018/05/17',\n",
       "    'doi': '10.1093/ecco-jcc/jjy047',\n",
       "    'pmcid': 'PMC6065483',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065483/pdf'},\n",
       "   {'title': ' Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting',\n",
       "    'authors': 'Siew C Ng, Ida Normiha Hilmi, Aimee Blake, Fatima Bhayat, Shashi Adsul, Qasim Rana Khan, Deng-Chyang Wu',\n",
       "    'date': '2018/05/04',\n",
       "    'doi': '10.1093/ibd/izy153',\n",
       "    'pmcid': 'PMC6185254',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185254/pdf'},\n",
       "   {'title': ' What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?',\n",
       "    'authors': 'Timothy Card, Jing Xu, Huifang Liang, Fatima Bhayat',\n",
       "    'date': '2018/04/13',\n",
       "    'doi': '10.1093/ibd/izx097',\n",
       "    'pmcid': 'PMC6176885',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176885/pdf'},\n",
       "   {'title': ' A Review of the Clinical Pharmacokinetics',\n",
       "    'authors': 'Maria Rosario, Nathanael L. Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant, Eric Fedyk, Irving Fox',\n",
       "    'date': '2017/05/18',\n",
       "    'doi': '10.1007/s40262-017-0546-0',\n",
       "    'pmcid': 'PMC5648740',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648740/pdf'},\n",
       "   {'title': ' DRUG EVALUATION: Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis',\n",
       "    'authors': 'Leon P. McLean, Raymond K. Cross',\n",
       "    'date': '2016/05/12',\n",
       "    'doi': '10.1080/17425255.2016.1181171Correction',\n",
       "    'pmcid': 'PMC4917449',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917449/pdf'},\n",
       "   {'title': ' Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice',\n",
       "    'authors': 'Emily E. Vivio, Navya Kanuri, Joanna J. Gilbertsen, Kelly Monroe, Neelendu Dey, Chien-Huan Chen, Alexandra M. Gutierrez, Matthew A. Ciorba',\n",
       "    'date': '2015/12/17',\n",
       "    'doi': '10.1093/ecco-jcc/jjv226',\n",
       "    'pmcid': 'PMC4946762',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946762/pdf'},\n",
       "   {'title': ' Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases',\n",
       "    'authors': 'Kate D. Lynch, Roger W. Chapman, Satish Keshav, Aldo J. Montano-Loza, Andrew L. Mason, Andreas E. Kremer, Marcel Vetter, Manon de Krijger, Cyriel Y. Ponsioen, Palak Trivedi, Gideon Hirschfield, Christoph Schramm, Chung Heng Liu, Christopher L. Bowlus, Derek J. Estes, Daniel Pratt, Charlotte Hedin, Annika Bergquist, Annemarie C. de Vries, C. Janneke van der Woude, Lei Yu, David N. Assis, James Boyer, Henriette Ytting, Emina Hallibasic, Michael Trauner, Hanns-Ulrich Marschall, Luigi M. Daretti, Marco Marzioni, Kidist K. Yimam, Nicola Perin, Annarosa Floreani, Benedetta Terziroli Beretta-Piccoli, Jennifer K. Rogers, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Cynthia Levy',\n",
       "    'date': '0000/00/00',\n",
       "    'doi': '10.1016/j.cgh.2019.05.013',\n",
       "    'pmcid': 'PMC6941216',\n",
       "    'pdflink': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941216/pdf'}]}}"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event = {\"search\": \"Entyvio\"}\n",
    "lambda_handler(event, \"context\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.1"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
